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ABSTRACT 
 
 
Acute myeloid leukaemia (AML) is a highly heterogeneous disease with regard to clinical 
outcome, and molecular markers with prognostic impact can be used to stratify patients for 
risk-adapted therapy. CEBPA mutations have been associated with a favourable prognosis, 
however several questions remained, in particular whether one (CEBPA-single) or two 
(CEBPA-double) mutations were necessary for this benefit, and their interaction with other 
molecular markers. A method of detecting CEBPA mutations in patient samples using 
denaturing HPLC was developed and the CEBPA status of 1427 young adult AML patients 
(median age 43 years, range 15-68 years) determined. Overall, 107 (7%) were CEBPA-
mutant: 48 (45%) CEBPA-single and 59 (55%) CEBPA-double. The majority of CEBPA-
double patients (83%) had an out-of-frame insertion/deletion in the N-terminus and a 
mutation in the C-terminal DNA-binding/leucine zipper domains (DBD/LZD) that were on 
different alleles as determined by cloning. By contrast, mutations in CEBPA-single cases 
were distributed across the gene. CEBPA-double patients were less likely to have a 
FLT3/ITD (P=.04) and highly unlikely to have an NPM1 mutation (P<.0001) compared to 
CEBPA-WT/CEBPA-single cases. Eight year overall survival (OS) was higher in CEBPA-
double patients compared to CEBPA-WT and CEBPA-single cases (54%, 34%, 31%, 
respectively, P=.004). In multivariate analyses, CEBPA-double, but not CEBPA-single, was 
an independent favourable factor for OS (P=.004) and relapse (P=.02). However, this benefit 
was completely lost in the presence of a FLT3/ITD. The mutant level of 101 mutations was 
determined by fragment analysis and the majority were of a level consistent with a 
heterozygous mutation present in most cells. The impact of ten atypical CEBPA mutations 
on C/EBPα transactivation activity was explored by a luciferase reporter assay. Only 
mutations affecting the DBD or LZD functional domains had an impact on transactivation 
activity. This work provides insight into the biology of CEBPA mutations and their use as 
clinical markers. 
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CHAPTER 1: INTRODUCTION 
 
Acute myeloid leukaemia (AML) is an aggressive malignancy characterised by an 
accumulation of malignant white cells of the myeloid lineage in the bone marrow (BM) and 
peripheral blood of patients. Whilst the presence of these leukaemic blast cells is the 
common feature between cases, there is considerable heterogeneity between patients with 
respect to a number of characteristics, such that AML may more accurately be described as a 
collection of related malignancies. Variable features include morphology, 
immunophenotype, karyotype and gene mutations, and this variability is reflected in the 
significant differences that may be seen in the response to therapy and longer term prognosis 
between patients. 
 
This thesis describes the investigation of mutations in CEBPA, a gene coding for the 
CCAAT/enhancer binding protein α, in AML and detailed information regarding C/EBPα 
structure and function and CEBPA mutations is given in the introductions to the relevant 
chapters. This chapter will seek to place the work into context by giving an overview of 
AML with respect to its presentation, classification and treatment. The heterogeneity of the 
disease and the factors which are currently known to be important in patient outcome will 
also be introduced. 
 
  
1.1 Haemopoiesis 
 
The leukaemic blast cells that accumulate in the BM and peripheral blood of patients are the 
result of disorder in the normal process of haemopoiesis. Haemopoiesis is the formation of 
blood cells of different lineages from haemopoietic stem cells (HSCs), and an overview is 
given in Figure 1.1. This process occurs throughout life and, in adults, the primary sites of 
haemopoiesis are in the BM of the central skeleton and the proximal ends of the femurs and 
humeri. HSCs are rare, estimated to be only 1 in 20 x10
6
 BM cells, pluripotent and have the 
capacity for self-renewal, providing the homeostatic maintenance of the haemopoietic 
system (Kondo et al, 2003). The current roadmap suggests that HSCs generate the 
multipotent common myeloid progenitor (CMP) and common lymphoid progenitor (CLP) 
cells, which can differentiate into cells of the myeloid and lymphoid lineages, respectively 
(Orkin & Zon, 2008). The CMP produces megakaryocyte/erythroid progenitors (MEPs), 
which then give rise to erythrocytes and megakaryocytes, and granulocyte/macrophage 
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Figure 1.1 Overview of haemopoiesis, figure from Orkin and Zon (2008) Haemopoiesis 
is the process of formation of mature blood cells by differentiation from the pluripotent long-
term haemopoietic stem cells (LT-HSC) and short-term HSCs (ST-HSC), to multipotent 
progenitors, committed precursors and ultimately terminally differentiated cells. This 
process requires a number of different transcriptions factors and the stages at which 
haemopoiesis is blocked in the absence of a given transcription factor, as determined through 
conventional gene knockouts, are indicated by red bars. Abbreviations: CMP, common 
myeloid progenitor; CLP, common lymphoid progenitor; MEP, megakaryocyte/erythroid 
progenitor; GMP, granulocyte/macrophage progenitor; RBCs, red blood cells.  
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progenitors (GMPs), which can differentiate through more lineage-restricted committed 
precursor cells into terminally differentiated cells, such as neutrophils and macrophages. As 
cells become more differentiated, they lose self-renewal capacity and pluripotency which are 
characteristics of the HSC. This process relies upon the closely regulated activity of specific 
transcription factors and haemopoietic growth factors. 
 
 
1.2 AML 
 
1.2.1 Leukaemic stem cells and leukaemogenesis 
 
The leukaemic stem cell (LSC) generating leukaemic blast cells in AML is analogous to the 
hierarchical arrangement of HSCs, committed progenitors and terminally differentiated 
blood cells in normal haemopoiesis (Bonnet & Dick, 1997). Leukaemia initiating cells 
(LICs), the putative LSCs, were first described through xenotransplantation assays, where 
the immature CD34
+
CD38
-
 fraction of human AML tumour cells, when transplanted into 
severe combined immunodeficient (SCID) mice, was uniquely able to initiate leukaemic 
engraftment and produce large numbers of mature blast cells (Lapidot et al, 1994). More 
recent data has found that both the CD34
+
 and CD34
-
 fractions of primary AML samples 
may contain cells able to initiate leukaemia in mice (Taussig et al, 2010). LSCs are cells in 
the tumour that have stem cell-like properties, in particular self-renewal and repopulation 
capacity, with potential for these characteristics varying between LSCs (Dick, 2008). LSCs 
may also be quiescent, and it is hypothesised that their dormancy may confer drug resistance 
to conventional chemotherapy agents, allowing survival of the LSC, which can then cause 
disease relapse in patients who enter remission (Dick, 2008). The normal haemopoietic cell 
from which the LSC is derived, the cell of origin, is the subject of some discussion (Dick, 
2008). The cell of origin may be a multipotent HSC which has undergone leukaemic 
transformation, as suggested by the immature phenotype in common between LICs and 
HSCs. Alternatively, a more committed myeloid progenitor cell may have acquired some 
stem-cell properties, in particular self-renewal capacity, during leukaemogenesis, with the 
maturation state of the leukaemic blasts a reflection of the maturation state of the cell of 
origin (Krivtsov et al, 2006;Goardon et al, 2011). 
 
The transformation of normal haemopoietic cells to leukaemic cells involves the acquisition 
of multiple genetic alterations, such as chromosomal translocations or gene mutations, over a 
period of time, in a multistep process (Kelly & Gilliland, 2002). The advent of next 
generation sequencing technologies has enabled the sequencing of individual cancer 
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genomes, revealing large numbers (1,000 to 100,000) of somatically acquired genetic 
alterations, which may be divided into driver and passenger mutations (Stratton et al, 2009). 
Driver mutations are defined as conferring a selection advantage on the cells that acquire 
them and are generally in cancer-associated genes. Passenger mutations do not confer a 
selection advantage, but may have been acquired in a cell before it acquired a driver 
mutation. It is hypothesised that most cancers have more than one driver mutation and that 
their frequency varies between cancer types, with an estimate of between 5 and 20 in an 
individual cancer (Stratton et al, 2009). These genetic “hits” disrupt normal cellular 
processes and their accumulation in a clone results in a cancerous phenotype, identified by 
the “hallmarks of cancer”. These may include the ability to sustain proliferative signalling, 
evade growth suppressors, resist apoptosis and induce replicative immortality (Hanahan & 
Weinberg, 2011). In AML, for example, an increase in cell proliferation and/or survival may 
be caused by activating mutations in the growth factor receptor fms-like tyrosine kinase 3 
(FLT3) or signal transduction pathway components NRAS and KRAS. Another 
characteristic feature of AML is a block in the normal differentiation programme and 
subsequent apoptosis. This is caused by “hits” such as the fusion proteins produced by the 
chromosomal translocations t(8;21) and t(15;17), and through mutations in haemopoietic 
transcription factors, such as C/EBPα and RUNX1 (Kelly & Gilliland, 2002). The growth 
advantage the leukaemic blast cells have over normal cells cause out-growth of the 
leukaemic clone and accumulation of leukaemic blasts in the peripheral blood and BM. 
 
1.2.2 Presentation and aetiology 
 
The result of the accumulation of immature blast cells is BM failure. This leads to a broad 
range of symptoms at presentation, for instance, fatigue and breathlessness caused by 
anaemia, infections, particularly of the chest, mouth and skin, caused by neutropenia and 
bleeding caused by thrombocytopenia. Infiltration of organs such as the liver, spleen and 
lymph nodes may also occur. 
 
The incidence of AML is approximately 2-3 cases per 100,000 people per year, although this 
incidence rises with age to about 12-15 cases per 100,000 people per year in patients in their 
seventh and eighth decades (Burnett et al, 2011). In the majority of cases there is no known 
direct cause, although there is an association with irradiation, smoking and certain conditions 
which pre-dispose to AML, such as Down’s syndrome. The most commonly identified 
causes are progression from a pre-existing myeloproliferative or myelodysplastic disease 
(secondary AML) or as a result of prior chemotherapy for a different malignancy (therapy-
related AML). 
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1.3 Classification of AML 
 
Historically, AML has been classified using the French-American-British (FAB) sub-types 
(Bennett et al, 1976;Bennett et al, 1985). These are primarily based on the morphology and 
cytochemistry of the leukaemic cells, with at least 30% blasts in the BM required. The 
different sub-types are given in Table 1.1. It has also long been known that non-random 
chromosomal abnormalities can be present in tumour cells, occurring in approximately 60% 
of patients (Grimwade et al, 1998), and including either structural gains or loss of 
chromosomal material as well as balanced translocations. Certain chromosomal 
abnormalities are associated with particular FAB types, such as t(8;21)(q22;q22) with M2, 
t(15;17)(q22;q12) with M3 and inv(16)(q23) with M4Eo.  
 
In recent times, however, more detailed genetic information has been obtained, and this, in 
combination with cytogenetic, morphological, and immunophenotypic information, was 
used by the World Health Organization (WHO) to develop a classification system, first 
reported in 2001 (Jaffe et al, 2001), which was updated recently (Table 1.2) (Swerdlow et al, 
2008). In this scheme, acute leukaemia is defined as at least 20% blasts in the BM, although 
this limit is not applied if one of the recurrent genetic abnormalities (Table 1.2) is detected. 
There are 6 main groups within this classification: AML with myelodysplasia-related 
changes, myeloid neoplasms related to therapy, those related to Down’s syndrome, AML not 
otherwise specified, and AML with recurrent genetic abnormalities. The latter group largely 
comprises those with specific cytogenetic abnormalities, such as t(8;21) or t(15;17), 
however, there are also two provisional entries for patients with mutations in the 
nucleophosmin (NPM1) or CEBPA genes. While most patients can be classified by a specific 
genetic abnormality, around a third of cases are placed, by default, into the group of “AML, 
not otherwise specified”. However, an ever increasing number of gene mutations are being 
detected in patients at diagnosis which will, likely, aid in the classification of these cases in 
the future, leading to amendments to the current scheme. 
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Table 1.1 French-American-British (FAB) classification of AML 
 
FAB subtype Name 
M0 Undifferentiated acute myeloblastic leukaemia 
M1 Acute myeloblastic leukaemia with minimal maturation 
M2 Acute myeloblastic leukaemia with maturation 
M3 Acute promyelocytic leukaemia 
M4 Acute myelomonocytic leukaemia 
M4Eo Acute myelomonocytic leukaemia with eosinophilia 
M5 Acute monoblastic leukaemia 
M6 Acute erythroid leukaemia 
M7 Acute megakaryoblastic leukaemia 
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Table 1.2 WHO classification of AML* 
 
Acute myeloid leukaemia with 
recurrent genetic abnormalities 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
AML with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); 
CBFB-MYH11 
APL with t(15;17)(q22;q12); PML-RARA 
AML with t(9;11)(p22;q23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21;q26.2) or t(3;3)(q21;q26.2);  
RPN1-EVI1 
AML (megakaryoblastic) with t(1;22)(p13;q13);  
RBM15-MKL1 
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
Acute myeloid leukaemia with myelodysplasia-related changes 
Therapy-related myeloid neoplasms (t-AML) 
Acute myeloid leukaemia, not 
otherwise specified 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Acute erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related 
to Down’s syndrome 
Transient abnormal myelopoiesis 
Myeloid leukaemia associated with Down’s syndrome 
 
*Adapted from Vardiman et al (2009) 
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1.4 Factors associated with patient outcome in AML 
 
The prognosis of patients with AML is highly heterogeneous, and there are a number of 
features that are known to be associated with particular clinical outcomes. There is 
considerable interest in understanding factors that may be used to stratify patients by risk 
and thereby develop risk-adapted protocols for personalised therapy. For example, given the 
toxicity of conventional chemotherapy it may be beneficial to reduce treatment intensity for 
patients with a favourable prognosis. By contrast, patients where a poor outcome is predicted 
could receive more intensive or experimental therapy. Some of the factors known to impact 
on patient outcome are introduced below, with a particular focus on those important for 
young adult AML patients, as this group of patients is the focus of the work in this thesis. 
 
1.4.1 Clinical features 
 
The highest incidence of AML is in patients greater than 60 years of age and higher age is an 
independent adverse factor for outcome, with very poor long-term survival rates for older 
patients of less than 10% (Appelbaum et al, 2006;Juliusson et al, 2009). When patients are 
stratified by age at diagnosis, from infants to the elderly, rates of remission are lower and 
overall survival decreases with increasing age (Smith et al, 2011). Other factors at diagnosis 
associated with an adverse impact on patient outcome include higher WHO performance 
status scores, secondary or therapy-related rather than de novo AML, and higher white blood 
counts (WBC) (Wheatley et al, 1999;Dohner et al, 2010). In addition to characteristics at 
diagnosis, the response to therapy and the course of the disease are of major importance for 
patient outcome. For instance, the length of remission is a prognostic factor, with early 
disease relapse within 6 months of achieving remission associated with poorer patient 
outcome (Dohner et al, 2010), and a higher percentage of BM blasts after induction therapy 
also negatively impacts upon prognosis (Wheatley et al, 1999). Response to therapy and the 
maintenance of remission may also be monitored through assessment of minimal residual 
disease (MRD). MRD positivity after induction or consolidation therapy is associated with 
higher relapse rates and poorer patient survival (Grimwade et al, 2010b), moreover, 
molecular relapse can be detected prior to morphological relapse (Schnittger et al, 2009). 
Techniques for MRD detection include flow cytometry, used to identify cells with particular 
immunophenotypes, and real-time quantitative polymerase chain reaction (RQ-PCR) assays, 
which can be used to detect leukaemia-specific targets, such as fusion genes or particular 
mutations (Grimwade et al, 2010b). 
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1.4.2 Cytogenetics 
 
Non-random chromosomal changes are present in the leukaemic cells of approximately 60% 
of AML patients, as defined by analysis of metaphase spreads from BM aspirates, and 
karyotype at diagnosis has long been known to be an important determinant of patient 
outcome. Analysis of 1,612 patients aged up to 55 years treated in the UK Medical Research 
Council (MRC) AML 10 trial enabled classification of patients by karyotype into one of 
three prognostic risk groups: favourable, intermediate or adverse (Table 1.3) (Grimwade et 
al, 1998). The MRC classification was recently refined through analysis of 5,876 young 
adult patients aged 16-59 years treated in three successive MRC trials (Table 1.3) 
(Grimwade et al, 2010a). In general, there is a great deal of concordance between the MRC 
classification and those devised by other study groups (Grimwade & Hills, 2009).  
 
The favourable-risk group accounts for approximately one quarter of young adult patients, 
and is defined by the presence of the t(15;17), t(8;21) or inv(16)/t(16;16) chromosomal 
translocations. The latter two abnormalities cause the transcription of the fusion proteins 
RUNX1-RUNX1T1 and CBFB-MYH11, respectively, and are known as core-binding factor 
(CBF) leukaemia abnormalities. Patients with favourable-risk cytogenetics have a 
significantly better long-term overall survival (OS) compared to patients with a normal 
karyotype (NK), in addition to lower rates of relapse in t(8;21) and t(15;17) cases 
(Grimwade et al, 2010a). There is some discussion regarding the prognostic impact of 
additional abnormalities in the CBF leukaemias, for instance the HOVON/SAKK 
classification excludes inv(16) cases with additional unfavourable abnormalities from the 
favourable-risk group (Cornelissen et al, 2007). However, no adverse effect was observed 
for additional abnormalities in CBF leukaemias in the very large cohort analysed by the 
MRC (Grimwade et al, 2010a).  
 
The adverse-risk group comprises approximately 10% of young adult patients, and there are 
a number of different karyotypes that are associated with poorer patient outcome (Table 1.3). 
These include monosomies of chromosomes 5 or 7, and deletions of the long arm of 
chromosome 5, which are designated as myelodysplasia-related (MDS-related) changes in 
the 2008 WHO classification (Table 1.2). In young adults, these karyotypes are associated 
with very poor rates of remission (less than 60%), high rates of relapse, and a very 
25 
 
Table 1.3 Cytogenetic risk group classification of young adult AML 
 
Risk group Proportion of 
patients
1
 
Original MRC
1
 Refined MRC
2
 
Favourable 12% t(15;17) t(15;17) 
8% t(8;21) t(8;21) 
3% inv(16) or t(16;16) inv(16) or t(16;16) 
    
Intermediate 42% Normal karyotype Normal karyotype 
25% Other non-complex Other non-complex 
    
Adverse 10% abn(3q) abn(3q) excluding t(3;5) 
 inv(3) or t(3;3) 
-5 or del(5q) add(5q), del(5q) or -5 
-7 -7, add(7q) or del(7q) 
 t(6;11) 
 t(10;11) 
 t(9;22) 
 t(11q23) excluding t(9;11) 
and t(11;19) 
 -17 or abn(17p) 
Complex (≥ 5 unrelated 
abn) 
Complex (≥ 4 unrelated abn) 
Excluding those with 
favourable changes 
Excluding those with 
favourable changes 
 
1
Grimwade et al, 1998. 
2
Grimwade et al, 2010a. Abbreviations: MRC, Medical Research 
Council; abn, abnormality; del, deletion; add, addition; t, translocation. 
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poor long-term overall survival of less than 15% at either 4 or 10 years (Grimwade et al, 
2010a). The presence of certain translocation partners involved in 11q23 abnormalities is 
also associated with poor patient outcome. This locus is commonly involved in reciprocal 
translocations in AML, normally targeting the myeloid/lymphoid leukaemia (MLL) gene, 
and patients with either t(6;11) (Krauter et al, 2009) or t(10;11) (Grimwade et al, 2010a) 
have been reported to have a survival of less than 15% at 10 years, although these 
abnormalities were not individually identified in the original MRC classification. In addition 
to these specific abnormalities, a complex karyotype has also been found to be associated 
with poor patient outcome. Whilst the original MRC classification defined this as 5 or more 
unrelated abnormalities (Grimwade et al, 1998), this was recently updated to 4 or more 
unrelated abnormalities, as this was found to be the most useful cut-off (Grimwade et al, 
2010a). However, a number of other classification systems use a definition of 3 or more 
unrelated abnormalities (Grimwade & Hills, 2009). A further group of patients with a very 
poor clinical outcome are those with a monosomal karyotype (MK), with a 4-year OS of 4% 
(Breems et al, 2008). An MK is defined as the presence of either two or more autosomal 
monosomies, or a single autosomal monosomy in combination with at least one structural 
abnormality. Whilst an MK is not recognised separately within the MRC classification, 
nearly all patients satisfying the criteria for an MK were found to have karyotypes placing 
them in the adverse-risk group (Grimwade et al, 2010a). 
 
Patients with an NK or karyotypic abnormalities that are neither adverse- nor favourable-risk 
are generally assigned, by default, to the intermediate-risk group. Typical abnormalities in 
intermediate-risk karyotype patients include trisomies of chromosomes 8 or 21, and 
deletions of 13q. Approximately 40% of AML patients have an NK, so that this single 
karyotype comprises the largest number of patients in the intermediate-risk cytogenetics 
group. Despite the large number of patients classified as intermediate-risk, karyotype at 
diagnosis currently remains a key way to stratify patients according to risk. 
 
In addition to the large number of different cytogenetic abnormalities found in AML 
patients, there is also variation in diagnostic karyotypes according to patient age. In older 
patients, it has been observed that adverse-risk karyotypes are more common and 
favourable-risk abnormalities less common than in younger adult patients (Grimwade et al, 
2001). The distribution of chromosomal abnormalities is also different in children with 
AML, compared to adults. For instance, whilst the incidence of an NK is lower in paediatric 
patients at approximately 25%, the incidence of certain abnormalities is higher, such as 
translocations affecting the MLL locus (Harrison et al, 2010). It has also been shown that the 
prognostic impact of cytogenetics may be affected by patient age, for instance it has been 
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reported that a complex karyotype does not have a significant effect on outcome in 
paediatric patients (Harrison et al, 2010). 
 
1.4.3 Gene mutations 
 
There are a large number of genes that have been found to be recurrently mutated in the 
leukaemic cells of AML patients, which, in combination with the variety of chromosomal 
abnormalities, is the basis of the vast heterogeneity seen in this disease. Kelly and Gilliland 
proposed a two-hit model hypothesis, which divides mutations and other genetic alterations 
into two classes, I and II (2002). Class I mutations are those which confer a proliferative 
and/or survival advantage to the leukaemic cells. These include mutations in genes 
considered to be classical oncogenes, for instance activating mutations in genes for growth 
factor receptors, such as the receptor tyrosine kinases (RTKs) FLT3 (fms-like tyrosine 
kinase 3) and c-KIT (proto-oncogene c-KIT), and in components of signal transduction 
pathways important for proliferation, such as the RAS family members neuroblastoma-RAS 
(NRAS) and Kirsten-RAS (KRAS). Class II mutations impair normal differentiation and 
typical class II mutations include loss-of-function mutations in the genes encoding 
transcription factors important for normal haemopoietic differentiation, such as RUNX1 and 
CEBPA. Kelly and Gilliland hypothesised that class I mutations collaborate with class II 
mutations to cause an AML phenotype. Indeed, mouse models of leukaemogenesis have 
been able to show cooperation between different genetic lesions, such as the combination of 
CEBPA and FLT3 mutations (Reckzeh et al, 2012).  
 
However, a two-hit model is probably an over-simplification for most leukaemias in 
humans, with evidence that tumourigenesis in human cells may require perturbation of six 
pathways, compared to just two in murine cells (Rangarajan et al, 2004). The advent of next 
generation sequencing (NGS) technology has allowed DNA sequencing of a cancer genome 
or exome, which has revealed a much broader spectrum of genes affected by mutations. The 
sequencing of an AML genome was first published in 2008 (Ley et al, 2008), and 
subsequent studies of other AML genomes or exomes have, over a very short period of time, 
facilitated the detection of recurrent mutations in genes that would not necessarily have been 
predicted to have a role in leukaemogenesis, for instance, mutations in the metabolic enzyme 
isocitrate dehydrogenase 1 (IDH1) in 2009 (Mardis et al, 2009), and the DNA 
methyltransferase DNMT3A in 2010 (Ley et al, 2010). In addition, these studies have given 
an indication of the number of acquired mutations in known coding regions or splice sites in 
an AML genome, which varies from case to case but was approximately 21 per patient in 
one study (Ding et al, 2012). 
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The association of the presence of specific gene mutations with patient outcome has long 
been an area of intensive research. Whilst for some molecular markers a general consensus 
has been reached regarding their impact on patient prognosis, for others, either a lack of 
impact has been reported, or the impact remains under investigation, with conflicting data 
reported. Further complexity is added due to the frequent presence of multiple mutations in 
the same patient, with the particular combination of mutations often important for patient 
outcome. FLT3 and NPM1 are the two genes most commonly utilised as molecular markers 
in clinical practice, particularly in the context of an intermediate-risk karyotype, due to their 
frequency, impact on patient outcome and utility for patient management. These are highly 
relevant markers for the work in this thesis, and are introduced below in sections 1.4.3.1 and 
1.4.3.2, respectively. CEBPA mutation status may be investigated during the diagnostic 
work-up of a new AML case, and CEBPA mutations and their impact on patient prognosis 
are explored in detail in chapters 3 and 4. Some of the other genes that are commonly 
mutated in AML are briefly introduced in section 1.4.3.3, along with a summary of the 
impact they are reported to have, if any, on the outcome of patients. However, this is not an 
exhaustive list, particularly given the rate at which novel gene mutations are being detected. 
 
1.4.3.1 FLT3 
 
FLT3 is a class III tyrosine kinase receptor, which is normally expressed on the surface of 
haemopoietic progenitor cells and plays an important role in cell proliferation, differentiation 
and survival (Small, 2006). There are two classes of acquired mutations described in FLT3, 
internal tandem duplications (ITD, also known as length mutations) in the juxtamembrane 
domain, and tyrosine kinase domain (TKD) mutations.  
 
FLT3/ITDs were first described by Nakao et al in 1996, and are present in approximately 
25% of young adult AML patients, rising to approximately a third of those with an NK 
(Small, 2006). They are in-frame insertions of between 3 and more than 400 base pairs (bp), 
and cause constitutive activation of the receptor through disruption of the negative 
regulatory activity of the juxtamembrane domain. FLT3/ITD mutations are associated with 
poor patient prognosis, including higher rates of relapse and lower OS (Small, 2006). In 
addition, there is evidence that loss of the normal FLT3 allele, caused by uniparental disomy 
(Raghavan et al, 2005;Griffiths et al, 2005), is associated with a particularly poor outcome 
(Gale et al, 2008). 
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FLT3/TKD mutations are generally missense mutations or small in-frame size changes, 
primarily affecting residues Asp835 and Ile836. These are less common than FLT3/ITD 
mutations, occurring in approximately 7% of patients (Abu-Duhier et al, 2001;Yamamoto et 
al, 2001), but are also known to cause aberrant receptor activation through constitutive 
tyrosine phosphorylation. However, the outcome of FLT3/TKD-mutant patients remains 
controversial, with either no significant impact of a FLT3/TKD mutation on OS (Yamamoto 
et al, 2001;Frohling et al, 2002), an adverse impact (Thiede et al, 2002), a favourable impact 
(Mead et al, 2007), or an adverse impact in certain subgroups (Bacher et al, 2008) all 
variously reported. 
 
1.4.3.2 NPM1 
 
NPM1 is a nuclear histone chaperone which shuttles between the nucleus and cytoplasm, and 
has a number of roles including in ribosome biogenesis, cell survival and centrosome 
duplication (Colombo et al, 2011). First detected in 2005, NPM1 mutations are currently the 
most commonly identified gene mutations in AML, found in approximately 28% to 41% of 
all adult patients (Verhaak et al, 2005;Thiede et al, 2006;Gale et al, 2008), with the 
incidence rising to between 35% and 62% in cases with an NK (Falini et al, 2005;Schnittger 
et al, 2005;Dohner et al, 2005;Thiede et al, 2006;Gale et al, 2008). Mutations are 
heterozygous and are generally 4 bp insertions in exon 12 of NPM1, with the resultant 
frame-shift causing loss of the nuclear localisation signal and aberrant localisation of the 
protein to the cytoplasm. The latter is detectable by immunohistochemistry (Falini et al, 
2005). The exact role of mutant NPM1 in leukaemogenesis is still under investigation, 
however, loss of normal NPM1 has been associated with genomic instability and accelerated 
oncogenesis in mice models (Grisendi et al, 2005). 
 
NPM1 mutations are considered a favourable factor for patient prognosis (Schnittger et al, 
2005;Dohner et al, 2005;Verhaak et al, 2005;Thiede et al, 2006;Gale et al, 2008). In 
addition, there is a correlation between the presence of NPM1 mutations and FLT3/ITDs, 
with some debate over the interaction between the two markers. Whilst it is widely accepted 
that the presence of an NPM1 mutation without a FLT3/ITD is a favourable genotype and a 
FLT3/ITD without an NPM1 mutation is unfavourable, the outcome of patients either 
lacking or positive for both markers remains controversial. Data from our own large cohort 
of young adult AML patients found no evidence for an interaction between the two 
mutations, with a benefit seen for an NPM1 mutation in both FLT3/ITD-positive and 
negative cases, and an overall intermediate prognosis for those with either both mutations or 
neither (Gale et al, 2008). In other reported cohorts, the favourable effect of an NPM1 
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mutation was not seen in the presence of a FLT3/ITD (Schnittger et al, 2005;Dohner et al, 
2005;Verhaak et al, 2005;Thiede et al, 2006). 
 
1.4.3.3 Other recurrently mutated genes in AML 
 
Apart from FLT3, NPM1 and CEBPA mutations there are a number of other genes 
recurrently mutated in AML, and a selection of these are summarised in Table 1.4. 
Abnormalities in several of these genes are generally associated with an adverse impact on 
patient prognosis, such as mutations of DNMT3A, WT1, TET2 or RUNX1, and partial tandem 
duplications of the MLL gene (Table 1.4). However, not all gene mutations have been 
associated with patient outcome, for instance NRAS and KRAS mutations, where no impact 
on prognosis has been observed (Bowen et al, 2005). In addition, there remains considerable 
debate regarding the clinical impact of certain mutations, such as IDH1 and IDH2, with 
different outcomes and interacting mutations reported by different study groups (Table 1.4). 
 
Whilst many of the recurrent mutations, such as DNMT3A, IDH1, IDH2 and WT1 mutations, 
are associated with intermediate-risk karyotypes, in particular an NK, some are more 
common in those with particular chromosomal abnormalities. For instance, activating 
mutations in the c-KIT receptor tyrosine kinase are frequent in patients with the favourable-
risk CBF leukaemias, and may have an adverse effect on prognosis, although there is 
evidence that the impact may depend upon the type of c-KIT mutation and the karyotype, 
inv(16) or t(8;21) (Table 1.4). By contrast, loss-of-function mutations in the tumour 
suppressor gene TP53 are associated with adverse-risk karyotypes. In one study, 60% of 
patients with complex karyotypes had a TP53 mutation, and these were found to predict a 
particularly dismal patient outcome (Rucker et al, 2012). In another study, there were no 
significant differences in outcome between TP53 mutant or WT 
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Table 1.4 Summary of selected recurrent gene mutations detected in AML 
 
Gene Function Commonly detected 
mutations 
Approximate 
incidence 
Impact on outcome References 
DNMT3A DNA methyltransferase 3A: 
Catalyses the de novo 
methylation of CpG 
dinucleotides 
Missense 
Nonsense 
Frame-shift 
Splice-site 
18% - 23% 
29% - 34% (NK) 
Adverse Ley et al, 2010 
Thol et al, 2011 
Yan et al, 2011 
Marcucci et al, 2012 
Renneville et al, 2012 
Ribeiro et al, 2012 
IDH1 Isocitrate dehydrogenase 1: 
Cytosolic metabolic enzyme 
catalysing conversion of 
isocitrate to α-ketoglutarate 
Missense at Arg132 4% - 11% Unclear: 
• Favourable in FLT3/ITD-
positive and adverse in 
FLT3/ITD-negative cases 
• No impact 
• Adverse when analysed with 
IDH2 mutant cases in 
NK/NPM1-mutant/FLT3-
ITD-negative patients 
Mardis et al, 2009 
Abbas et al, 2010 
Boissel et al, 2010 
Chou et al, 2010 
Green et al, 2010 
Ho et al, 2010 
Paschka et al, 2010 
Wagner et al, 2010 
 
IDH2 Isocitrate dehydrogenase 2: 
Mitochondrial metabolic 
enzyme catalysing conversion 
of isocitrate to α-ketoglutarate 
Missense at Arg140 or 
Arg172 
 9% - 12% Unclear: 
• R140 favourable and R172 
adverse 
• Any mutant favourable 
• No impact 
Abbas et al, 2010 
Marcucci et al, 2010 
Paschka et al, 2010 
Thol et al, 2010 
Chou et al, 2011b 
Green et al, 2011 
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Table 1.4 Continued 
 
Gene Function Commonly detected 
mutations 
Approximate 
incidence 
Impact on outcome References 
TET2 Tet oncogene family member 
2: 
Catalyses conversion of 5-
methylcytosine to 5-
hydroxymethylcytosine 
 
Missense 
Nonsense 
Frame-shift 
8% - 13% 
23% (NK) 
Unclear: 
• Adverse 
• No impact 
Chou et al, 2011a 
Metzeler et al, 2011 
Gaidzik et al, 2012 
WT1 Wilms’ tumour 1: 
Transcription factor expressed 
in immature haemopoietic cells 
Missense 
Nonsense 
Frame-shift 
 
10% - 13% (NK) Unclear: 
• Adverse 
• No impact 
Paschka et al, 2008 
Virappane et al, 2008 
Gaidzik et al, 2009 
RUNX1 Runt-related transcription 
factor 1: 
Haemopoietic transcription 
factor frequently involved in 
chromosomal translocations 
Missense 
Nonsense 
Frame-shift 
6% - 13% Adverse Tang et al, 2009 
Gaidzik et al, 2011 
Schnittger et al, 2011b 
 
MLL Myeloid/lymphoid leukaemia 
gene: 
Frequently involved in 
chromosomal translocations 
Partial tandem duplications 
(PTD) 
5% - 8% Adverse Schnittger et al, 2000 
Dohner et al, 2002 
Steudel et al, 2003 
NRAS Neuroblastoma-RAS: 
GTPase component of signal 
transduction pathways 
Missense at Gly12, Gly13 
or Gly61 
10% - 11% No impact Bowen et al, 2005 
Bacher et al, 2006 
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Table 1.4 Continued 
 
Gene Function Commonly detected 
mutations 
Approximate 
incidence 
Impact on outcome References 
KRAS Kirsten-RAS: 
GTPase component of signal 
transduction pathways 
Missense at Gly12, Gly13 
or Gly61 
5% No impact Bowen et al, 2005 
c-KIT Proto-oncogene c-KIT: 
Class III receptor tyrosine 
kinase, receptor for stem cell 
factor 
Missense (activation loop 
or transmembrane domain) 
In-frame indels (extra-
cellular domain) 
In-frame insertions/tandem 
duplications 
(juxtamembrane domain) 
17% - 46% (CBF) Adverse 
Evidence impact affected by: 
• Type of mutation 
• Karyotype, t(8;21) or 
inv(16) 
Care et al, 2003 
Boissel et al, 2006 
Cairoli et al, 2006 
Paschka et al, 2006 
Allen et al, 2011 
TP53 Encodes the tumour suppressor 
p53, a regulator of the cell 
cycle 
Missense 
Nonsense 
Frame-shifts 
In-frame indels 
53% - 60%  
(Complex karyotype) 
Adverse Bowen et al, 2009 
Rucker et al, 2012 
 
Abbreviations: NK, normal karyotype; CBF, core binding factor leukaemias; NPM1, nucleophosmin; FLT3/ITD, internal tandem duplications of the fms-like 
tyrosine kinase 3. 
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complex karyotype patients, however, 5 year overall survival was extremely poor for all 
patients at 0% and 2%, respectively (Bowen et al, 2009). 
 
In addition to associations of mutations with particular karyotypes, mutations in different 
genes may show positive or negative correlations with one another. For instance, NPM1 
mutations are commonly detected in the same patients as FLT3/ITDs (see section 1.4.3.2) 
and they also frequently co-exist with either IDH1 or IDH2 mutations, with an NPM1 
mutation detected in 65% of IDH1-mutant and 61% of IDH2-mutant patients in our own 
cohort (Green et al, 2010;Green et al, 2011). By contrast, IDH1, IDH2 and TET2 mutations 
are generally mutually exclusive in patients, thought to be due to overlapping roles in 
leukaemogenesis in that they may all disrupt the same epigenetic pathway (Figueroa et al, 
2010). The particular combination of mutations is also often important, for instance clinical 
outcome is different between patients with an NPM1 mutation with or without a FLT3/ITD 
(see section 1.4.3.2). FLT3/ITD status also determined the impact of an IDH1 mutation on 
outcome in our own study. In the whole cohort there was no difference in prognosis between 
IDH1-mutant and IDH1-WT cases. When patients were stratified by their FLT3/ITD status 
there was a beneficial impact of a mutation in FLT3/ITD-positive cases, but a negative 
impact in FLT3/ITD-negative cases (Green et al, 2010). 
 
Another observation that can be made from these studies is that different mutations within 
the same gene may differ in their impact on patient outcome. This is the case for FLT3/ITD 
and FLT3/TKD mutations, with a poor patient outcome consistently reported for FLT3/ITD-
positive patients and a more controversial impact on prognosis seen for FLT3/TKD 
mutations (see section 1.4.3.1), which is likely a reflection of the different impact that the 
mutations have on signalling (Small, 2006). Whilst the prognostic impact of IDH2 mutations 
remains the subject of debate (Table 4.1), there are several reports indicating that the 
outcome of patients with IDH2-R140 mutations is very different from those with IDH2-
R172 mutations. In our own study of patients enrolled on the UK MRC AML 10 and AML 
12 trials, IDH2 mutations were associated with improved clinical outcome, however when 
patients were stratified by the type of IDH2 mutation it was found that only those with 
IDH2-R140 mutations had a good outcome, comparable to those with favourable-risk 
cytogenetics. Patients with mutations affecting IDH2-R172 had a very poor long-term 
outcome (Green et al, 2011). Evidence from other study groups also shows an IDH2-R172 
mutation confers an extremely poor prognosis (Boissel et al, 2010;Marcucci et al, 2010). 
The functional basis for this difference is not yet clear, however, as both mutations have 
been reported to cause loss of the normal enzymatic function catalysing the conversion of 
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isocitrate to α-ketoglutarate and gain of a neomorphic function in converting α-ketoglutarate 
to 2-hydroxyglutarate (Ward et al, 2010). 
 
NGS of AML genomes or exomes has enabled the detection of mutations in numerous other 
genes in tumour cells, many of which remain to be validated as leukaemogenic. The 
evolution of a tumour from diagnosis to relapse may also be explored through NGS, with 
intra-tumour heterogeneity indicated by the identification of subclones within the founding 
clone that may predominate at relapse (Ding et al, 2012). The complexity caused by the 
variety of mutations and the way in which they may interact with other markers means that 
determining the prognostic value of gene mutations remains a challenge. This is particularly 
true if a marker is only present in a small proportion of patients, and large cohorts of patients 
are therefore required for meaningful subgroup analyses. 
 
1.4.4 Other molecular markers 
 
In addition to gene mutations, there are a number of other molecular markers that have been 
associated with patient prognosis. These may be genome-wide patterns of gene expression, 
microRNA expression and methylation, or expression of individual genes or microRNAs 
(Marcucci et al, 2011). Of these, gene expression has been the most heavily investigated and 
genome-wide gene expression profiles (GEPs), generated by microarray-based techniques, 
have been used to identify particular patterns of gene expression in cohorts of AML samples. 
These signatures can be characteristic and predictive of sub-types of AML that are already 
defined by a prognostically relevant molecular marker, for instance inv(16) or CEBPA 
mutations, although patients with markers such as MLL rearrangements or FLT3 mutations 
are not accurately predicted  (Valk et al, 2004;Mrozek et al, 2009). The GEP may also 
provide additional prognostic information to that from known molecular markers, for 
instance a prognostic score base on the GEP of a particular probe set has been developed that 
is predictive of patient outcome in NK AML (Metzeler et al, 2008). Altered expression of 
several genes, such as BAALC, MN1, ERG and EVI1, has also been linked to prognosis in 
AML (Marcucci et al, 2011). However, at present genome-wide expression profiling 
remains a tool for research, rather than for clinical practice, largely due to difficulties in 
standardisation of assays and establishment of validated cut-offs. 
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1.5 Treatment of AML 
 
1.5.1 Chemotherapy 
 
The backbone of treatment in AML is intensive chemotherapy with drugs such as the 
nucleoside analogue cytarabine, in combination with an anthracycline such as daunorubicin, 
and this has been the standard of care for the last 40 years (Burnett et al, 2011). However, 
these drugs have limited specificity for leukaemic cells over normal BM cells, and their 
toxic effects cause periods of severe marrow failure and pancytopenia. For this reason, a 
number of patients are not considered fit for intensive therapy, in particular older patients (≥ 
60 years) in whom comorbidities and resistant disease are more frequent, and a more 
palliative approach may be adopted. Where intensive chemotherapy is considered 
appropriate, the aim is to induce a complete remission (CR), usually defined as fewer than 
5% blasts in the BM with recovery of blood cell counts. CR is generally achieved after 
induction therapy in between 70% and 80% of younger patients (< 60 years), which 
decreases to between 40% and 65% of older patients (Burnett et al, 2011). Once in CR, 
induction therapy is then consolidated with further courses of chemotherapy, with the hope 
of eliminating the disease. Throughout treatment, supportive care for BM failure is essential, 
for instance through fungal and antibiotic prophylaxis or transfusion support, as required. 
Whilst remission is achieved in most cases, the majority will relapse within 2 to 3 years of 
presentation, with relapse more likely in older patients: 50% to 55% of younger patients 
compared to around 85% of older patients within this time frame (Burnett et al, 2011). 
 
1.5.2 Stem cell transplantation 
 
Haemopoietic stem cell transplantation (SCT) is an alternative option to further 
chemotherapy. SCT from a human leucocyte antigen (HLA)-matched sibling donor (sibling 
allograft) has long been part of standard care and can be effective at preventing relapse 
(Cornelissen et al, 2007), due in part to a potent graft-versus-leukaemia (GVL) effect. 
However, this is an aggressive therapy associated with significant treatment-related 
mortality (TRM), due to both the intensive treatment required to ablate the recipients’ BM, 
as well as the effects of the donated cells. Complications of allografts (allo-SCT) include 
graft-versus-host disease (GVHD), graft failure and severe infections, in particular 
cytomegalovirus (CMV)-associated interstitial pneumonitis. The risk of these complications 
increases with age and, therefore, this treatment is normally reserved for younger patients, 
with some evidence that the benefit of an allo-SCT is restricted to patients less than 35 years 
of age (Cornelissen et al, 2007). 
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The choice of whether to deploy an allo-SCT in an individual patient is a balance between 
the relapse risk of the disease if treated with chemotherapy alone versus the risk of the 
procedure itself, with the benefit for a transplant seen when relapse risk at 4 years is greater 
than approximately 35% (Cornelissen et al, 2007). An assessment of the risk of transplant in 
an individual case can be quantified in a risk score (Gratwohl et al, 2009), which takes into 
account factors that impact on the likelihood of a successful transplant. These include the 
age of the donor and recipient, donor-recipient sex combination, disease stage, time interval 
from diagnosis to transplant, donor type (HLA-identical sibling or unrelated) and CMV 
status of the donor and recipient (Gratwohl et al, 2009;Dohner et al, 2010). The relapse risk 
of the disease is reliant on a number of factors, which are discussed in detail in section 1.4. 
The relapse risk of the disease if treated with chemotherapy alone is also important in 
determining the timing of the transplant, in particular whether it should be performed in the 
first or second remission. For instance, if it is considered likely that a second remission can 
be achieved if a patient relapses, a rationale exists for delaying transplant to the second 
remission. 
 
Reduced-intensity conditioning (RIC) transplants, which involve immunosuppression rather 
than ablation of the host BM, are also being explored. This is due to the limited applicability 
of traditional transplant regimens, in particular for older patients. Lacking the intensive 
conditioning of a standard allo-SCT, RIC transplants rely upon the GVL effect to maintain 
remission. There is also some evidence that this is a feasible approach in older patients, or 
those with comorbidities, with full chimeric engraftment observed (Hegenbart et al, 
2006;Herr et al, 2007). 
 
An alternative to allo-SCT is an autologous SCT, especially in cases where an HLA-matched 
donor is not available. Autologous SCT is associated with a relative lack of toxicity, and 
complications such as GVHD are avoided. However, this approach lacks the benefit of a 
GVL effect, and the possibility remains that leukaemic cells contaminating the graft will 
contribute to relapse. Whilst autologous SCT as a post-induction therapy can be at least as 
effective as intensive chemotherapy, there remains some debate as to which groups of 
patients may benefit, and at which stage of treatment transplant should be deployed (Breems 
& Lowenberg, 2007).  
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1.5.3 Targeted therapies 
 
Greater understanding of the molecular basis of AML has identified newer targets for 
therapy. One of these is aberrant signalling through receptor tyrosine kinases (RTKs) in 
leukaemic cells, caused by mutations in genes such as FLT3 and c-KIT. This has led to the 
development of tyrosine kinase inhibitors, primarily as inhibitors of FLT3, although most 
also inhibit other RTKs (Fathi & Levis, 2011). Many of these RTK inhibitors are already 
being tested in combination with chemotherapy as part of multi-centre phase III clinical 
trials, for instance midostaurin in a Cancer and Leukemia Group B (CALGB) study and 
lestaurtinib (CEP-701) in the UK National Cancer Research Institute (NCRI) AML 15 and 
AML 17 trials. These agents seem to be well tolerated, although the patient benefit remains 
to be fully determined (Fathi & Levis, 2011). Other small molecule inhibitors under early 
investigation include the aminopeptidase inhibitor Tosedostat, the mammalian target of 
rapamycin (mTOR) inhibitor voreloxin and demethylating agents, such as azacytidine and 
decitabine (Burnett et al, 2011). 
 
1.5.4 Treatment of acute promyelocytic leukaemia 
 
Acute promyelocytic leukaemia (APL) is a special sub-type of AML characterised by the 
translocation t(15;17)(q22;q12), and patients with APL are treated differently to those with 
other types of AML. In this translocation, part of the promyelocyte leukaemia gene (PML) 
on chromosome 15 is fused to the retinoic acid receptor α gene (RARA) on chromosome 17, 
leading to translation of the PML-RARα fusion protein. This fusion protein is a 
transcriptional repressor of both RARα and non-RARα target genes and disrupts PML 
nuclear bodies, causing proliferation and the inhibition of terminal differentiation (de The & 
Chen, 2010). It has been recognised for nearly 30 years that the presence of t(15;17) predicts 
for sensitivity to treatment with all-trans- retinoic acid (ATRA) (de The & Chen, 2010). 
Together, ATRA and arsenic trioxide induce differentiation and apoptosis of APL cells 
through transcriptional de-repression and degradation of the PML-RARα fusion protein (de 
The & Chen, 2010). Current therapy, combining treatment with ATRA, arsenic trioxide and 
an anthracycline, such as idarubicin, can cure up to 90% of patients, with relapse rates as 
low as 5% (Grimwade et al, 2009;de The & Chen, 2010).  
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1.6 Combining prognostic factors and risk-adapted therapy 
 
As detailed above, there are many factors that can impact upon patient outcome, and while 
karyotype at diagnosis has provided the most effective way of stratifying cases, the 
intermediate-risk group remains the largest and most heterogeneous. Efforts have been made 
to combine different prognostic markers so that clinical, cytogenetic and other molecular 
data can be utilised to refine stratification of patients into risk-groups beyond those defined 
by cytogenetics alone, with the aim of helping therapy decisions.  A risk score has been 
developed by analysis of data from MRC trial patients which combines patient and disease 
characteristics (age, sex and de novo or secondary AML), cytogenetics, and response to 
induction therapy, to delineate three patient risk groups (Burnett et al, 2006). An alternative 
risk score for NK AML has been developed using age, WBC, and specific molecular 
markers: mutations in FLT3/ITD, NPM1 and CEBPA, a WT1 polymorphism and expression 
of BAALC, ERG, MN1 and WT1 (Damm et al, 2011). Whilst this risk score enabled 
stratification of patients into three groups with different clinical outcomes, whether it is 
necessary to investigate such a large panel of molecular markers in all patients with an NK 
remains to be determined, especially given the cost implications. The European 
LeukemiaNet currently recommends a molecular risk reporting system which combines 
cytogenetic data with the mutation status of FLT3/ITD, NPM1 and CEBPA (Dohner et al, 
2010). In this classification, the favourable-risk genetic group includes the CBF leukaemias 
and NK patients with either mutated CEBPA or mutated NPM1 without a FLT3/ITD. The 
large intermediate-risk group is further divided into two groups, with the intermediate-I 
group containing NK patients with all other NPM1 and FLT3/ITD genotypes and the 
intermediate-II group made up of those with a t(9;11)(p22:q23) translocation and all other 
cytogenetic abnormalities not classified as favourable- or adverse-risk. There is evidence 
that this is a useful system for younger adult AML patients (Rollig et al, 2011), however 
newer markers, such as DNMT3A mutations, remain to be incorporated into such 
classification schemes. 
 
One area where validated risk stratification schemes may be used is in making transplant 
decisions. Specific genetic markers can also be useful in deciding whether to perform a 
transplant in first remission or not. In those patients with favourable-risk cytogenetics, an 
allo-SCT has been shown to provide no benefit (Cornelissen et al, 2007). Conversely, there 
is evidence that a transplant from an HLA-matched sibling donor in first remission is 
beneficial for those with intermediate or adverse-risk cytogenetics, particularly younger 
patients, with the benefit for a transplant seen when relapse risk at 4 years is greater than 
approximately 35% (Cornelissen et al, 2007). Gene mutations with prognostic value have 
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also been investigated in the context of transplant decisions, particularly within the 
heterogeneous intermediate-risk cytogenetics group. For instance, in NK patients it has been 
reported that those with the favourable genotype of mutant NPM1, without an additional 
FLT3/ITD, gain no benefit from a transplant (Schlenk et al, 2008). By contrast, those with 
either a FLT3/ITD or those without an NPM1 or CEBPA mutation had an improved relapse-
free survival in this study if an HLA-matched related donor was available. However, the use 
of transplant in patients with FLT3/ITD mutations remains the subject of debate (Gale et al, 
2005;Meshinchi et al, 2006;Bornhauser et al, 2007). 
 
 
1.7 Aims of this thesis 
 
This thesis presents data investigating CEBPA mutations in younger adult AML with respect 
to their incidence and types of mutations (chapter 3), the characteristics and clinical outcome 
of CEBPA-mutated patients, and the factors which modify this impact (chapter 4). The 
mutations detected are further explored in terms of their mutant level and allelic distribution 
(chapter 5), and the impact of non-classical mutations on C/EBPα protein function (chapter 
6). 
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CHAPTER 2: MATERIALS AND METHODS 
 
Specific methods are discussed in the relevant results chapter. 
 
2.1 Molecular Biology 
 
2.1.1 Reagents 
 
Acetonitrile (VWR International Ltd., Lutterworth, UK) 
Agar (Sigma-Aldrich Company Ltd., Poole, UK) 
Agarose (Bioline, London, UK) 
Betaine (Sigma-Aldrich Company Ltd., Poole, UK) 
BIOTAQ
 
DNA polymerase (Bioline, London, UK) 
BIOTAQ DNA polymerase buffer and magnesium chloride (Bioline, London, UK) 
Boric acid (VWR International Ltd., Lutterworth, UK) 
Bromophenol blue (Merck, Frankfurt, Germany) 
Carbenicillin (Melford Laboratories Ltd., Ipswich, UK) 
Dimethylformamide (Sigma-Aldrich Company Ltd., Poole, UK) 
Dimethyl sulfoxide (DMSO) (Sigma-Aldrich Company Ltd., Poole, UK) 
dNTPs (Bioline, London, UK) 
Ethylenediamine tetraacetic acid disodium salt (EDTA) (VWR International Ltd., 
Lutterworth, UK) 
Ethidium bromide (Sigma-Aldrich Company Ltd., Poole, UK) 
Glycerol (VWR International Ltd., Lutterworth, UK) 
Luria-Bertani (LB) broth capsules (MP Biomedicals, London, UK) 
One Shot Max Efficiency DH5α-T1 competent E. coli (Invitrogen Life Technologies, 
Paisley, UK) 
Phusion Hot Start High-Fidelity DNA Polymerase (New England Biolabs UK Ltd., Hitchin, 
UK) 
Phusion
 
HF buffer (New England Biolabs UK Ltd., Hitchin, UK) 
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Primers, unlabelled (Integrated DNA Technologies, Leuven, Belgium) 
QIAprep Spin Miniprep Kit and HiSpeed Plasmid Midi Kit (QIAGEN, Crawley, UK) 
QIAquick Gel Extraction kit (QIAGEN, Crawley, UK) 
QIAquick PCR Purification kit (QIAGEN, Crawley, UK) 
Restriction enzymes and buffers (New England Biolabs UK Ltd., Hitchin, UK) 
Super optimal broth with catabolite repression (SOC) (Invitrogen Life Technologies, 
Paisley, UK) 
T4 DNA ligase (New England Biolabs UK Ltd., Hitchin, UK) 
T4 DNA ligase buffer (New England Biolabs UK Ltd., Hitchin, UK) 
TOPO cloning kit (Invitrogen Life Technologies, Paisley, UK) 
Tri-ethylene ammonium acetate (TEAA) (Transgenomic Ltd., Glasgow, UK) 
Tris base (Tris(hydroxymethyl)aminomethane) (VWR International Ltd., Lutterworth, UK) 
WellRED oligos (Sigma-Aldrich Company Ltd., Poole, UK) 
X-Gal (Invitrogen Life Technologies, Paisley, UK) 
 
2.1.2 Polymerase chain reaction (PCR) 
 
The PCR was used to amplify specific regions of a DNA template (genomic, complementary 
or plasmid) by cycling between temperatures that caused denaturation of the template DNA 
followed by annealing of sequence-specific forward and reverse oligonucleotide primers, 
which defined the region to be amplified, and finally an extension step of DNA 
polymerisation. A master mix of all required reagents, sufficient for all the samples in each 
PCR, was made and divided into aliquots before addition of the DNA template. This ensured 
consistency in the reaction mix between samples. A negative control, where water was 
added instead of DNA template, was included in all PCRs to ensure no contamination was 
present. There were two different DNA polymerases used during this work: BIOTAQ DNA 
polymerase (Bioline, London, UK) and Phusion Hot Start High-Fidelity DNA Polymerase 
(New England Biolabs UK Ltd., Hitchin, UK).  
 
The standard reaction mix for a 20µl PCR using BIOTAQ DNA Polymerase contained 2µl 
10x NH4 reaction buffer (670nM Tris-HCl, 160mM (NH4)2SO4, 100mM KCl, 0.1% 
stabiliser), 1mM MgCl2, 200µM of each dNTP, 0.5µM each of the forward and reverse 
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primers, 0.5U BIOTAQ DNA Polymerase and 10-100ng DNA template. The annealing 
temperature used was specific to the primers and this information is given in the relevant 
chapters. The standard cycling conditions were 35 cycles of denaturation at 95°C for 30 
seconds, annealing of primers for 30 seconds and extension at 72°C for 30 seconds, followed 
by a final extension incubation of 5 minutes at 72°C.  
 
The standard reaction mix for a 20µl PCR using Phusion Hot Start High-Fidelity DNA 
Polymerase contained 4µl 5x Phusion HF buffer (containing 7.5 mM MgCl2, providing 
1.5mM MgCl2 in the final reaction), 200µM of each dNTP, 0.5µM each of the forward and 
reverse primers, 0.2U Phusion Hot Start High-Fidelity DNA Polymerase and 10-100ng DNA 
template. The standard cycling conditions used were an initial denaturation step of 98°C for 
2 minutes, then 35 cycles of denaturation at 98°C for 42 seconds, annealing of primers for 
42 seconds and extension at 72°C for 42 seconds, followed by a final extension incubation 
of 5 minutes at 72°C. As indicated in the specific chapters, PCR additives such as betaine 
and DMSO were also added to PCR reaction mixes to enable amplification of difficult 
templates. 
 
2.1.3 Agarose gel electrophoresis 
 
Buffers  
10x TBE: 108.9g Tris base, 55.7g boric acid and 7.4g EDTA in 1 litre of ddH2O 
5x Loading buffer: 30% glycerol and 0.025% bromophenol blue in 1x TBE 
 
Agarose gel electrophoresis was used to both detect PCR products and to separate different 
fragments of DNA by size, for instance after restriction enzyme digestion. An appropriate 
amount of agarose (between 1% and 3% weight/volume, depending on the purpose) was 
dissolved in 35ml of 1xTBE by heating in a microwave oven. Once cooled slightly, 3.5µl of 
a 1mg/ml ethidium bromide solution was added before pouring into a mould. After the gel 
had set, it was covered in running buffer of 1x TBE containing the same concentration of 
ethidium bromide as the gel (0.1µg/ml). The desired volume of sample to be analysed was 
mixed with an appropriate volume of loading buffer before loading into a well in the gel. 
Samples were electrophoresed at a current of approximately 70mA for the required amount 
of time and fragments were detected by fluorescence of ethidium bromide intercalated in 
DNA under UV illumination. The result was documented in a digital photograph. 
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2.1.4 dHPLC analysis on the WAVE platform 
 
Denaturing high-performance liquid chromatography (dHPLC) on the WAVE platform 
(Transgenomic Ltd., Glasgow, UK) was used to detect sequence changes in DNA PCR 
products. The process is outlined in Figure 2.1. In analysis by WAVE, the sample is injected 
into the flow path of buffer containing triethylammonium acetate (TEAA) and acetonitrile 
(ACN) and flows through a polystyrene-divinyl benzene copolymer DNA separation column 
located in an oven at the temperature required for analysis. TEAA acts as an ion-pairing 
agent and forms TEA+ ions in solution, which have both hydrophobic and hydrophilic 
portions. The positively charged TEA+ forms an association with the negatively charged 
phosphate backbone of the DNA creating a hydrophobic layer on the fragment that causes it 
to be attracted to the hydrophobic beads of the DNA separation column and leads to binding 
of the PCR products to the column. Over time, the proportion of ACN in the buffer is then 
increased in a specific gradient. As the ACN concentration increases, the ion-pairing 
properties of the TEAA decreases, eventually causing the elution of DNA from the column. 
Heteroduplexes containing mismatched bases adopt different conformations and bind less 
strongly to the column than the homoduplexes, and so are released from the column first 
followed by the homoduplexes. DNA eluting from the column passes through a UV detector, 
which records the absorbance at 260 nm. Results are displayed in the form of a 
chromatogram of absorbance over time. A sample containing only homoduplexes should 
produce a single peak on the chromatogram. The presence of additional heteroduplexes will 
create extra peaks on the chromatogram, for example the four peaks shown in Figure 2.1. 
This is dependent on the particular sequence and chromatograms can be characteristic of 
specific sequence alterations. All WAVE analysis runs performed in these studies contained 
PCR product with known wild-type (WT) sequence to enable a direct comparison between 
the WT WAVE chromatogram and that of test samples. 
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Figure 2.1 Overview of heteroduplex generation and dHPLC analysis for mutation 
detection. The polymerase chain reaction (PCR) was used to amplify the region of interest 
and the resulting amplicons were denatured and then re-annealed slowly to enable 
heteroduplex formation. These were then analysed by dHPLC at a specific temperature. 
Heteroduplexes eluted from the column and were detected first, followed by the 
homoduplexes.  
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PCR was used to amplify the region of interest from a template DNA or complementary 
DNA (cDNA), using a proof-reading enzyme, where possible, to reduce errors in base 
inclusion and thus reduce potential false heteroduplex formation. The presence of PCR 
products was checked by agarose gel electrophoresis. PCR products were denatured by 
incubation at 95°C for 5 minutes followed by 40 cycles of 1 minute incubations starting at 
92°C and reducing by 1.5°C per cycle. This gradual cooling encouraged heteroduplex 
formation if a mutation was present, as shown in Figure 2.1. If only one type of allele, either 
wild-type (WT) or mutant, was present in the sample then just one homoduplex species was 
produced. 
 
Navigator software (Transgenomic Ltd) was used to determine the temperature(s) at which 
to analyse the sample, which is dependent on the melting profile predicted by the software 
from the sequence of the amplicon. In general, a temperature was chosen at which the 
proportion of PCR product predicted to be helical was between 50% and 95%. The same 
sample may need to be analysed at more than one temperature depending on the percentage 
helicity across the amplicon.  
 
Where enrichment of a particular species was required, a fraction collector was used in 
combination with WAVE analysis, by which specific fractions of the eluate from the column 
could be collected into separate vials. The fractions could then be further analysed by re-
amplification by PCR, using the eluate as a template, for nucleotide sequencing. For samples 
where the heteroduplex species was present at a low level, WAVE analysis and collection 
was performed at a denaturing analysis temperature that enabled the collection and 
enrichment of the heteroduplex species. For samples with size changes where the sequence 
was difficult to determine by direct sequencing, WAVE analysis and collection at a non-
denaturing temperature of 50°C allowed separation of different species by size, and so 
differently sized fragments could be collected in separate vials for further analysis. 
 
2.1.5 Direct nucleotide sequencing 
 
PCR products to be sequenced by standard Sanger sequencing were purified using the 
QIAquick PCR Purification Kit (QIAGEN, Crawley, UK). The concentration of DNA in the 
purified PCR product was quantified using a NanoDrop 1000 Spectrophotometer (Fisher 
Scientific UK Ltd., Loughborough, UK) and the product was then diluted with water to a 
concentration of 1ng/µl per 100 bp to be sequenced. This product was submitted, together 
with the appropriate primer at a concentration of 5pmol/µl, to the Scientific Support Service 
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at UCL Cancer Institute for direct nucleotide sequencing. Plasmids to be sequenced were 
submitted at a concentration of between 30ng/µl and 100ng/µl. 
 
2.1.6 Restriction enzyme digests 
 
All restriction enzymes were supplied by New England Biolabs (Hitchin, UK). Restriction 
digest reaction mixes and incubation temperatures were as according to manufacturers’ 
instructions. Incubation times varied according to the required temperature: 37°C 
incubations were between 4 and 16 hours in duration, while incubations above 50°C were 
between 2 and 3 hours. 
 
2.1.7 LB broth and agar plates 
 
LB broth: 13 LB capsules in 500ml ddH2O 
LB agar plates: 13 LB capsules and 7.5g agar in 500ml ddH2O 
 
For both broth and plates, the reagents were autoclaved and cooled to below 50°C before 
addition of carbenicillin to a final concentration of 100µg/ml. Plates were then poured and 
left to set. Both broth and plates were stored at 4°C until required. 
 
2.1.8 TOPO TA cloning of PCR products 
 
The TOPO TA cloning kit (Invitrogen Life Technologies, Paisley, UK) enables cloning of 
PCR products produced by non-proof reading Taq DNA polymerases, such as BIOTAQ 
DNA Polymerase, because they add a single deoxyadenosine (A) to the 3´ ends of PCR 
products. The linearised pCR 2.1-TOPO vector is supplied complete with single 3´-
thymidine (T) overhangs and topoisomerase I covalently bound to the vector. These “sticky 
ends” on PCR product and vector allow for easy ligation of the PCR product into the vector 
in a reaction catalysed by the topoisomerase. For the TOPO reaction, 1µl of PCR product 
was incubated with 1µl of the linearised pCR 2.1-TOPO vector, 1µl of the provided salt 
solution and 3µl of water at room temperature for 5 minutes.  
 
 
2.1.9 Transformation of One Shot Max Efficiency DH5α-T1 E. coli competent cells 
 
One vial of One Shot Max Efficiency DH5α-T1 E. coli cells was thawed on ice for each 
transformation. To each vial, 1µl of ligation reaction from section 2.1.8 or 10ng of circular 
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plasmid DNA, as required, was added and incubated on ice for 30 minutes. The cells were 
then heat-shocked for 30 seconds at 42°C, 250µl of SOC medium (2% tryptone, 0.5% yeast 
extract, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10mM MgSO4, 20mM glucose) was 
added per vial and the cells were incubated at 37°C in a shaking incubator for 1 hour. During 
this incubation, LB agar plates containing 100µg/ml carbenicillin were pre-warmed to 37°C. 
If the pCR 2.1-TOPO vector (section 2.1.8) was used for the transformation, plates were pre-
coated with 40µl of a 40mg/ml X-gal solution in dimethylformamide to enable blue/white 
screening of colonies. In this system, the LacZα gene in the pCR 2.1-TOPO vector was 
disrupted if an insert was successfully ligated, as indicated by the formation of white 
colonies. If no insert was present, a functional LacZα gene was maintained and hydrolysis of 
X-gal caused the formation of blue colonies. Between 20µl and 100µl of transformed 
bacteria were spread per plate and plates were incubated overnight at 37°C to allow colony 
formation. 
 
2.1.10 Identification and growth of transformed bacterial clones 
 
To enable screening of individual bacterial colonies for the presence of particular inserts, 
colonies were plucked and seeded into 200µl of LB containing 100µg/ml carbenicillin in a 
well of a 96-well plate and incubated at 37°C overnight. The bacterial culture was then used 
as a template for PCR amplification, with specific primers and reaction conditions as given 
in the relevant chapters. Where plasmid isolation was required, the bacterial culture was 
used to inoculate 4ml of LB containing 100µg/ml carbenicillin, which was incubated 
overnight at 37°C with shaking. Glycerol stocks of clones were made by adding 150µl 
autoclaved glycerol to 850µl of the bacterial culture in a sterilised microfuge tube. This was 
vortexed thoroughly and stored at -80°C. Plasmid DNA from the remaining culture was 
extracted using the QIAprep Spin Miniprep Kit (QIAGEN, Crawley, UK) and the entire 
insert was sequenced to ensure that the constructs were correct. If larger amounts of plasmid 
DNA were required, the glycerol stock was used to inoculate 5ml of LB containing 
100µg/ml carbenicillin and this was grown at 37°C in a shaking incubator for approximately 
8 hours. This pre-culture was then added to 200ml of LB containing 100µg/ml carbenicillin 
and grown overnight. Plasmid DNA was extracted using the HiSpeed Plasmid Midi Kit 
(QIAGEN). 
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2.2 Cell Culture 
 
2.2.1  Cell line 
 
HEK 293T: Human embryonal kidney line, adherent, growth factor independent. 
Expresses the simian virus 40 (SV40) large T cell antigen 
 
2.2.2  Cell culture general reagents 
 
0.25% Trypsin- 0.02% EDTA solution (Sigma-Aldrich Company Ltd., Poole, UK) 
Dulbecco’s modified Eagle medium (DMEM) (PAA Laboratories Ltd., Yeovil, UK) 
Foetal bovine serum (FBS) – heat inactivated (Sigma-Aldrich Company Ltd., Poole, UK) 
GeneJuice Transfection Reagent (VWR International Ltd., Lutterworth, UK) 
Penicillin (10,000 units/ml)-Streptomycin (10mg/ml) solution (Sigma-Aldrich Company 
Ltd., Poole, UK) 
Phosphate buffered saline (PBS) (Sigma-Aldrich Company Ltd., Poole, UK) 
 
2.2.3  Culture of 293T cells 
 
293T cells were grown in 75cm
2
 flasks (VWR International Ltd.) in DMEM supplemented 
with 10% FBS and 1% penicillin-streptomycin solution in a humidified atmosphere at 37°C 
with 5% CO2. When cells reached 90-95% confluency, the growth medium was removed 
and the cell layer washed gently with DMEM. Trypsin-EDTA solution (3ml) was added to 
the cells and the flask incubated until cells dissociated from the flask. Cells were then re-
suspended in 10ml of growth medium, transferred to a 15ml Falcon tube and centrifuged at 
450g for 5 minutes. The supernatant was removed and the cells were re-suspended in 10ml 
of fresh growth medium. For maintenance, 2ml of the cell suspension was added to 18ml of 
growth medium in a fresh 75cm
2
 flask. 
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2.2.4 Transient transfection of 293T cells 
 
During passage of a 75cm
2
 flask of 293T cells, 2ml of the cell suspension (section 2.2.3) was 
diluted in 12ml of growth medium per plate to be seeded. Each well of a 24-well or 6-well 
plate was seeded with 500µl or 2ml, respectively, of the diluted cell suspension and cells 
were left to adhere in a humidified atmosphere at 37°C with 5% CO2 for at least 24hrs, until 
50-80% confluent. For transfection of 6-well plates, 5µl of GeneJuice and 95µl of DMEM 
were used per well and for 24-well plates 1.25µl and 23.75µl, respectively. The total amount 
of GeneJuice and DMEM required for the whole experiment were mixed and incubated at 
room temperature for 5 minutes. Aliquots of appropriate volumes of GeneJuice in DMEM 
were prepared and the required volume of plasmid DNA added and incubated at room 
temperature for 15 minutes. The transfection mixture was added drop-wise to the plated 
cells. The plate was then gently rocked to mix and placed back in the incubator for 24 hours. 
 
 
2.3 Cell lysis and immunoblotting 
 
2.3.1  Reagents 
 
30% (w/v) Acrylamide/ 0.8% bisacrylamide solution (National Diagnostics, Atlanta, USA) 
Ammonium persulfate (APS) (Scientific Laboratory Supplies Ltd., Hessle, UK) 
Bovine serum albumin (BSA) (PAA Laboratories Ltd., Yeovil, UK) 
Bromophenol blue (Merck, Frankfurt, Germany) 
Complete Mini Protease Inhibitor Cocktail Tablets (Roche Diagnostics Ltd., Burgess Hill, 
UK) 
ECL Plus Western Blotting Detection Reagent (GE Healthcare UK Ltd., Little Chalfont, 
UK) 
Full-range rainbow molecular weight markers (GE Healthcare UK Ltd., Little Chalfont, UK) 
Detergent-Compatible (DC) Protein Assay (Bio-Rad Laboratories Ltd., Hemel Hempstead, 
UK) 
Glycerol (VWR International Ltd., Lutterworth, UK) 
Hybond-C Extra nitrocellulose membrane (GE Healthcare UK Ltd., Little Chalfont, UK) 
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Hyperfilm MP – High performance autoradiography film (GE Healthcare UK Ltd., Little 
Chalfont, UK) 
2-Mercaptoethanol (Sigma-Aldrich Company Ltd., Poole, UK) 
N,N,N′,N′-Tetramethylethylenediamine  (TEMED) (Sigma-Aldrich Company Ltd., Poole, 
UK) 
Non-fat milk powder (Marvel) 
Nonidet-P40 (NP-40) (Sigma-Aldrich Company Ltd., Poole, UK) 
Phosphate buffered saline (PBS) (Sigma-Aldrich Company Ltd., Poole, UK) 
Sodium azide (Sigma-Aldrich Company Ltd., Poole, UK) 
Sodium chloride (NaCl) (VWR International Ltd., Lutterworth, UK) 
Sodium deoxycholate (VWR International Ltd., Lutterworth, UK) 
Sodium dodecyl sulphate (SDS) (Scientific Laboratory Supplies Ltd., Hessle, UK) 
Tris base (VWR International Ltd., Lutterworth, UK) 
Tris-HCl (VWR International Ltd., Lutterworth, UK) 
Tween-20 (Sigma-Aldrich Company Ltd., Poole, UK) 
 
2.3.2 Buffers 
 
Radioimmunoprecipitation (RIPA) buffer: 25mm Tris pH 7.6, 1% NP-40, 1% sodium 
deoxycholate, 150mM NaCl, 0.1% SDS 
5x Laemmli sample buffer: 313mM Tris-HCl, 10% SDS, 50% glycerol, 25% 2-
mercaptoethanol, 0.01% bromophenol blue 
Running buffer: 25mM Tris, 250mM glycine, 0.1% SDS 
Transfer buffer: 48mM Tris pH 9.1, 39mM glycine, 20% methanol, 0.038% SDS 
TBST (Tris buffered saline Tween-20): 20mM Tris pH 7.5, 150mM NaCl, 0.05% Tween-
20 
Stripping buffer: 62.5mM Tris-HCl pH 6.7, 100mM 2-mercaptoethanol, 2% SDS 
7x Protease inhibitor solution: 1 Complete Mini Protease Inhibitor Cocktail Tablet in 
1.5ml water 
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2.3.3 Antibodies 
 
Rabbit anti-C/EBPα #2295 (Cell Signaling Technology from New England Biolabs UK Ltd., 
Hitchin, UK) 
Rabbit anti-C/EBPα antibody #2843 (Cell Signaling Technology from New England Biolabs 
UK Ltd., Hitchin, UK) 
Murine anti-Tubulin (Sigma-Aldrich Company Ltd., Poole, UK) 
Sheep anti-mouse IgG, ECL horseradish peroxidase-linked whole antibody (GE Healthcare 
UK Ltd., Little Chalfont, UK) 
Donkey anti-rabbit IgG, ECL horseradish peroxidase-linked whole antibody (GE Healthcare 
UK Ltd., Little Chalfont, UK) 
 
2.3.4 Preparation of cell lysates 
 
Lysates were made from 293T cells that had been cultured in 6-well plates. All growth 
medium was removed and the cells washed twice with ice-cold PBS before the addition of 
300µl per well of RIPA buffer containing an appropriate volume of protease inhibitor 
solution. The plate was placed on ice and rotated occasionally for 10 minutes. The cell 
lysates were then transferred to microcentrifuge tubes and centrifuged at 20,000g for 10 
minutes at 4°C, after which the supernatants were transferred to clean microcentrifuge tubes 
and stored at -80°C until required. 
 
2.3.5 Protein quantification 
 
The concentration of protein in cell lysates was determined using the DC Protein Assay 
Reagents (Bio-Rad, Hemel Hempstead, UK). Protein standards of BSA in RIPA buffer at 6 
different concentrations of between 0 and 1.5mg/ml were prepared. For every 1ml of the 
Assay Reagent A, 20µl of Reagent S was added to make Reagent A′, as the sample buffer 
contained detergent. In a 96-well plate, 25µl of Reagent A′ was added to 5µl of each 
standard or cell lysate. Reagent B, 200µl, was added to each well and samples were mixed 
and incubated for 15 minutes at room temperature. The absorbance was read at 750nm in a 
Varioskan Flash Multimode Reader (Thermo Fisher Scientific). Cell lysates were diluted 10-
fold for quantification and each sample was measured in triplicate. The absorbance of the 
protein standards was used to generate a standard curve from which the protein 
concentration of cell lysates could be calculated. 
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2.3.6 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
semi-dry transfer 
 
12.5% Running gel (for 2 gels): 2ml ddH2O, 3.74ml 1M Tris pH 8.8, 4.2ml 30% (w/v) 
acrylamide/ 0.8% bisacrylamide solution, 100µl 10% SDS, 75µl 10% APS, 9µl TEMED 
Stacking gel (for 2 gels): 3.49ml water, 625µl 1M Tris pH 6.8, 835ml 30% (w/v) 
acrylamide/ 0.8% bisacrylamide solution, 50µl 10% SDS, 38µl 10% APS, 7.5µl TEMED 
 
Polyacrylamide gels were freshly made as required, with gel casting and electrophoresis 
performed using the Mini-PROTEAN Tetra Electrophoresis System (Bio-Rad Laboratories 
Ltd., Hemel Hempstead, UK). Reagents for a 12.5% running gel were mixed and pipetted 
into the glass plate casting module. This was covered with a layer of ddH2O and the gel left 
to polymerise. Once set, the ddH2O was poured off and the surface of the gel dried with 
fibre-free paper. The stacking gel was then pipetted on top and a comb inserted to form 
either 10 or 15 loading wells, as required, and left to polymerise. Cell lysates to be analysed 
were mixed with Laemmli sample buffer and boiled in a heat block for 5 minutes. The set 
gel was submerged in running buffer, and samples and a molecular weight marker were 
loaded into wells and electrophoresed at between 100V and 140V until the bromophenol 
blue dye front had travelled the required distance through the gel. 
 
For semi-dry transfer of proteins, a nitrocellulose membrane and two pieces of Extra Thick 
Blot Paper (Bio-Rad) were cut to size and soaked in transfer buffer together with the gel for 
10 minutes. These were then assembled in a sandwich in a Trans-Blot SD Semi-Dry 
Transfer Cell (Bio-Rad) and the proteins were transferred from the gel to the membrane at 
20V for 30 minutes. 
 
2.3.7 Probing and detection 
 
All membranes were blocked in 5% non-fat milk powder in TBST for between 1 and 2 hours 
at room temperature on a rocking platform. Incubation with the primary antibody was 
performed as specified and the membrane was then washed in TBST for at least 30 minutes, 
with the wash buffer changed at least 5 times. The appropriate secondary antibody, either 
anti-mouse IgG or anti-rabbit IgG, was used at a dilution of 1:10,000 in 3% non-fat milk 
powder in TBST and incubated with the membrane for 1-2 hours, then the membrane was 
washed as before. The membrane was then rinsed in PBS. Detection was performed using 
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the ECL Plus Western Blotting Detection Reagent kit and the enhanced chemiluminescence 
documented by exposure to autoradiography film. The film was then developed in an 
automated film developer (Konica Minolta SRX-101A). 
 
2.3.8 Stripping 
 
If required for re-probing, membranes were stripped to remove the original primary and 
secondary antibodies by incubation in stripping buffer for 10 minutes at 50°C. The 
membrane was then washed in TBST for at least 20 minutes, with the wash buffer changed 
at least 3 times. Blocking of the membrane was performed again before re-probing. 
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CHAPTER 3: DETECTION OF CEBPA MUTATIONS IN AML 
 
3.1 Introduction 
 
Transcription factors play a major role in the process of haemopoiesis and are up or down-
regulated at specific points during differentiation as required for their target genes to be 
switched on or off. CCAAT enhancer binding protein alpha (C/EBPα) is one such 
transcription factor with a pivotal role in myelopoiesis. 
 
3.1.1 C/EBPα structure and function 
 
C/EBPα is coded for by the intronless gene CEBPA, found on the long arm of chromosome 
19 at 19q13.1, and is the founding member of the C/EBP family of basic region leucine 
zipper (bZIP) transcription factors. The C/EBPα protein contains several domains that are 
characteristic of this family as shown in Figure 3.1. These include two transactivation 
domains (TAD1 and 2), and a DNA-binding domain (DBD) and leucine zipper domain 
(LZD) at the C-terminus. C/EBPα functions as a dimer, with dimerisation mediated by the 
LZD (Figure 3.2). This domain contains an α-helical structure that interacts with the α-helix 
in the binding partner to form a coiled-coil structure. C/EBPα can either form a homodimer 
or can heterodimerise with other family members, such as C/EBPβ and C/EBPδ, due to the 
conserved nature of the bZIP domain. Dimerisation is a pre-requisite for DNA binding, 
which is mediated by the DBD and occurs in the major groove of DNA (Figure 3.2) at 
sequence-specific sites, usually found in the promoters or enhancers of target genes. Once 
bound to DNA, the transactivation domains can function to activate transcription of target 
genes. There are two main isoforms of C/EBPα: the full-length 42 kDa protein (p42) and a 
truncated 30 kDa protein (p30). The p30 isoform is translated from an internal start site in 
the mRNA and the protein lacks the first 119 amino acids of the N-terminus, which includes 
TAD1. It has been found that the p30 protein has a lower transcriptional activation potential 
than the p42 protein (Pabst et al, 2001b). 
 
C/EBPα is expressed in a number of different tissues including adipose, lung epithelium and 
liver, in which it plays several important roles, for instance in the generation of mature 
adipocytes (Ramji & Foka, 2002).
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Figure 3.1 Functional domains of C/EBPα. C/EBPα contains functional domains that are typical of the C/EBP family of basic region leucine zipper 
transcription factors. These include transactivation domains 1 and 2 (TAD1 and TAD2), a DNA-binding domain (DBD) and a leucine zipper domain (LZD). 
Translational start sites for the two major isoforms p42 and p30, amino acid (aa) and nucleotide (nt) numbering are indicated. Adapted from Mueller et al, 
2006. 
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It is also one of several transcriptions factors, including PU.1, C/EBPβ and C/EBPε, 
involved in myelopoiesis, where their expression is tightly controlled (Friedman, 2007). 
C/EBPα is predominantly expressed in early myeloid progenitors, in both common myeloid 
progenitors (CMP) and granulocyte/monocyte progenitors (GMP), and its level decreases 
through granulocytic differentiation (Ramji & Foka, 2002). By contrast, C/EBPε 
predominates in more mature granulocytes.  
 
Studies of C/EBPα function in vitro and in vivo using mouse models have shed much light 
on the role it plays in haemopoiesis. Mice with a homozygous deletion of the gene coding 
for C/EBPα (cebpa) died within 8 hours of birth due to hypoglycaemia, caused by a lack of 
glycogen storage in the liver, and dramatically reduced lipid accumulation in either 
hepatocytes or adipose tissue (Wang et al, 1995). It was also observed that these mice had no 
mature granulocytes and an accumulation of myeloid blasts, although other haemopoietic 
lineages were unaffected (Zhang et al, 1997). Mice that were heterozygous for the deletion 
did not display this phenotype and were comparable to wild-type animals. Subsequent 
studies knocked out C/EBPα in adult mice and showed that the block in differentiation was 
at the CMP to GMP transition. However, C/EBPα was not required for differentiation after 
the GMP stage (Zhang et al, 2004). 
 
As part of its role in granulopoiesis, there are a number of target genes that are regulated by 
C/EBPα in myeloid cells. These include genes that encode growth factor receptors such as 
the granulocyte colony-stimulating factor (G-CSF) receptor, granulocyte-macrophage 
colony-stimulating factor (GM-CSF) receptor and macrophage colony-stimulating factor 
(M-CSF) receptor to enable cells to respond to these cytokines. Other targets are those 
involved in granulocyte function, for instance myeloperoxidase, neutrophil elastase, 
lactoferrin and lysozyme, or genes associated with an acute phase response to a bacterial 
infection such as interleukin-6 or tumour necrosis factor-α (Ramji & Foka, 
2002;Koschmieder et al, 2009).  
 
C/EBPα not only promotes differentiation, it also arrests cell proliferation. This was initially 
observed in adipoblasts where C/EBPα expression caused a halt in mitotic growth (Umek et 
al, 1991), but subsequently has been described in other tissues. 
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Figure 3.2 Structure of the C/EBPα dimer-DNA complex. Crystal structure of the C-
terminal amino acids (281 to 340) of rat C/EBPα bound as a dimer to a 21-mer DNA duplex. 
The leucine zipper (LZ) domain enables dimerisation through formation of a coiled-coil 
structure while the basic region (BR) mediates DNA sequence recognition and binding in the 
major groove of DNA. Figure from Miller et al, 2003. 
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The mechanism for this effect has been extensively studied and it was found that, in addition 
to activating the transcription of target genes, for instance early studies found that it 
increased p21 expression, a potent inhibitor of cyclin-dependent kinases (Timchenko et al, 
1996), C/EBPα can interact directly with other proteins or complexes. Slomiany and 
colleagues reported that C/EBPα induced repression of E2F, a transcription factor that 
targets genes such as cyclins which drive cell cycle progression, and the two proteins were 
detected together in a complex (Slomiany et al, 2000). Additionally, C/EBPα that had been 
mutated so that the ability to repress E2F-dependent transcription was lost did not support 
either adipocyte or granulocyte differentiation in mice, indicating a crucial role for C/EBPα-
induced E2F repression in terminal differentiation (Porse et al, 2001). C/EBPα also directly 
interacts with both cdk2 and cdk4, cyclin-dependent kinases important for progression 
through the cell cycle. A region of the TAD2 (Figure 3.1) of C/EBPα was found to mediate 
these interactions, which caused inhibition of the activity of these kinases (Wang et al, 
2001), although this region was not required for C/EBPα-dependent growth regulation in a 
mouse model (Porse et al, 2006). 
 
3.1.2 Mutations in the CEBPA gene in AML 
 
A possible role for C/EBPα in AML, in which a key feature is a block in the differentiation 
of myeloid blasts, was investigated by Pabst and colleagues in 2001 given its involvement in 
myelopoiesis and cell cycle arrest (Pabst et al, 2001b). They sequenced the CEBPA gene in 
samples from 137 AML patients and found 8 (6%) cases with mutations predicted to cause 
non-synonymous amino acid changes. One patient had a nonsense point mutation and four 
had frame-shifting deletions in the N-terminus, one of whom also had an in-frame insertion 
in the C-terminus. These frame-shifts and the nonsense mutation all occurred before the 
translation initiation site for the truncated p30 isoform and it was shown that they caused 
loss of the full-length p42 and a concomitant increase in p30. Two patients had frame-
shifting mutations after the p30 start site and one had a missense mutation in the N-terminus. 
All mutations, except the missense mutation in the N-terminus, caused either a complete 
lack of or reduced binding to a target DNA sequence, and most showed reduced 
transactivational potential compared to wild-type (WT) protein in a luciferase reporter assay. 
In patients with a single alteration, all mutations were found to be heterozygous, with one 
WT allele maintained. It was also shown in vitro that the p30 isoform had a dominant-
negative effect over normal p42 in transactivation assays when they were co-expressed 
together. 
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After this first report of recurring mutations in CEBPA in AML patients, a number of other 
groups went on to replicate and extend these findings. Overall, it was found that mutations 
occurred at a frequency of between 6-18% in AML patients (Pabst et al, 2001b;Snaddon et 
al, 2003;Frohling et al, 2004;Bienz et al, 2005;Marcucci et al, 2008;Wouters et al, 
2009;Pabst et al, 2009;Hou et al, 2009;Renneville et al, 2009a;Dufour et al, 2010). Putting 
these 10 studies together, of 3184 cases examined, 315 (10%) had at least one mutation in 
CEBPA and the ratio of cases with one mutation, hereafter called CEBPA-single, compared 
to those with two mutations (CEBPA-double) varied widely at between 1:2.1 and 6.7:1.  
 
In general, two common types of mutations have been detected: out-of-frame insertions or 
deletions in the N-terminus predicted to cause loss of the p42 protein and an increase in p30 
isoform expression, and in-frame insertions or deletions in the DBD or LZD, predicted to 
impair DNA-binding or dimerisation. CEBPA-double cases typically have both an N-
terminal frame-shifting insertion or deletion and an in-frame insertion or deletion in the C-
terminus.  
 
In addition to the two classic types, mutations have also been found across the whole 
CEBPA gene and can be either point mutations or small or large insertions or deletions. The 
vast majority of mutations are heterozygous, affecting one allele only. However, 
homozygous mutations have been described in a small number of cases (6 of 2641, 0.2%) 
(Pabst et al, 2001b;Snaddon et al, 2003;Frohling et al, 2004;Bienz et al, 2005;Marcucci et 
al, 2008;Wouters et al, 2009;Pabst et al, 2009;Hou et al, 2009;Renneville et al, 
2009a;Dufour et al, 2010), with uniparental disomy identified as a recurrent mechanism for 
their occurrence (Fitzgibbon et al, 2005;Wouters et al, 2007c). 
 
CEBPA mutations have been shown to be relatively stable markers of disease with, in the 
majority of cases, the same CEBPA mutation(s) detected in samples taken at both 
presentation and relapse but not in remission (Tiesmeier et al, 2003;Lin et al, 2005;Shih et 
al, 2006). Studies of paired presentation and remission samples have also demonstrated 
germline CEBPA mutations in a small number of pedigrees with a history of familial AML. 
Of the 18 patients from 9 different kindreds who developed AML, all had a constitutional 
frame-shifting insertion or deletion in the N-terminus of CEBPA, with members of the same 
pedigree carrying the same mutation. At disease presentation, 14 (78%) of these patients had 
acquired an additional C-terminal mutation in the leukaemic cells. The acquisition of this 
second CEBPA mutation, and the specific DNA change involved, differed between affected 
members of the same pedigree (Smith et al, 2004;Sellick et al, 2005;Nanri et al, 
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2006;Corbacioglu et al, 2007;Pabst et al, 2008;Renneville et al, 2009b;Taskesen et al, 
2011). 
 
Single nucleotide polymorphisms (SNPs) are well known to occur in the CEBPA gene. The 
most common in the general population is the G/T SNP at nucleotide 690 (numbering from 
the A of the ATG for the p42 translation initiation codon as nucleotide 1), rs34529039, 
which codes for the silent T230T. The most prevalent allele in European populations is G, 
with G/T heterozygotes comprising about 25% (NCBI dbSNP). In addition, there are several 
reports of rarer point mutations also predicted to cause silent amino acid changes (Pabst et 
al, 2001b;Preudhomme et al, 2002;Frohling et al, 2004;Lin et al, 2005). Of greater interest 
is a duplication of 6 base pairs in a proline-rich region of TAD2 (584_589dup), predicted to 
cause H195_P196dup (also termed HP196_197ins or P194_H195dup). First recorded as a 
recurrent mutation (Frohling et al, 2004), it was found in both AML cases and 7 of 19 (39%) 
healthy volunteers by Lin et al (2005), who discounted it as pathogenic (Lin et al, 2005). 
This work was further extended by Wouters et al (2007b) who detected this change in 21 of 
587 (4%) AML cases and 22 of 274 (8%) non-leukaemic blood samples, and found that the 
gene expression profiles of H195_P196dup AML cases did not cluster with that of other 
CEBPA-mutant cases (Wouters et al, 2007b). Additionally, H195_P196dup has been 
reported to lack prognostic value in AML (Biggio et al, 2008;Schnittger et al, 2011a), unlike 
CEBPA mutations, as will be discussed in chapter 4. The classification of H195_P196dup as 
a polymorphism has important implications for the assignment of nucleotide changes as 
pathogenic mutations, particularly when those changes are in-frame alterations in repetitive 
regions of the gene. 
 
3.1.3 Techniques used to detect CEBPA mutations 
 
There are several approaches that different groups have used to screen CEBPA for 
mutations, these are summarised in Table 3.1. The amino acid coding sequence of the 
CEBPA gene is a single exon of 1077 base pairs (bp) and most studies have used PCR to 
amplify the entire coding sequence in a small number of separate reactions to generate 
overlapping amplicons. Sanger sequencing of these PCR products, either directly or after 
cloning, has been the most commonly used technique to determine CEBPA mutation status. 
The advantage of nucleotide sequencing is that all types of mutation can be detected 
62 
 
Table 3.1 Studies of CEBPA mutation detection in patients with AML 
 
Screening 
Technique 
Study Incidence of 
CEBPA-mutant (%) 
Details 
Sanger sequencing Pabst et al, 2001b 
Lin et al, 2005 
Hou et al, 2009 
8 of 137 (6) 
16 of 104 (15) 
71 of 543 (13) 
2 overlapping PCR products covering entire coding sequence 
generated and sequenced. 4 further products in cases of 
abnormal or ambiguous results. 
Gombart et al, 2002 8 of 78 (10) 4 overlapping PCR products covering entire coding sequence 
generated, cloned and sequenced. 
Preudhomme et al, 2002 
Renneville et al, 2009a 
15 of 135 (11) 
53 of 638 (8) 
PCR products generated as per Pabst et al, 2001b, cloned and 
sequenced. 
Frohling et al, 2004 
Marcucci et al, 2008 
33 of 236 (14) 
32 of 175 (18) 
4 overlapping PCR products covering entire coding sequence 
generated and sequenced. 
Bienz et al, 2005 
Pabst et al, 2009 
12 of 67 (18) 
19 of 224 (8) 
3 overlapping PCR products covering entire coding sequence 
generated and sequenced. 
Shih et al, 2006 22 of 149 (15) 2 overlapping PCR products covering entire coding sequence 
generated and sequenced. 
Fragment analysis Juhl-Christensen et al, 2008 20 of 446 (4) 4 overlapping fluorescently labelled PCR products covering 
entire coding sequence generated. Products for each patient 
pooled and fragment sizes analysed by capillary electrophoresis. 
Benthaus et al, 2008 
Dufour et al, 2010 
38 of 469 (8) 
38 of 467 (8) 
4 overlapping fluorescently labelled PCR products covering 
entire coding sequence generated in two multiplexed reactions. 
Products for each patient pooled and fragment sizes analysed by 
capillary electrophoresis. 
Agarose gel analysis Barjesteh et al, 2003 12 of 277 (4) C-terminus only amplified and analysed by agarose gel 
electrophoresis for size changes. In positive cases, C-terminus 
and N-terminus amplified, cloned and sequenced. 
PCR-SSCP analysis Snaddon et al, 2003 8 of 99 (8) 4 overlapping PCR products covering entire coding sequence 
generated using primers as per Pabst et al, 2001b. Products 
analysed by SSCP and positive cases cloned and sequenced. 
dHPLC Wouters et al, 2009 
Taskesen et al, 2011 
41 of 598 (7) 
151 of 1182 (13) 
3 overlapping PCR products covering entire coding sequence 
generated. Heteroduplex analysis on dHPLC WAVE platform. 
Mutations confirmed by sequencing. 
Abbreviations: PCR, polymerase chain reaction; dHPLC, denaturing high-performance liquid chromatography; SSCP, single-strand conformational 
polymorphism. Note: In all studies, cases with H195_P196dup or synonymous sequence changes only have been classified as CEBPA-WT. 
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whether they are heterozygous, homozygous, point mutations, insertions or deletions. 
However, the process is relatively labour-intensive and expensive, especially for a large 
cohort of patient samples. In addition, it can be easy to miss mutations in cases with low 
mutant level, for instance where the mutation was present in only a sub-clone of the tumour 
population. 
 
Size separation of products by agarose gel electrophoresis to detect insertions or deletions 
has been utilised as a quick method of screening the C-terminus of CEBPA (Barjesteh van 
Waalwijk van Doorn-Khosrovani et al, 2003). However, this technique lacks sensitivity for 
smaller size changes and would not detect point mutations at all. Indeed, the proportion of 
CEBPA-mutant cases found in this report was lower than would be expected (4% compared 
to 10% in other studies). A more sensitive method of looking at size changes in the CEBPA 
gene is PCR with a labelled primer and fragment analysis by capillary electrophoresis. This 
technique has been utilised by several groups (Table 3.1) and has been shown to be effective 
at detecting low-level size changes and even single base pair insertions or deletions. 
However, mutations that do not cause an alteration in product length, both point mutations 
and indels that do not change the overall size, will be missed and these types of mutations 
are present in a significant number of CEBPA-mutant patients (Ahn et al, 2009). PCR-SSCP 
analysis has been utilised in a small study of AML patients (Snaddon et al, 2003), however 
it is technically demanding. A more sensitive method to detect different species within a 
PCR product is denaturing high-performance liquid chromatography (dHPLC). 
 
The technique of dHPLC on the WAVE platform (Transgenomic Ltd, Glasgow, UK) for 
mutation detection relies on heteroduplex analysis and has been used effectively to 
determine CEBPA mutation status in a large series of AML samples (Wouters et al, 2009). 
Both point mutations and size changes can be detected with an appropriate degree of 
sensitivity and with a reasonably high throughput, given that analysis of a single PCR 
product takes between 3 and 7 minutes, depending on the DNA separation column used, as 
detailed in chapter 2. In addition, only samples with chromatograms different to that of a 
known WT sample will need to be subjected to direct nucleotide sequencing or another 
confirmatory method, minimising cost. Therefore, the method chosen to detect CEBPA 
mutations in this work was dHPLC on the WAVE platform. 
 
This chapter outlines the optimisation of an effective method for screening the CEBPA gene 
in patient samples using dHPLC and the application of this method to a large, well-
characterised cohort of younger adult AML patients. 
 
64 
 
3.2 Materials and Methods 
 
3.2.1 Optimising PCR protocols 
 
The initial step for detecting CEBPA mutations in patient samples by dHPLC was to obtain 
suitable PCR products from genomic DNA (gDNA) or complementary DNA (cDNA). This 
can be challenging because the GC content of the coding sequence is high at 75%, causing 
secondary structure formation that can interfere with DNA polymerase activity. Issues with 
GC-rich templates can be overcome through the use of PCR additives such as betaine, 
dimethyl sulfoxide (DMSO) and proprietary formulations e.g. PCRx Enhancer System 
(Invitrogen Life Technologies, Paisley, UK). However, for products to be analysed by 
WAVE, the DNA separation cartridge warranty limits the final concentration of betaine to 
2.5M, DMSO to 10% and rules out the use of proprietary formulas. Another consideration 
for WAVE analysis is the preferred use of high-fidelity DNA polymerases that possess both 
5′ to 3′ and 3′ to 5′ exonuclease activity. This is because small errors in DNA replication, 
especially in an early PCR cycle, can lead to spurious heteroduplex formation, which may 
interfere in the detection of heteroduplexes caused by mutations. 
 
In order to look for mutations across the entire coding sequence, three pairs of primers were 
designed  to generate overlapping amplicons called fragments 1, 2 and 3 so that all the 
coding sequence and a portion of the 5′ and 3′ untranslated regions were covered, as shown 
in Figure 3.3 A. The first primer pairs designed were CEBPA/1F and CEBPA/1R, 
CEBPA/2F and CEBPA/2R, and CEBPA/3F and CEBPA/3R for fragments 1, 2 and 3, 
respectively. All primer sequences are given in Appendix Table 1. Initial tests of the primer 
pairs were performed with a non-proof-reading enzyme BIOTAQ DNA Polymerase (Bioline 
Ltd, London, UK) using a standard reaction mix, apart from the addition of reagents to aid 
amplification of GC-rich templates, and standard cycling conditions as detailed in chapter 2. 
These initial PCRs tested various annealing temperatures and the addition of either betaine 
or DMSO at different final concentrations of up to 2.5M and 10% respectively. The aim was 
to generate a single band of the correct size and strong intensity as detected by agarose gel 
electrophoresis and ethidium bromide staining. The initial primer pairs were unsuccessful for 
both fragments 1 and 2 and it was necessary to design further forward and reverse primers 
for each fragment and test these with the original primers using a mix and match approach. 
In addition, touch-down PCR cycling protocols and the use of nested primers in two rounds 
of PCR were also investigated. After satisfactory preliminary primer pair tests using 
BIOTAQ DNA Polymerase were obtained, two DNA polymerases with proof-reading 
capabilities were tried: Optimase Polymerase (Transgenomic Ltd., Glasgow, UK) and 
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Phusion Hot Start High-Fidelity DNA Polymerase (New England Biolabs, Hitchin, UK). 
Once PCR protocols using a proof-reading DNA polymerase had been optimised, Navigator 
software (Transgenomic Ltd., Glasgow, UK) was utilised to generate amplicon-specific 
temperatures at which to analyse the products by dHPLC. For fragment 3, PCR products 
from only a single primer pair were tested by dHPLC, but for fragments 1 and 2 products 
from more than one primer pair were run on the WAVE at their specific analysis 
temperatures. A primer pair was selected that generated a WAVE chromatogram consisting 
of a single, sharp peak using DNA from a cell line with known wild-type (WT) CEBPA, for 
instance HL60 or NB4.  
 
The PCR reaction mix, cycling conditions and WAVE protocols were optimised for each 
fragment and this information is detailed below as well as summarised in Table 3.2. 
Examples of the PCR products generated, as viewed on a 2% agarose gel stained with 
ethidium bromide under UV illumination, are given in Figure 3.3 B. The conditions used 
were the same for gDNA and cDNA. 
 
3.2.2 Detection of mutations in fragment 1 
 
Fragment 1 contains the N-terminus including the translation initiation sites for p42 and p30, 
TAD1 and part of TAD2 (Figure 3.3 A). Amplicons of 548 bp were generated from primers 
CEBPA/1F and CEBPA/1R3 using Phusion Hot Start High-Fidelity DNA Polymerase. The 
standard Phusion Hot Start High-Fidelity DNA Polymerase reaction mix detailed in chapter 
2 (section 2.1.2) was scaled up for a total reaction volume of 25µl and 5% DMSO was 
included. The standard cycling conditions were used with an annealing temperature of 62°C. 
Products were checked on a 2% agarose gel stained with ethidium bromide and, where 
present, were denatured (see section 2.1.4). Three temperatures were selected for WAVE 
analysis: 66.7°C, 68.1°C and 69.9°C. Figure 3.4 shows the sequence-specific melting profile 
across fragment 1 at each specified temperature, as generated by the Navigator software. 
Each WAVE run also contained a PCR product from a cell line with known WT CEBPA, 
such as HL60 or NB4.
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Table 3.2 Summary of optimised CEBPA PCR protocols 
 
Amplicon name Forward primer Reverse primer Size of 
product (bp) 
DNA Polymerase Annealing 
temperature 
Additive 
in PCR 
Fragment 1 CEBPA/1F CEBPA/1R3 548 Phusion HS HF 62°C 5% DMSO 
Fragment 2 CEBPA/2F2 CEBPA/2R 333 BIOTAQ 62°C 5% DMSO 
Fragment 3 CEBPA/3F CEBPA/3R 424 Phusion HS HF 64°C 5% DMSO 
G/T nt 690 
confirmation 
CEBPA/2F2 CEBPA/C693G/ 
R(MM) 
242 BIOTAQ 62°C 5% DMSO 
 
All primer sequences are given in Appendix Table 1. 
Abbreviations: bp, base pairs; PCR, polymerase chain reaction; nt, nucleotide; HS, hot start; HF, high-fidelity; DMSO, dimethyl sulfoxide; MM, mismatch. 
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B 
 
 
 
Figure 3.3 PCR fragments used for the detection of CEBPA mutations  
A. Diagram of the functional domains in CEBPA with the locations of fragments 1, 2 and 3 
for WAVE analysis.  
B. PCR products from 2 DNA samples (1 and 2) for fragments 1 (548 base pairs [bp]), 2 
(333 bp) and 3 (424 bp) and the no template (NT) negative controls, separated by agarose 
gel electrophoresis. The first lane is a DNA size standard ladder (L) with band sizes as 
indicated.  
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3.2.3 Detection of mutations in fragment 2 
 
Fragment 2, 333 bp, was generated from primers CEBPA/2F2 and CEBPA/2R using 
BIOTAQ DNA Polymerase. Although this is a non-proof-reading enzyme, despite extensive 
optimisation it was not possible to obtain products from proof-reading polymerases that gave 
WAVE chromatograms. Nevertheless, heterozygosity for the common G/T SNP at 
nucleotide (nt) 690 present in fragment 2 was easily detected using this enzyme, giving 
confidence that lack of a proof-reading activity did not appear to hamper the detection of 
sequence alterations in this case. The basic BIOTAQ DNA Polymerase reaction mix given in 
chapter 2 (section 2.1.2) was altered to include 5% DMSO and scaled up to a total volume of 
25µl. Cycling conditions were as standard, with an annealing temperature of 62°C. Products 
were checked on a 2% agarose gel stained with ethidium bromide and, where present, were 
denatured. WAVE analysis was performed at 65.5°C, 69.2°C and 70.1°C (Figure 3.4). Each 
WAVE run contained PCR products from a known CEBPA-WT case and one heterozygous 
for the G/T SNP at nt 690 to allow for direct comparison.  
 
3.2.4 Detection of mutations in fragment 3  
 
Fragment 3 covers the DBD and LZD in the C-terminus and amplicons of 424 bp were 
generated from primers CEBPA/3F and CEBPA/3R using Phusion Hot Start High-Fidelity 
DNA Polymerase and 5% DMSO in a total volume of 20µl. The standard Phusion Hot Start 
High-Fidelity DNA Polymerase reaction mix was used, except the addition of 5% DMSO, 
and standard cycling conditions with an annealing temperature of 64°C. Products were 
checked on a 2% agarose gel stained with ethidium bromide and, where present, denatured. 
WAVE analysis was performed at 66.2°C and 68.9°C (Figure 3.4), with each run containing 
a known WT PCR product. 
 
PCR products from all three fragments were analysed by WAVE for all patients in the 
cohort and all WAVE chromatograms were scored by two individuals independently. Those 
resembling the WT control for that fragment were scored as negative. All others were scored 
as positive and investigated further as detailed in sections 3.2.5 and 3.2.6. 
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Figure 3.4 Amplicon melting curve profiles. Melting curve profiles for fragments 1, 2 and 
3 at the temperatures selected for WAVE analysis, displayed as the helical fraction against 
the base position in the PCR product. 
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3.2.5 Confirmation of common polymorphisms 
 
Samples heterozygous for the synonymous G/T SNP at nt 690 were identified by a 
characteristic WAVE chromatogram of fragment 2 (Figure 3.5 A). The presence of this 
polymorphism was confirmed by sequencing and/or by PCR and restriction enzyme 
digestion. For the PCR, a 242 bp amplicon was generated using the screening primer for 
fragment 2, CEBPA/2F2, and primer CEBPA/C693G/R(MM) (Appendix Table 1), which 
introduced a mismatched base at nucleotide 693. PCR products were generated using the 
standard 20µl BIOTAQ DNA Polymerase reaction mix, with the addition of 5% DMSO, and 
cycling conditions, with an annealing temperature of 62°C. The introduced mismatch meant 
that digestion with restriction enzyme SgrAI discriminated between alleles in a nucleotide-
specific manner, giving bands of 22 and 220 bp for G-alleles and a single band of 242 bp for 
the T-alleles (Figure 3.5 B). The H195_P196dup polymorphism in fragment 2 was also 
identified by a characteristic WAVE chromatogram (Figure 3.5 C) and was confirmed by 
sequencing and/or by capillary electrophoresis as detailed in chapter 5. Cases with these 
polymorphisms as the sole change were scored as WT.  
 
3.2.6 Confirmation of CEBPA mutations 
 
All fragments with an abnormal WAVE chromatogram not scored as one of the two 
common polymorphisms were re-amplified using the appropriate screening primers, purified 
using the QIAquick PCR Purification Kit (Qiagen) and sent to UCL Cancer Institute 
sequencing service for direct nucleotide sequencing.  
 
In the case of size changes that were difficult to determine from the sequence due to the 
relative level of the mutant compared to WT sequence or due to a large insertion/deletion, a 
PCR product was generated as before and run on the WAVE at 50
°
C, a non-denaturing 
temperature that separates different species in the sample by size, with smaller fragments 
eluting first. Specific fractions of the eluate were collected, re-amplified and sequenced. 
Fraction collection was also performed for samples with low level mutations that could not 
be identified from direct sequencing but that gave clear heteroduplex peaks. In these cases 
the analysis temperature at which the heteroduplex species was most clearly visible in the 
WAVE chromatogram was selected for the fraction collection run and heteroduplex peaks 
were collected, re-amplified and sequenced. 
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Figure 3.5 Identification and confirmation of common CEBPA polymorphisms 
A. Characteristic fragment 2 WAVE chromatograms of a case that is heterozygous (G/T) for 
the synonymous SNP at nucleotide (nt) 690. B. Genotyping of G/T alleles at nt 690 by 
amplification with a mismatch primer designed to introduce an SgrAI digestion site in G-
alleles but not T-alleles. The result of the SgrAI digest is shown as visualised on a 2% 
agarose gel stained with ethidium bromide. C. Characteristic fragment 2 WAVE 
chromatograms of a case with the H195_P196dup polymorphism.  
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3.2.7 Detection of homozygous CEBPA mutations 
 
Homozygous CEBPA mutations have been described in the literature, however these may be 
harder to detect using dHPLC as the WAVE platform relies upon the formation of 
heteroduplexes of WT and mutated PCR products. If there were only a few contaminating 
normal cells or non-mutated leukaemic cells in the sample, then a homozygous mutation 
may be missed. In order to detect homozygous mutations, PCR products were generated 
using the same PCR protocols given above from both patient samples and NB4 cell line 
DNA, which is WT for CEBPA mutations. The products were mixed in equal quantities 
before denaturing and WAVE analysis at the appropriate temperatures. All fragments with 
abnormal chromatograms were re-amplified using the appropriate primers and sequenced. 
This additional screen was only performed for fragments 1 and 3, containing the mutation 
hotspots, of samples from normal karyotype patients scored as having neither a mutation nor 
a polymorphism. Patients with a heterozygous mutation or polymorphism were assumed not 
to have uniparental disomy at the CEBPA locus. 
 
 
3.3 Results 
 
DNA (gDNA = 1382, cDNA = 45) was available from peripheral blood or bone marrow 
samples taken at diagnosis from 1427 non-APL patients entered into the United Kingdom 
Medical Research Council AML 10 (n = 510) or AML 12 (n = 917) trials between 1988 and 
2002. Ethical approval for the trials and tissue collection for research was obtained from the 
Multi-Centre Research Committee of Wales and informed consent obtained in accordance 
with the Declaration of Helsinki. The clinical and molecular characteristics of the cohort are 
described in detail in chapter 4. 
 
Due to the large number of patients in the study, the cohort was split into two groups for 
CEBPA mutation detection: cases with a normal karyotype (n = 583) and those with an 
abnormal or unknown karyotype (n = 844). I am very grateful to Kenneth Koo who 
performed PCRs, WAVE analysis and mutation confirmation for the majority of the latter 
group. 
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3.3.1 Detection of CEBPA sequence alterations by WAVE analysis 
 
Of the 1427 patients investigated, 469 (33%) had one or more fragments with abnormal 
WAVE chromatograms. In 382 cases, a characteristic fragment 2 pattern indicated one of the 
two common polymorphisms (G/T at nt 690 and H195_P196dup), which were confirmed as 
detailed in section 3.3.2. In a further 12 cases, direct nucleotide sequencing showed either a 
synonymous coding change (n = 5) or a substitution in the 3′ untranslated region (n = 7). All 
patients in whom these were the only changes were scored as CEBPA-WT.  
 
In the remaining 107 (7%) patients, at least one coding change predicted to be non-
synonymous (CEBPA-mutant) was identified and, in the case of most mutations (85%), it 
was possible to determine the change by direct nucleotide sequencing. There were 23 
mutations (14%) where it was difficult to identify the nucleotide change from the direct 
sequencing due to either a low proportion of mutant or to a large size change. The fraction 
collection facility on the WAVE was used in these cases to either purify the heteroduplex 
species at a denaturing temperature (n = 13) or to separate differently sized fragments at a 
non-denaturing temperature (n = 10). The remaining mutations (n = 2) were determined by 
sequencing cloned PCR products (see chapter 5 for cloning method). Mutations were 
detected in all three fragments and included point mutations and size changes. Figure 3.6 A 
and B show representative WAVE chromatograms from typical heterozygous mutations of 
these types. Additional screening for homozygous mutations by dHPLC of mixed patient 
and known WT PCR products from fragments 1 and 3 was performed in 373 of the 393 
(95%) patients with a normal karyotype lacking either a heterozygous mutation or 
polymorphism. PCR products for mixing could not be obtained for the remaining 20 
patients. Homozygous mutations were detected in three patients that had not been seen in 
analysis of their unmixed fragments, an example of which is shown in Figure 3.6 C. In one 
case the WAVE chromatogram indicated a low level mutant (Figure 3.6 D) which could 
only be detected in the sequencing chromatogram after fraction collection (Figure 3.6 E). In 
31 of 34 (91%) cases where a mutation was only detected in either fragment 1 or 3, the other 
fragment was sequenced, regardless of the WAVE analysis result. No additional mutations 
were detected. In the remaining three cases either further PCR product could not be obtained 
for sequencing or the sequencing reaction failed. 
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Figure 3.6 Detection of CEBPA mutations by WAVE analysis (A to C) 
A to C. Representative WAVE chromatograms of patient samples normalised and compared 
to that of a known wild-type (WT) control. A. A 1 base pair deletion in fragment 1. B. A 
heterozygous point mutation in fragment 2. C. A homozygous point mutation in fragment 3, 
only detected when patient PCR product was mixed with WT PCR product prior to WAVE 
analysis and not detected in un-mixed sample.  
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Figure 3.6 continued (D and E) 
D. WAVE chromatograms of fragment 1 from patient 23 normalised and compared to that of 
a known WT control with a low level mutant indicated by the arrows. E. Direct sequencing 
of the fragment from patient 23 did not show a mutation. The fraction collection facility of 
the WAVE was therefore used to purify the heteroduplex, which was amplified and re-
sequencing showed a 7 base pair deletion. The relevant section of the sequencing 
chromatograms is shown, with Nt indicating the nucleotides displayed, numbered from the 
p42 ATG. 
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3.3.2 Confirmation of common CEBPA polymorphisms 
 
There were 316 (22%) cases which were scored as heterozygous for the G/T SNP at nt 690 
from the characteristic WAVE chromatogram of fragment 2 (Figure 3.5 A). This was 
confirmed in 98% of these cases by an alternative method, 13 by direct nucleotide 
sequencing, 288 by PCR with a mismatch primer and SgrAI digestion (Figure 3.5 B) and 9 
cases by both techniques. PCR product either for sequencing or for SgrAI digestion could 
not be obtained in the 6 patients where confirmation was not performed. The incidence of 
heterozygotes for this SNP did not differ between CEBPA-WT and CEBPA-mutant cases 
(288 of 1320 [22%] vs. 28 of 107 [26%], P = .30, Pearson’s Chi-square). The 
H195_P196dup polymorphism was present in 68 (5%) patients, as scored from the WAVE 
chromatogram (Figure 3.5 C). This was confirmed in 97% of these cases by sequencing (n = 
1), fragment analysis of labelled PCR products (n = 57, described in detail in chapter 5) or 
by both methods (n = 8). PCR product could not be obtained in the two cases where 
confirmation was not performed. The incidence of H195_P196dup was 64 of 1320 (5%) in 
CEBPA-WT and 4 of 107 (4%) in CEBPA-mutant cases, which was not significantly 
different (P = .18, Fisher’s exact test). There were two cases who were both G/T 
heterozygotes at nt 690 and H195_P196dup. 
 
3.3.3 Characteristics of CEBPA mutations 
 
Overall, of the 107 CEBPA-mutant cases, 48 (45%) were CEBPA-single and 59 (55%) were 
CEBPA-double. A complete list of all sequence changes, apart from the two common 
polymorphisms, is given in Appendix Table 2 along with the classification of the cases as 
CEBPA-single, CEBPA-double or SNP. One case (patient 66) had two heterozygous 
mutations on the same allele, as determined by cloning of PCR products (see chapter 5 for 
cloning method), and so was scored as CEBPA-single. One further case (patient 4) had two 
mutations each of approximately an intermediate level on different alleles, however the 
sequencing chromatogram showed WT allele present at about the 50% level. Consequently it 
was judged more likely that the mutations were in different cells than present as compound 
heterozygote frame-shifting N-terminal mutations in the same cell, a situation not described 
in the literature, and this case was classified as CEBPA-single. Cases with a homozygous 
mutation were scored as CEBPA-double. 
 
There were notable differences between CEBPA-single and CEBPA-double cases in terms of 
the types and locations of mutations detected. The location s of all the mutations are shown 
in Figure 3.7 and a summary of this information is given in Table 3.3. Mutations in CEBPA-
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single patients were distributed across the entire gene: 28 patients (58%) had classical N- or 
C-terminal hotspot mutations, 12 patients (25%) had changes in the middle region (between 
the p30 start codon and the DBD) that were predicted to cause non-functional proteins 
through frame-shifting or nonsense mutations and eight patients (17%) had changes of 
unknown consequence in the middle region, such as in-frame insertions/deletions and 
missense mutations. By contrast, mutations in CEBPA-double patients clustered quite tightly 
in the N- and C-terminal hotspots. Most CEBPA-double cases (83%) had both an out-of-
frame insertion in the N-terminus in combination with a DBD or LZD (bZIP) mutation in the 
C-terminus, and a further four patients (7%) had an N-terminal change with a nonsense 
mutation or frame-shift alteration in the middle region. Assuming that these mutations were 
on different alleles, they were all predicted to cause p30 translation from one allele and a 
non-functional or truncated protein from the other. Of the remaining six CEBPA-double 
patients, two had two different bZIP mutations, one had two changes in the middle region 
and three had homozygous mutations in the C-terminus. 
 
Samples taken during complete remission (CR) were available from nine CEBPA-mutant 
cases, seven CEBPA-double including one homozygous mutant and two CEBPA-single 
patients, as indicated in Appendix Table 2. No CEBPA mutations were detected in any of 
these samples, indicating that they were acquired rather than germline. 
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Figure 3.7 Location of all CEBPA mutations detected. Location and type of mutations detected in patients that were either CEBPA-single or CEBPA-
double mutant-positive. Translation initiation sites for the p42 and p30 isoforms are indicated as well as the major functional domains: transactivation 
domains 1 and 2 (TAD1 and TAD2), DNA-binding domain (DBD) and leucine zipper domain (LZD).   
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Table 3.3 Summary of CEBPA mutations detected 
  Mutation 1 Mutation 2   
  N-terminus Middle C-terminus Middle C-terminus   
  1st to 2nd start sites 2nd start site to DBD DBD and LZD 2nd start site to DBD DBD and LZD No. of  
  AA 1-120 AA 121-277 AA 278-358 AA 121-277 AA 278-358 patients 
Single: Out-of-frame ins/del         11 
  Nonsense         1 
    Out-of-frame ins/del      11 
    Nonsense       1 
    In-frame ins/del       3 
    Missense       5 
      Out-of-frame ins/del     3 
      In-frame ins/del     8 
      Missense     5 
Total        48 
Double: Out-of-frame ins/del       In-frame ins/del 46 
  Out-of-frame ins/del       Out-of-frame ins/del 1 
  Out-of-frame ins/del       Missense 2 
  Out-of-frame ins/del     Out-of-frame ins/del  3 
  Out-of-frame ins/del     Nonsense   1 
    Out-of-frame ins/del   Missense  1 
      Out-of-frame ins/del   In-frame ins/del 1 
      In-frame ins/del   Missense 1 
      Missense-HOM     2 
      In-frame ins/del-HOM    1 
Total           59 
Unless indicated otherwise, all mutations were heterozygous. Abbreviations: DBD, DNA-binding domain; LZD, leucine zipper domain; AA, amino acid; ins, insertion; del, 
deletion; HOM, homozygous mutation. 
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3.4 Discussion 
 
There are a number of recurrent gene mutations that have been identified in AML and 
effective methods to detect these markers in patient samples are required. The data presented 
in this chapter shows the development of a method to screen for CEBPA mutations and the 
application of this method to a large cohort of young adult AML patients. PCR amplification 
of three overlapping fragments and analysis by dHPLC on the WAVE platform was selected 
because it enabled sensitive detection of both point mutations and size changes in patient 
samples with minimal processing of PCR products. The PCR protocols required extensive 
optimisation due to the GC-rich nature of CEBPA, however a method was developed that 
was practical for a large number of samples. 
 
In total, of the 1427 cases analysed by dHPLC on the WAVE platform, 107 (7%) patients 
had one or more CEBPA mutation(s). This incidence is significantly lower than that reported 
in 10 other studies combined together (315 of 3184, 10%, P = .009 Pearson’s Chi-square) 
(Pabst et al, 2001b;Snaddon et al, 2003;Frohling et al, 2004;Bienz et al, 2005;Marcucci et 
al, 2008;Wouters et al, 2009;Pabst et al, 2009;Hou et al, 2009;Renneville et al, 
2009a;Dufour et al, 2010). However, several of these studies only looked at cases with 
normal karyotypes, where CEBPA mutations are more common (see chapter 4). When 
compared to those studies that included all karyotypes (including APL), our incidence is not 
different (192 of 2140, 9%, P = .120 Pearson’s Chi-square) (Pabst et al, 2001b;Wouters et 
al, 2009;Pabst et al, 2009;Hou et al, 2009;Renneville et al, 2009a). The results obtained 
indicated that the selected method was appropriate and as efficient at detecting CEBPA 
mutations as publications using other methods, including sequencing. Further evidence in 
support of this was that no additional mutations were found when direct sequencing was 
performed on the other end of the gene in 31 cases scored as CEBPA-single on WAVE 
analysis with a fragment 1 or 3 mutation. Of note, it was found that running each fragment at 
more than one temperature was required, as indicated by the melting profiles of the 
amplicons. Although heteroduplex peaks were visible at all analysis temperatures for some 
sequence changes (Figure 3.5 C), there were cases where the heteroduplex was only visible 
at one of the temperatures (Figure 3.6 B). 
 
The frequency of homozygous mutations in this cohort (3 of 1427, 0.2%) is equivalent to 
that reported in other studies (6 of 2641, 0.2%) (Pabst et al, 2001b;Snaddon et al, 
2003;Frohling et al, 2004;Bienz et al, 2005;Marcucci et al, 2008;Wouters et al, 2009;Pabst 
et al, 2009;Renneville et al, 2009a;Dufour et al, 2010). Although the WAVE platform relies 
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upon heteroduplex formation for mutation detection, past experience in the department has 
shown that homozygous mutations in other genes are usually still detected by dHPLC of un-
mixed PCR products (Mead et al, 2007), due to a low proportion of either normal or non-
mutated leukaemic cells in the sample. However, this was not the case in this study as the 
three patients with homozygous CEBPA mutations were only detected through mixing of 
patient and WT PCR products (Figure 3.6 C). The additional screen was only performed in 
fragments 1 and 3 of normal karyotype cases without a heterozygous mutation or 
polymorphism. Mutations are most commonly associated with a normal karyotype (chapter 
4) and of the 6 cases of homozygous mutations reported in the literature, none have been in 
fragment 2, therefore it was considered appropriate not to include this region in the 
additional screen. It is possible that homozygous mutations in other cases may have been 
missed, but it is likely to be a very limited number as the reported incidence overall is so low 
(0.2%). Of the three cases with a homozygous CEBPA mutation, two had data available 
from genotyping arrays (Gupta et al, 2008). Both of these cases were found to have 
uniparental disomy on chromosome 19 at the CEBPA locus, in line with published data on 
the mechanism of homozygous mutation acquisition in this gene (Fitzgibbon et al, 
2005;Wouters et al, 2007c). 
 
In addition to detecting CEBPA mutations, WAVE analysis also identified the two common 
polymorphisms (rs34529039 and H195_P196dup) at similar incidences to those previously 
reported for other European cohorts (NCBI dbSNP) (Wouters et al, 2007b). The WAVE 
chromatogram for both of these polymorphisms was highly characteristic and, where 
confirmation was performed (376 of 382, 98%), results were concordant. The incidence of 
either of these polymorphisms did not differ between CEBPA-WT and CEBPA-mutant cases, 
although Schnittger et al (2011a) found no co-incidence of an H195_P196dup and a CEBPA 
mutation in two separate cohorts of patients totalling 2266 cases and suggested that the 
H195_P196dup may have a protective effect against the acquisition of CEBPA mutations. 
 
Of the 107 CEBPA-mutant cases detected in this study, 48 (45%) were CEBPA-single and 
59 (55%) were CEBPA-double, giving a ratio of CEBPA-single to CEBPA-double cases of 
1:1.2. As discussed previously, the reported ratio of CEBPA-single to CEBPA-double cases 
has varied widely across 10 different studies at between 1:2.1 and 6.7:1 (Pabst et al, 
2001b;Snaddon et al, 2003;Frohling et al, 2004;Bienz et al, 2005;Marcucci et al, 
2008;Wouters et al, 2009;Pabst et al, 2009;Hou et al, 2009;Renneville et al, 2009a;Dufour 
et al, 2010). Overall, however, the average proportion of CEBPA-mutant cases that were 
CEBPA-single or CEBPA-double was 57% and 43%, respectively (1.3:1). This is broadly in 
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agreement with the data from the current cohort, and indicates that CEBPA-mutant cases are 
split roughly equally between CEBPA-single and CEBPA-double. 
 
There were striking differences noticed between CEBPA-single and CEBPA-double cases in 
terms of the types and locations of mutations detected (Figure 3.7). Of the CEBPA-double 
cases, 83% had both a classical frame-shifting size change in the N-terminus in combination 
with a classical mutation in the C-terminus (Table 3.3), predicted to cause p30 isoform 
expression from one allele and interfere with DNA binding or dimerisation of the protein 
from the other allele. This predominance of the “classic” CEBPA mutations is in line with 
data from other reported cohorts. However, while 58% of the CEBPA-single cases had one 
of either of these classic mutations or a nonsense mutation in the N-terminal, also predicted 
to cause p30 isoform expression, there were 20 cases with a non-classical mutation in the 
middle of the gene (Table 3.3). Of these, 12 were either frame-shifting or caused a stop 
codon, leaving 8 cases with an in-frame size change or missense mutation of unknown 
consequence. It is of note that a significant minority of CEBPA-mutant cases (20 of 107, 
19%) had non-classical mutations, and the implications of this will be investigated further in 
chapter 6. 
 
Germline mutations of CEBPA have previously been reported in rare pedigrees of patients 
with familial AML, although there is some data to suggest that the incidence of this may be 
more common than first assumed (Pabst et al, 2008). In this study, no CEBPA mutations 
were detected in samples taken during CR from patients who were CEBPA-mutant at 
diagnosis. However, it should be noted that remission material was only available from 9 of 
107 (8%) CEBPA-mutant cases in the cohort. 
 
The data presented in this chapter therefore shows that analysis of PCR products on the 
WAVE platform is a robust technique for the detection of mutations in the CEBPA gene in a 
large cohort of patient samples. Mutations were found in all fragments and of all different 
types, including point mutations and homozygous mutations, and at a frequency that is 
comparable to other studies. The method used in this chapter for further screening of 
homozygous mutations in a selected cohort only was appropriate for this large retrospective 
study. However, if samples were being screened prospectively then this should be extended 
to all cases and fragments to ensure that mutations are not missed. The cohort of patients 
studied here is large and well-characterised, both in terms of other molecular markers and in 
the availability of clinical data, including long follow-up. Determining the CEBPA mutation 
status in these patients enabled a thorough study of the characteristics of CEBPA-mutant 
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AML, the impact mutations have on patient outcome and how this is affected by the 
presence, or lack, of other gene mutations, and these topics are the subject of chapter 4. 
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CHAPTER 4: PROGNOSTIC IMPACT OF CEBPA MUTATIONS 
IN YOUNG ADULT PATIENTS 
 
4.1 Introduction 
 
CEBPA mutations are commonly acquired in AML patients, as described in chapter 3, and 
are known to be associated with certain clinical characteristics and to impact on patient 
outcome. 
 
4.1.1 Clinical characteristics of AML patients with CEBPA mutations 
 
A number of different groups have investigated the characteristics of CEBPA-mutant AML 
through screening for mutations in cohorts of patients, and these are summarised in Table 
4.1. There are several features found to be associated with CEBPA-mutant AML that are in 
common between the different studies. For instance, where FAB type has been studied, all 
groups have reported an association with the M1 and M2 subtypes. In addition, all groups 
have found mutations to be more frequent in intermediate-risk karyotype patients, the largest 
proportion of whom have an NK. Indeed, several studies have focussed entirely on CEBPA 
mutations in NK AML, and when these studies are combined the incidence of mutations in 
this subgroup is 266 of 2127 (13%) (Frohling et al, 2004;Bienz et al, 2005;Marcucci et al, 
2008;Dufour et al, 2010;Taskesen et al, 2011), which is significantly higher than that found 
in 8 studies where karyotype was not selected (245 of 2528, 10%, P = .002 Pearson’s Chi-
square) (Pabst et al, 2001b;Preudhomme et al, 2002;Lin et al, 2005;Shih et al, 2006;Wouters 
et al, 2009;Pabst et al, 2009;Hou et al, 2009;Renneville et al, 2009a). CEBPA mutations 
have also been specifically associated with deletions of chromosome 9q not in a complex 
karyotype (Frohling et al, 2005). Most groups have also reported no difference in the age, 
sex or presenting white blood cell count (WBC) of CEBPA-mutant patients compared to 
CEBPA-WT. This broadly remained the same when CEBPA-single and CEBPA-double 
cases were analysed separately, apart from single reports that CEBPA-single cases were 
more likely to be female (Dufour et al, 2010) and CEBPA-double cases to be of lower age 
(Taskesen et al, 2011) mutated patients. 
 
While these associations have been consistently noted across studies, other characteristics 
have been more variably reported, in particular the coincidence of CEBPA mutations with 
other molecular markers. When comparing patients with CEBPA mutations to those without, 
several studies reported no difference in the incidence of FLT3/ITDs between the two groups 
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(Preudhomme et al, 2002;Lin et al, 2005;Shih et al, 2006;Renneville et al, 2009a), whereas 
others reported a lower incidence of FLT3/ITDs in CEBPA-mutant AML (Barjesteh van 
Waalwijk van Doorn-Khosrovani et al, 2003;Frohling et al, 2004;Marcucci et al, 2008). In 
addition, a lower incidence of NPM1 mutations in CEBPA-mutant patients compared to 
CEBPA-WT has also been described (Marcucci et al, 2008;Pabst et al, 2009;Renneville et 
al, 2009a). Interestingly, differences in the coincidence of CEBPA mutations with other 
molecular markers are more striking in studies where CEBPA-single and CEBPA-double 
patients have been analysed separately. In comparison to CEBPA-singles, CEBPA-double 
cases have consistently fewer NPM1 mutations and FLT3/ITDs (Wouters et al, 2009;Hou et 
al, 2009;Dufour et al, 2010;Taskesen et al, 2011). 
 
4.1.2 Impact of CEBPA mutations on response to therapy and patient outcome in AML 
 
Over the last decade, there have been numerous studies on the clinical impact of CEBPA 
mutations in AML and these are summarised in Table 4.2. Initial studies were performed in 
relatively small cohorts and, at the time at which the work in this thesis was commenced, 
there were 4 reports, together describing outcome in 72 CEBPA-mutant cases of 625 patients 
studied (12%) (Preudhomme et al, 2002;Barjesteh van Waalwijk van Doorn-Khosrovani et 
al, 2003;Frohling et al, 2004;Bienz et al, 2005). By 2009, 2 further studies of NK-only 
patients had been published (Schlenk et al, 2008;Marcucci et al, 2008), the largest of which 
had screened 509 patients for CEBPA mutations. In terms of complete remission (CR) rate, 
all of these studies found no impact of a CEBPA mutation, apart from Schlenk et al (2008) 
who reported an increase in the CR rate in CEBPA-mutant cases. However, all reported that 
CEBPA-mutant patients had a significantly better outcome than CEBPA-WT, both in terms 
of overall survival (OS) and of endpoints reflecting relapse rates such as event-free survival 
(EFS), disease-free survival (DFS) or relapse-free survival (RFS) depending on the study. 
All groups found that mutated CEBPA was an independent favourable factor for outcome in 
multivariate analyses. 
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Table 4.1 Studies reported on the characteristics of AML patients with CEBPA mutations 
 
Reference Total no. 
in study 
Median age, 
years (range) 
No. mutants 
(% of total) 
Cytogenetics † FAB type † Clinical 
Characteristics and 
Immunophenotype † 
Co-incidence with 
other mutations † 
Pabst et al, 
2001b 
137 NR 81 (6) 
Increased: 
NK 
Increased: 
M1 and M2 
NR NR 
Preudhomme  
et al, 2002 
135 45 (15-65) 15 (11) 
All intermediate risk 
(P=.06) 
Increased: 
M1 (P=.02) 
No difference: Age, sex and 
WBC 
No difference: 
FLT3/ITD 
Barjesteh et al, 
2003 
277 43 (15-60) 12 (4) 
All intermediate risk 92% M1 or M2 No difference: 
Age, sex and WBC 
Only 1 of 12 FLT3/ITD 
mutant 
Frohling et al, 
2004 
236 
NK only 
47 (16-60) 332 (14) N/A 72% M1 or M2 Increased: Hb (P=.01) 
% PB blasts (P=.008) 
Decreased: Plt (P=.04) 
No difference: Age, sex, WBC 
Decreased: FLT3/ITD or 
D835 or both (P=.01) 
Lin et al, 
2005 
104 46 (1-85) 16 (15) Increased: 
NK 
Intermediate risk 
(P=.004) 
Increased:  
M1 and M2  
(P = 0.001) 
Increased: CD7 (P<.001), CD15 
(P=.005), CD34 (P=.008), 
HLA-DR (P=.034), Hb 
(P=.036) 
No difference: Age, sex, WBC 
No difference: FLT3/ITD 
Bienz et al, 
2005 
67 
NK only 
49 (18-71) 12 (18) N/A Increased: 
M1 and M2 
Increased: CD7 (P=.0023) 
Decreased: LDH (P=.015), 
WBC (P=.18) 
No difference: Age and sex 
NR 
Shih et al, 
2006 
149 (0.4-74) 22 (15) Increased: 
Intermediate risk 
(P=.002) 
Increased: 
 M1 and M2 
(P=.022) 
No difference: 
Age, sex, Hb, and WBC 
No difference: FLT3/ITD, 
FLT3/TKD, NRAS, KRAS 
Marcucci et al, 
2008 
175 
NK only 
(18-59) 32 (18) N/A NR Increased: Hb (P=.02) 
Decreased: Plt (P=.009) 
No difference: Age, sex and 
WBC 
Decreased:  
NPM1 (P=.0001) 
FLT3/ITD (P=.07) 
No difference: FLT3/TKD 
Wouters et al, 
2009 * 
598 46.5 (15-77) 41 (7) 
13 Single 
28 Double 
Increased: 
Intermediate risk 
Increased: 
M1 and M2 
No difference: Age, sex, WBC Double vs. Single  
Decreased: 
NPM1 (P=.026), 
FLT3/ITD (P=.081), 
FLT3/TKD (P=.094) 
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Table 4.1 Continued 
 
Reference Total no. 
in study 
Median age, 
years (range) 
No. mutants 
(% of total) 
Cytogenetics FAB type Clinical 
Characteristics and 
Immunophenotype 
Co-incidence with 
other mutations 
Pabst et al, 
2009 * 
224 53 (<61) 19 (8) 
7 Single 
12 Double 
Increased: 
Intermediate risk 
All M1 or M2 Decreased: WBC (P=.012), 
LDH (P=.032) 
No difference: Age, sex 
Decreased: 
FLT3/ITD (P=.023), NPM1 
(P=.008) 
Renneville et al, 
2009a 
638 (16-70) 53 (8) Increased: 
Intermediate risk 
(P=.05), NK (P=.01) 
NR Increased: Males (P=.06) 
No difference: Age, WBC 
Decreased:  
NPM1 (P=.008) 
No difference: FLT3/ITD 
Hou et al, 
2009 * 
543 NR 71 (13) 
24 Single 
47 Double 
Single vs. Double 
No difference 
Single vs. Double 
No difference 
Single vs. Double 
Increased: CD56 (P=.038) 
Decreased: HLA-DR 
(P=.0014), CD7 (P=.006), 
CD15 (P<.0001) 
No difference: Age, sex, WBC, 
LDH 
Single vs. Double 
Increased: 
NPM1 (P=.0109), 
FLT3/ITD (21% vs. 11%, 
N.S.) 
Dufour et al, 
2010 * 
467 
NK only 
61 (17-85) 38 (8) 
18 Single 
20 Double 
N/A Increased: 
M1 and M2 
(P=.009) 
Across WT, Single and Double 
No difference: Age, WBC 
Singles – Increased females 
(P=.006) 
Doubles – Increased Hb 
(P=.035) 
Double vs. Single  
Decreased: 
NPM1 (P=.002), 
FLT3/ITD (P=.007) 
Taskesen et al, 
2011 * 
1182 
NK only 
(16-60) 151 (13) 
60 Single 
91 Double 
N/A NR No difference: Age, sex, WBC 
Double vs. WT 
Decreased: Age (P=.04), Plt 
(P<.0001) 
Double vs. Single 
Decreased: 
NPM1 (P<.0001), 
FLT3/ITD (P<.001) 
Single vs. WT 
Decreased: NPM1 (P=.018) 
† All comparisons are made for CEBPA-mutant vs. CEBPA-wild-type (WT) cases. 1 Two cases with synonymous point mutations alone have been excluded from the 
CEBPA-mutant cases given in this report. 2 Three cases with H195_P196dup alone have been excluded from the CEBPA-mutant cases given in the article. *In these reports, 
characteristics for CEBPA-single and CEBPA-double cases were available separately. Characteristics in the table are still given as CEBPA-mutant versus CEBPA-wild-type 
(WT) but where differences between CEBPA-single (Single) and CEBPA-double (Double) cases were reported these are indicated specifically. Abbreviations: NK, normal 
karyotype; NR, not reported; N/A, not applicable; FAB, French-American-British; Hb, haemoglobin; WBC, white blood cell count; PB, peripheral blood; LDH, lactate 
dehydrogenase; Plt, platelets; N.S., not significant 
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The first analysis of CEBPA-single and CEBPA-double patients separately was published by 
Wouters et al in 2009. They obtained gene expression profiles (GEP) on 524 AML cases 
with known CEBPA mutant status, including 12 CEBPA-single and 26 CEBPA-double cases, 
and found that, whilst they could derive a signature for cases with CEBPA mutations, it had 
limited ability to detect all CEBPA-mutant cases. However, the misclassification was found 
to be of CEBPA-single cases, with CEBPA-double cases predicted accurately. In their 
outcome analysis, as previously reported, CEBPA-mutant cases had an improved clinical 
outcome over CEBPA-WT cases. However, the heterogeneity in the GEP between CEBPA-
single and CEBPA-double patients led them to analyse these groups separately and they 
found that the benefit in outcome was restricted to CEBPA-double patients only, with a 
CEBPA-single mutant having no impact. Whilst this heterogeneity in outcome between 
CEBPA-single and CEBPA-double cases was replicated in another smaller cohort of 224 
patients (Pabst et al, 2009), a larger study of 638 patients enrolled in the Acute Leukaemia 
French Association trials (ALFA) (Renneville et al, 2009a) found little difference between 
29 CEBPA-single and 24 CEBPA-double patients in terms of outcome. No significant 
differences were found for CR rate, RFS or DFS and only a trend for better OS in CEBPA-
double patients (P=.09), with no significance found in multivariate analysis. Therefore, 
numerous questions remained regarding the impact of CEBPA mutations in AML and 
whether one or two mutations were necessary to see a clinical benefit. 
 
4.1.3 Factors modifying the impact of CEBPA mutations in AML 
 
There are a number of other factors that are known to affect patient outcome in AML 
(chapter 1), which need to be considered when investigating the impact of CEBPA 
mutations. The effect of karyotype in CEBPA-mutant AML has not been well studied, in part 
because a large number of groups have focussed solely on NK patients, and also because 
mutations tend to occur only in either NK patients or those with an AK that is neither 
adverse nor favourable risk. One group has reported that the benefit of a CEBPA mutation is 
limited to those with an NK and that CEBPA-mutant patients with an AK should be 
considered as intermediate rather than favourable risk (Renneville et al, 2009a), however, 
this has not been confirmed in other cohorts. 
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Table 4.2 Studies reported on the impact of CEBPA mutations on clinical outcome in AML 
 
 Cohort  CR rate Outcome compared to CEBPA-WT  
Reference 
Total no.  
in study 
Median age, 
years (range) 
CEBPA 
Mutant 
n (%) 
Mutant  
vs. WT 
Single vs. 
Double 
CEBPA 
mutant 
CEBPA 
single 
CEBPA 
double 
Overall 
impact on 
outcome 
Preudhomme  
et al, 
2002 
135 45 (15-65) 15 (11) 
7 Single 
8 Double 
No 
difference 
NR Increased: 
OS (P=.04), EFS 
(P=.04), DFS (P=.05) 
Multivariate: 
Increased OS (P=.05), 
DFS (P=.05) 
NR NR Mutant 
favourable 
Barjesteh et al, 
2003 
1187 
IK only 
43 (15-60) 12 (6) 
12 Double 
No 
difference 
NR Increased: 
OS (P=.03), EFS 
(P=.02) 
Multivariate: 
Increased OS (P=.04), 
EFS (P=.03) 
NR NR Mutant 
favourable 
Frohling et al, 
2004 
236 
NK only 
47 (16-60) 233 (14) 
18 Single 
15 Double 
No 
difference 
NR Increased: 
Remission duration 
(P=.01), OS (P=.05) 
Multivariate for WT: 
Decreased remission 
duration (P=.01), 
OS (P=.04) 
NR NR Mutant 
favourable 
Bienz et al, 
2005 
67 
NK only 
49 (18-71) 12 (18) 
4 Single 
8 Double 
No 
difference 
NR Increased: 
OS (P=.0007), 
DFS (P=.0017) 
Multivariate: 
Increased  
OS (P=.0005), 
DFS (P=.0012) 
NR NR Mutant 
favourable 
Schlenk et al, 
2008 
509 
NK only 
348 (16-60) 67 (13) 
Single/ 
Double NR 
Increased NR Increased: 
OS (P<.0014), 
RFS (P<.0014) 
Multivariate: 
Increased OS, RFS 
NR NR Mutant 
favourable 
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Table 4.2 Continued 
 
 Cohort  CR rate Outcome compared to CEBPA-WT  
Reference 
Total no.  
in study 
Median age, 
years (range) 
CEBPA 
Mutant 
n (%) 
Mutant  
vs. WT 
Single vs. 
Double 
CEBPA 
mutant 
CEBPA 
single 
CEBPA 
double 
Overall 
impact on 
outcome 
Marcucci et al, 
2008 
175 
NK only 
NR (18-59) 32 (18) 
18 Single 
14 Double 
No 
difference 
NR Increased: 
EFS (P=.017), 
DFS (P=.075). 
No SD in OS (P=.10) 
Multivariate: 
Increased 
EFS (P=.007), 
DFS (P=.014), 
OS (P<.001) 
NR NR Mutant 
favourable 
Wouters et al, 
2009 
598 46.5 (15-77) 41 (7) 
13 Single 
28 Double 
NR NR Increased: 
OS (P=.027), EFS 
Multivariate: 
No difference for 
OS (P=.65), 
EFS (P=.16) 
Increased: 
OS (P=.004), 
EFS (P=.005) 
Multivariate: 
Increased 
OS (P<.001), 
EFS (P<.001) 
Double 
favourable 
Pabst et al, 
2009 
224 53 (<61) 19 (8) 
7 Single 
12 Double 
Increased No 
difference 
NR No difference: 
OS, DFS 
Multivariate: 
No difference for 
OS (P=.52), 
DFS (P=.28) 
Increased (vs. Single): 
OS (P=.006), 
DFS (P.013) 
Multivariate (vs. 
WT): 
Increased 
OS (P<.001), 
DFS (P<.001) 
Double 
favourable 
Renneville 
et al, 
2009a 
 
638 NR (16-70) 53 (8) 
29 Single 
24 Double 
No 
difference 
No 
difference 
Increased: 
RFS (P=.04), 
DFS (P=.03). No SD 
for OS (P=.11) 
Single vs. Double: 
Decreased OS (P=.09) 
No difference: RFS, DFS 
Mutant 
favourable in 
NK without 
FLT3/ITD 
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Table 4.2 Continued 
 Cohort  CR rate Outcome compared to CEBPA-WT  
Reference 
Total no.  
in study 
Median age, 
years (range) 
CEBPA 
Mutant 
n (%) 
Mutant  
vs. WT 
Single vs. 
Double 
CEBPA 
mutant 
CEBPA 
single 
CEBPA 
double 
Overall 
impact on 
outcome 
Hou et al, 
2009 
5397 NR 60 (15) 
16 Single 
44 Double 
NR Decreased 
(P = .0051) 
NR Multivariate: 
No difference for 
OS (P=.227), 
DFS (P=.629) 
Increased: 
OS (P=.013), 
DFS (P=.016) 
Multivariate: 
Increased 
OS (P=.004), 
DFS (P=.001) 
Double 
favourable 
Dufour et al, 
2010 
 
467 
NK only 
61 (17-85) 
 
38 (8) 
18 Single 
20 Double 
Single vs. WT: 
No difference 
Double vs. WT: 
Increased (P=.071) 
Increased: 
OS (P=.028) 
No difference: 
OS (P=.506), 
EFS (P=.771), 
RFS (P=.685) 
Multivariate: 
No difference for 
OS (P=.433), 
EFS (P=.736) 
Increased: 
OS (P=.018), 
EFS (P=.064). 
No difference: 
RFS (P=.209) 
Multivariate: 
Increased 
OS (P=.003), 
EFS (P=.008) 
Double 
favourable 
Taskesen et al, 
2011 
1182 
NK only 
NR (16-60) 151 (13) 
60 Single 
91 Double 
Single vs. WT: 
No difference 
Double vs. WT: 
Increased (P = .002) 
NR Increased: 
OS (P=.05), 
RFS (P=.02) 
No difference: 
EFS (P=.22) 
Multivariate: 
No difference for 
OS (P=.1), EFS 
(P=.4), RFS (P=.3) 
Increased: 
OS (P<.0001), 
EFS (P<.0001), 
DFS (P=.05) 
Multivariate: 
Increased  
OS (P<.0001), 
EFS (P<.0001), 
RFS (P.001) 
Double 
favourable 
P values ≤ 0.05 were considered significant. Abbreviations: Single, CEBPA-single; Double, CEBPA-double; NR, not reported; NK, normal karyotype; IK, intermediate-risk karyotype; CR, 
complete remission; WT, wild-type; OS, overall survival; DFS, disease-free survival; RFS, relapse-free survival; EFS, event-free survival; FLT3/ITD, internal tandem duplications of the FLT3 
gene; SD, significant difference. 1 Total cohort studied was 277 cases, outcome data only given for cases with intermediate-risk karyotypes. 2 Three cases with H195_P196dup polymorphism 
alone have been excluded from the CEBPA-mutant cases given in the article. They are still counted as CEBPA-mutant for outcome analyses, however CEBPA-mutant remained favourable for 
outcome in a later analysis with these cases re-classified as CEBPA-WT (Frohling et al, 2007). 3 Age reported for entire cohort (n=872), rather than the subset who had CEBPA mutation 
analysis. 4 P-value across CEBPA-mutant, NPM1-mutant without FLT3/ITD and other genotypes. 5 Total cohort studied was 543 patients (24 CEBPA-single, 47 CEBPA-double). Only patients 
receiving standard chemotherapy were enrolled into survival analysis.  
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A small number of groups have looked at the effect of co-incident FLT3/ITD mutations, 
with some conflicting data. Both studies on patients in the ALFA trials found that the benefit 
for a CEBPA mutation was lost in the presence of a FLT3/ITD (Preudhomme et al, 
2002;Renneville et al, 2009a), however a report from the German-Austrian AML Study 
Group saw no impact of a FLT3/ITD in CEBPA-mutant AML (Frohling et al, 2004). 
Analysis from the Cancer and Leukemia Group B in the group classified as molecular high-
risk (those with a FLT3/ITD and/or NPM1-WT) determined that a CEBPA mutation was still 
favourable in these patients. Even after adjustment for FLT3/ITD status, a CEBPA mutation 
still independently predicted longer DFS (P = .008) and longer OS (P = .009) in this study 
(Marcucci et al, 2008). It has also been suggested that a FLT3/TKD mutation could further 
improve the benefit in outcome seen in CEBPA-mutant patients (Bacher et al, 2008). 
However, this study compared a very small number of four FLT3/TKD-mutant/CEBPA-
mutant patients to 41 FLT3/TKD-WT/CEBPA-mutant patients and, whilst better estimates 
for both OS and EFS were described for the prior group, no significant differences were 
reported. Clarification of the role of FLT3 mutations in CEBPA-mutated AML is therefore 
still required and questions on the impact of NPM1 mutations in this context are yet to be 
explored. 
 
This chapter reports the results of an investigation into the impact of CEBPA mutations in a 
large cohort of non-APL young adult AML patients, in terms of patient characteristics, 
response to therapy and long-term outcome. The interaction with other factors such as 
karyotype and FLT3/ITD or NPM1 mutations are also explored. 
 
 
4.2 Patients, Materials and Methods 
 
4.2.1 Patients 
 
As detailed in chapter 3, diagnostic samples from 1427 patients with known FLT3/ITD and 
NPM1 status were available for CEBPA mutation screening and all had been entered into the 
United Kingdom MRC AML 10 (n = 510) or AML 12 (n = 917) trials between 1988 and 
2002. The clinical information was made available for this study by the chief investigator of 
the trials, Professor Alan K. Burnett, and all statistical analysis was performed by the trials’ 
statistician, Dr. Robert K. Hills. The details of the clinical and molecular characteristics of 
the cohort are given in Table 4.3. The cohort was mostly young adult cases (median age at 
trial entry was 43 years, range 15-68 years, only 35 cases were aged 60 years or more) and 
92% had de novo AML. Patients with APL were excluded from this study due to the distinct 
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biological basis and different patient treatment of this disease, as discussed in chapter 1. 
When compared to the 2341 non-APL adults in the trials who were not included in the study 
cohort, there were no significant differences in age, sex, presence of secondary disease or 
cytogenetics. Patients in the cohort analysed for CEBPA mutations did have higher 
presenting WBCs (P < .0001), which probably reflects a bias in samples available for tissue 
banking. Although patients included in the cohort had a marginally worse performance 
status (P = .04), OS was not significantly different. 
 
4.2.2 Therapy in AML 10 and AML 12 
 
The MRC AML 10 trial (Figure 4.1) (Hann et al, 1997) recruited patients between 1988 and 
1995, and was primarily for patients less than 56 years of age, with older patients entered if 
considered suitable for the intensive therapy. The initial randomisation in this trial was 
between two different induction regimens. One entailed 2 courses of DAT chemotherapy 
(daunorubicin [50 mg/m
2
 by slow intravenous push on days 1, 3 and 5]; cytarabine [100 
mg/m
2
 12-hourly by IV push on days 1 to 10 for the first course and 1 to 8 for the second 
course] and 6-thioguanine [100 mg/m
2
 12-hourly, orally days 1 to 10 for the first course and 
1 to 8 for the second course]). The other induction schedule consisted of ADE chemotherapy 
(daunorubicin and cytarabine as before and etoposide [100 mg/m
2
 by 1 hour IV infusion 
days 1 to 5]). After induction, patients who entered CR received 2 courses of consolidation 
therapy: MACE (amsacrine [100 mg/m
2
 by 1 hour IV infusion days 1 to 5]; cytarabine [200 
mg/m
2
 by continuous IV infusion days 1 to 5]; etoposide [100 mg/m
2
 by 1 hour IV infusion 
days 1 to 5]) then MiDAC (Mitoxantrone [10 mg/m
2
 by short IV infusion days 1 to 5]; 
cytarabine [1.0 g/m
2
 by short IV infusion days 1 to 5]). A second randomisation after 
completion of 4 courses of chemotherapy compared high-dose therapy with autologous bone 
marrow transplant (BMT) rescue versus no further therapy. Patients who had an HLA-
matched sibling donor were scheduled for allogeneic BMT after 4 courses of chemotherapy 
and were not randomised to receive autologous-BMT or not. 
 
The MRC AML 12 trial (Figure 4.1) (Burnett et al, 2010), which recruited patients between 
1994 and 2002, also randomised patients between different induction schedules. Initially, 
patients either received 2 cycles of ADE chemotherapy as used in AML 10 or 2 cycles of 
MAE (mitoxantrone [12 mg/m
2
 by IV infusion on days 1, 3 and 5]; cytarabine [100 mg/m
2
 
12-hourly by IV push on days 1 to 10 for the first course and 1 to 8 for the second course]; 
and etoposide [100 mg/m
2
 by 1 hour IV infusion days 1 to 5]). Of these patients, 29% were 
also randomly assigned to receive G-CSF or a placebo in course 1. From November 1998, a 
protocol amendment allowed randomisation between 2 courses of DAT induction 
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chemotherapy which included either standard-dose cytarabine (S-DAT, as for AML 10 DAT 
schedule) or high-dose cytarabine (H-DAT, as for S-DAT except a cytarabine dose of 200 
mg/m
2
, rather than 100 mg/m
2
). In this induction arm, 89% were also randomly assigned to 
receive all-trans-retinoic acid or not. In terms of consolidation therapy, patients entering CR 
received MACE (as AML 10 schedule) and then were randomised to receive either one or 
two further courses (four or five in total). In either case, those without favourable 
cytogenetics were randomly allocated between BMT (allogeneic where a matched sibling 
donor was available and autologous otherwise) and chemotherapy as a final course. Patients 
with favourable cytogenetics were not eligible for randomisation to receive a BMT. If only 
one further chemotherapy course was assigned, then MiDAC (as AML 10 schedule) was 
received. If two further chemotherapy courses were assigned then patients received ICE 
(idarubicin [10 mg/m
2
 on days 1 to 3]; cytarabine [100 mg/m
2
 by IV push days 1 to 5 every 
12 hours]; etoposide [100 mg/m
2
 by 1 hour IV infusion days 1 to 5]) followed by MiDAC. 
Where BMT had been assigned, patients proceeded to transplant after recovery from MACE 
for those allocated BMT as course 4 and after ICE for those allocated BMT as course 5. Poor 
risk patients were treated on an MRC relapsed/refractory protocol. Assigned chemotherapy 
and allocation of transplantation in first remission for the patients included in this study are 
given in Table 4.3. 
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Figure 4.1 Outline of the treatment protocols for the United Kingdom MRC AML 10 
and AML 12 trials.  For details of the trials and chemotherapy schedules see section 4.2.2. 
Abbreviations: R, randomisation event; DAT, daunorubicin, cytarabine and 6-thioguanine; 
ADE, cytarabine, daunorubicin and etoposide; MACE, amascrine, cytarabine and etoposide; 
MidAC, mitoxantrone and cytarabine; HLA donor, human leukocyte antigen matched donor; 
SCT, stem-cell transplantation; MAE, mitoxantrone, cytarabine and etoposide; S-DAT, 
cytarabine at standard dose, daunorubicin and 6-thioguanine; ATRA, all-trans-retinoic acid; 
H-DAT, cytarabine at twice standard dose, daunorubicin and 6-thioguanine; ICE, idarubicin, 
cytarabine and etoposide. Adapted from Virappane et al (2008). 
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4.2.3 Clinical end points 
 
CR was defined as a normocellular bone marrow containing less than 5% blasts and showing 
evidence of normal maturation of other marrow elements. Persistence of myelodysplastic 
features did not preclude the diagnosis of CR. Of the cases defined as CR, 91% achieved a 
neutrophil count of 1x10
9
/L and a platelet count of 100x10
9
/L. Remission failures were 
classified by the clinicians as either due to induction death (ID; death related to treatment 
and/or hypoplasia within 30 days of trial entry) or resistant disease (RD; failure to eliminate 
disease, including partial remission with 5% to 15% blasts in the bone marrow). Where the 
clinician’s evaluation was not available, deaths within 30 days of entry were classified as ID 
and deaths later than 30 days after entry as RD. OS was the time from randomisation to 
death. For patients achieving CR, RFS was the time from the date of first CR to an event 
(death in first CR or relapse) and cumulative incidence of relapse (CIR) was the incidence of 
relapse after CR with death in CR as a competing risk; the cumulative incidence of death in 
CR (CIDCR) was the incidence of death without relapse, with relapse as a competing risk. 
 
4.2.4 Statistical methods 
 
The Mantel-Haenszel test for trend (for ordinal data) and chi-squared tests were used to test 
for differences in clinical and demographic data by CEBPA status. Kaplan-Meier life tables 
were constructed for survival data and compared by means of the log-rank test. Multivariate 
Cox models (Cheson et al, 2003) were used to analyse CIR, RFS and OS. Models were fitted 
with variables added successively to the model, in order of significance, if adding the 
variable provided a significant improvement in fit (in terms of deviance) at P < .05. Initially, 
all main effects were added and the model checked to determine whether any effects added 
ceased to be significant. Interactions between those covariates entering the model were then 
explored. Tests for heterogeneity were used to compare subgroups (Early Breast Cancer 
Trialists' Collaborative Group, 1990). Odds ratios (ORs), hazard ratios (HRs) and 95% 
confidence intervals (CI) are quoted for all main endpoints. In all cases, a ratio <1 indicates 
benefit for CEBPA mutation(s). All P-values are two-tailed. 
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4.3 Results 
 
Surviving patients in the cohort of 1427 analysed for CEBPA mutations were censored on 
26
th
 October 2008, with follow-up complete for 97% of patients. Median follow-up was 11.7 
years (range 3.0 to 20.4 years). In total, 107 (7%) were CEBPA-mutant, comprising 48 
(45%) classified as CEBPA-single and 59 (55%) as CEBPA-double. Details of the mutations 
detected are given in chapter 3 and Appendix Table 2.  
 
4.3.1 Patient characteristics according to CEBPA genotype 
 
Details of patient characteristics stratified by CEBPA-WT, CEBPA-single and CEBPA-
double status are given in Table 4.3. There was no difference between these groups in terms 
of sex, presenting WBC or type of leukaemia (de novo or secondary). However, there was an 
association of younger age with a greater number of mutations (P = .02), in particular for 
CEBPA-double patients compared to CEBPA-WT and CEBPA-single cases together (P 
=.003). Consistent with the literature, CEBPA mutations were associated with FAB types 
M1 and M2, with 78 (73%) CEBPA-mutant patients classified as M1 or M2 compared with 
600 (45%) CEBPA-WT (P <.001, Pearson’s Chi square). Cytogenetic risk groups were 
allocated according to the MRC classification (Grimwade et al, 1998) and, in line with 
published data there was an association of CEBPA mutations with intermediate-risk 
karyotypes. No CEBPA mutations were found in any of the 167 patients with favourable-risk 
cytogenetics and, of the 141 cases with adverse-risk karyotypes, only four CEBPA-single 
and no CEBPA-double mutations were detected. The greatest number of CEBPA-mutant 
patients had an NK (60 of the 84 cases where karyotype was available, 71%), however the 
incidence of CEBPA mutations was similar between NK and intermediate-risk AK patients: 
4% and 6% of NK patients were CEBPA-single and CEBPA-double respectively compared 
with 3% and 5% of those with an intermediate-risk AK. In the intermediate-risk AK patients, 
there were no significant differences in the coincidence of particular CEBPA-mutant 
genotypes and abnormalities such as +8, +21 or del(13q). However, there was an association 
between del(9q) and CEBPA-double mutations: 3 of 13 (23%) intermediate-risk AK 
CEBPA-double patients had a del(9q) abnormality compared with 12 of 260 (5%) 
intermediate-risk AK CEBPA-WT or CEBPA-single patients (P = .03, Fisher’s exact test), 
an association which has been described previously (Frohling et al, 2005). 
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Table 4.3 Characteristics of patients studied according to CEBPA genotype 
 Characteristic Total No. 
CEBPA-WT  
No. (%) 
CEBPA-single 
No. (%) 
CEBPA-double 
No. (%) 
P across 
CEBPA-WT/ 
CEBPA-single/ 
CEBPA-double 
P  
CEBPA-mutant 
vs. CEBPA-WT 
P  
CEBPA-double  
vs. CEBPA-WT + 
CEBPA-single 
No. of patients 1427 1320 (93) 48 (3) 59 (4)     
              
Trial:             
AML 10 510 467 (92) 21 (44) 22 (37) 
0.5* 0.3† 0.8† 
AML 12 917 853 (93) 27 (56) 37 (63) 
Chemotherapy:        
ADE 501 460 (35) 24 (50) 17 (29) 
0.2† 0.4† 0.5† 
MAE 243 231 (18) 4 (8) 8 (14) 
S-DAT  449  412 (31)  14 (29)  23 (39) 
H-DAT 234 217 (16) 6 (13) 11 (19) 
Age, years:             
15-29 281 252 (19) 8 (17) 21 (36) 
0.02* 0.13* 0.003* 
30-39 292 272 (21) 8 (17) 12 (20) 
40-49 418 388 (29) 15 (31) 15 (25) 
50-59 401 377 (29) 15 (31) 9 (15) 
60 or more 35 31 (2) 2 (4) 2 (3) 
Median 
range 
43 
15-68 
43 
15-68 
46.5 
16-62 
35 
16-67 
    
    
Sex:             
Female 728 675 (51) 23 (48) 30 (51) 
0.8* 0.7† 1.0† 
Male 699 645 (49) 25 (52) 29 (49) 
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Table 4.3 Continued 
 Characteristic Total No. 
CEBPA-WT  
No. (%) 
CEBPA-single 
No. (%) 
CEBPA-double 
No. (%) 
P across 
CEBPA-WT/ 
CEBPA-single/ 
CEBPA-double 
P  
CEBPA-mutant 
vs. CEBPA-WT 
P  
CEBPA-double  
vs. CEBPA-WT + 
CEBPA-single 
Diagnosis:             
de Novo 1317 1215 (92) 44 (92) 58 (98) 
0.12* 0.2† 0.08† 
Secondary 110 105 (8) 4 (8) 1 (2) 
WBC, X 10
9
/L:             
<10 434 412 (32) 11 (23) 11 (19) 
0.19* 0.13* 0.4* 
10-19.9 222 200 (15) 9 (19) 13 (22) 
21-49.9 310 286 (22) 9 (19) 15 (26) 
50-99.9 215 195 (15) 8 (17) 12 (21) 
100+ 216 199 (15) 10 (21) 7 (12) 
Missing 30 28 1 1     
Median 
range 
22.9 
0.4-559 
22.2 
0.4-559 
33.0 
0.7-294 
19 
3.6-480   
  
FAB Type:             
M0 52 49 (4) 2 (4) 1 (2) 
0.01† 0.0002† 0.004† 
M1 268 233 (19) 15 (33) 20 (34) 
M2 410 367 (30) 16 (36) 27 (47) 
M4 353 339 (27) 7 (16) 7 (12) 
M5 171 166 (13) 3 (7) 2 (3) 
M6 42 41 (3) 1 (2) 0 
M7 22 22 (2) 0 0 
Bilineage 1 1 (<0.5) 0 0 
RAEB-t 21 19 (2) 1 (2) 1 (2) 
Other/Unknown 87 83 3 1     
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Table 4.3 Continued 
 Characteristic Total No. 
CEBPA-WT  
No. (%) 
CEBPA-single 
No. (%) 
CEBPA-double 
No. (%) 
P across 
CEBPA-WT/ 
CEBPA-single/ 
CEBPA-double 
P  
CEBPA-mutant 
vs. CEBPA-WT 
P  
CEBPA-double  
vs. CEBPA-WT + 
CEBPA-single 
1
Cytogenetics:             
Favourable 167 167 (15) 0 0 
<0.0001† <0.0001† 0.0004† 
Normal Karyotype 583 523 (48) 26 (70) 34 (72) 
Other Intermediate 273 253 (23) 7 (19) 13 (28) 
Adverse 141 137 (13) 4 (11) 0 
Unknown 263 240 11 12     
FLT3/ITD:             
Wild-type 1060 974 (74) 34 (71) 52 (88) 
0.04* 0.13† 0.01† 
Mutant 367 346 (26) 14 (29) 7 (12) 
NPM1:             
Wild-type 889 804 (61) 28 (58) 57 (97) 
<0.0001* 0.0001† <0.0001† 
Mutant 538 516 (39) 20 (42) 2 (3) 
ITD/NPM1:             
Wild-type/Wild-type 747 675 (51) 21 (44) 51 (86)     
Wild-type/Mutant 313 299 (23) 13 (27) 1 (2)     
Mutant/Wild-type 142 129 (10) 7 (15) 6 (10)     
Mutant/Mutant 225 217 (16) 7 (15) 1 (2)     
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Table 4.3 Continued 
 
 Characteristic Total No. 
CEBPA-WT  
No. (%) 
CEBPA-single 
No. (%) 
CEBPA-double 
No. (%) 
P across 
CEBPA-WT/ 
CEBPA-single/ 
CEBPA-double 
P  
CEBPA-mutant 
vs. CEBPA-WT 
P  
CEBPA-double  
vs. CEBPA-WT + 
CEBPA-single 
 SCT in first  
remission:           
  
None  1110  1026 (78) 38 (79) 46 (78) 
0.9† 0.5† 0.6† 
Sibling allograft  154 144 (11)  5 (10) 5 (8) 
Autograft 136 123 (9) 5 (10) 8 (14) 
MUD/UD 25 25 (2) 0 0 
Other/unknown 2 2 (<1) 0 0 
 
* Test for trend, † Test for heterogeneity. 1 Cytogenetic risk groups as per Grimwade et al (1998). Abbreviations: ADE, cytarabine, daunorubicin and etoposide; MAE, 
cytarabine, mitoxantrone and etoposide; S-DAT, cytarabine at standard dose, daunorubicin and thioguanine; H-DAT, cytarabine at twice standard dose, daunorubicin and 
thioguanine; RAEB-t, refractory anaemia with excess blasts in transformation; SCT, stem-cell transplantation; MUD, matched unrelated donor; UD, unrelated donor. For 
details of chemotherapy schedules see text. 
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In terms of the co-incidence with other gene mutations, when comparing CEBPA-mutant to 
CEBPA-WT patients there was no difference in the incidence of FLT3/ITDs (20% vs. 26%; 
P = .13), but CEBPA-mutant patients were less likely to have an NPM1 mutation (21% vs. 
39%; P = .0001). However, if CEBPA-single and CEBPA-double patients were analysed 
separately, it was clear that, while the incidence of a FLT3/ITD was similar in CEBPA-WT 
(26%) and CEBPA-single (29%) patients, there was a lower incidence in CEBPA-double 
patients (12%; P = .04). In addition, CEBPA-double cases were highly unlikely to have an 
NPM1 mutation compared with CEBPA-WT and CEBPA-single patients (3%, 39% and 42% 
respectively; P < .0001). 
 
4.3.2 Response to therapy and clinical outcome by CEBPA genotype 
 
There were no differences in the therapy received, either chemotherapy or transplantation, 
for CEBPA-WT, CEBPA-single or CEBPA-double patients (Table 4.3). For response to 
therapy measured by CR rate, RD or ID, there were no statistically significant differences 
when comparing CEBPA-mutant to CEBPA-WT cases, or if CEBPA-single and CEBPA-
double patients were analysed separately (Table 4.4). However, the highest CR rate was in 
the CEBPA-double patients (83%, 77% and 90% for CEBPA-WT, CEBPA-single and 
CEBPA-double respectively; P = .15 for CEBPA-double vs. CEBPA-WT and CEBPA-single 
together) as well as the lowest incidence of RD (11%, 13% and 5%; P = .17). 
 
When long term outcome was analysed, with all survival probabilities given at 8 years, OS 
was significantly better in CEBPA-mutant than CEBPA-WT patients (44% vs. 34%; P = .02; 
Figure 4.2 A and Table 4.4), as was RFS (41% vs. 34%; P = .05). However, this benefit was 
limited to CEBPA-double patients, with CEBPA-single patients having a similar outcome to 
CEBPA-WT in terms of both OS and RFS. OS was 34%, 31% and 54% for CEBPA-WT, 
CEBPA-single and CEBPA-double respectively (P = .004; Figure 4.2 B and Table 4.4) and 
RFS was 34%, 35% and 45% (P = .04; Table 4.4). Similar results were obtained if patients 
were censored at the time of transplantation (OS: 49%, 40% and 69% for CEBPA-WT, 
CEBPA-single and CEBPA-double, respectively; P = .02), and if only patients in the 
intermediate cytogenetic risk group were analysed (OS: 34%, 30% and 51%, respectively; P 
= .02). Although CEBPA-double cases had the lowest CIR, this was not statistically 
significant (50%, 60% and 44%; P = .2; Figure 4.2 C and Table 4.4).  
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Table 4.4: Unadjusted results for response to therapy and outcome at 8 years  
 
 CEBPA   CEBPA Dose effect  
CEBPA-double vs. 
CEBPA-WT+CEBPA-
single P 
  WT MUT OR/HR (95% CI) P WT Single Double OR/HR (95% CI) P   
No. of patients 1320 107   1320 48 59     
            
Response to  
therapy     
 
        
 
  
  
CR (OR) 83% 84%  0.91 (0.54-1.53) 0.7  83% 77% 90% 0.85 (0.60-1.21) 0.4 0.60 (0.30-1.20) 0.15 
RD (OR) 11%  8% 0.80 (0.42-1.52) 0.5 11% 13% 5% 0.78 (0.49-1.24) 0.3 0.55 (0.24-1.30) 0.17 
ID (OR) 7%  7% 1.13 (0.52-2.49) 0.8 7% 10% 5% 0.99 (0.61-1.61) 0.9 0.76 (0.27-2.15) 0.6 
                    
Outcome at  
8 years     
 
        
 
  
  
OS (HR) 34% 44% 0.77 (0.62-0.97) 0.02 34% 31% 54% 0.83 (0.72-0.95) 0.004 0.79 (0.57-1.11) 0.17 
RFS (HR) 34% 41% 0.79 (0.62-1.01) 0.05 34% 35% 45% 0.86 (0.74-0.99) 0.04 0.73 (0.54-1.00) 0.05 
CIR (HR) 50% 50% 0.87 (0.65-1.15) 0.3 50% 60% 44% 0.89 (0.75-1.05) 0.2 0.81 (0.55-1.17) 0.3 
CID in CR (HR) 17% 9% 0.59 (0.36-0.97) 0.03 17% 5% 12% 0.77 (0.58-1.03) 0.06 0.71 (0.38-1.32) 0.3 
 
 
Abbreviations: CR, complete remission; RD, resistant disease; ID, induction death; OS, overall survival; RFS, relapse-free survival; CIR, cumulative incidence of relapse; 
CID in CR, cumulative incidence of death in complete remission; WT, Wild-type; MUT, mutant; OR, odds ratio; HR, hazard ratio; CI, confidence intervals. 
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Multivariate analysis was performed considering the known prognostic factors: age, sex, 
type of leukaemia, cytogenetic risk group, WBC, performance status, FLT3/ITD and NPM1 
mutant status, and the data is shown in Table 4.5. CEBPA-double remained an independent 
favourable prognostic factor for both OS (P = .004) and RFS (P = .02). Although in 
univariate analysis CEBPA-double had not had a statistically significant beneficial impact on 
CIR, in multivariate analysis it was an independent favourable factor for relapse (P = .02), 
suggesting that other factors such as the relative lack of coincident NPM1 mutations had 
obscured its benefit previously. 
 
Mutations in CEBPA can be classified not only by their number but also by their type, and 
the possible impact of mutation location was therefore also investigated. Only patients with 
either or both of the two “classic” mutations, as described in detail in chapter 3, were 
included in this analysis, i.e. mutations predicted to cause p30 isoform translation (N-
terminal) and/or those predicted to cause loss of the C-terminal DNA-binding/leucine-zipper 
domain (C-terminal). The 14 patients excluded from this analysis, including the 3 with 
homozygous mutations, are indicated in Appendix Table 2. The outcome for both N-terminal 
and C-terminal CEBPA-single patients was similar to that of CEBPA-WT patients and was 
significantly worse than that of CEBPA-double patients. Estimates for OS were 34%, 17%, 
39% and 58% for CEBPA-WT, N-terminal alone, C-terminal alone and CEBPA-double, 
respectively (P = .008 for heterogeneity; Figure 4.2 D) and for CIR were 50%, 90%, 57% 
and 41% (P = .05). Although N-terminal alone patients had both the lowest OS (17%) and 
the highest CIR (90%), there were no statistical differences in outcome between CEBPA-
WT, N-terminal alone or C-terminal alone patients in pair-wise comparisons using the log-
rank test (OS: P = .8 for CEBPA-WT vs. N-terminal alone, P = .6 for CEBPA-WT vs. C-
terminal alone, P = .9 for N-terminal alone vs. C-terminal alone; CIR: P = .5, .6 and .3, 
respectively). 
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Figure 4.2 The impact of CEBPA mutant status on clinical outcome. Kaplan-Meier 
curves for overall survival stratified by (A) CEBPA-Wild-type (WT, no mutation) or 
CEBPA-mutant (any mutation)  status and (B) CEBPA-WT, CEBPA-single (1 mutation) or 
CEBPA-double (2 mutations) mutant status. (C) Cumulative incidence of relapse by 
CEBPA-WT, CEBPA-single or CEBPA-double mutant status. (D) OS stratified by CEBPA-
WT, single N-terminal (term), single C-term, or double N-term plus C-term mutant status. 
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Figure 4.2 Continued 
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Table 4.5: Multivariate analysis of outcome 
 
 Odds or hazard ratios (95% confidence intervals)* 
Variable CR OS RFS Relapse Death in CR 
Age 1.04 (1.04-1.06) 1.02 (1.01-1.03) 1.01 (1.01-1.02) 1.01 (1.00-1.02) 1.03 (1.01-1.04) 
WBC 1.006 (1.003-1.009) 1.002 (1.001-1.003) 1.001 (1.000-1.002) 1.001 (1.000-1.003) 1.001 (0.999-1.004) 
Performance Status 1.36 (1.16-1.60) 1.10 (1.03-1.18) 1.03 (0.95-1.11) 1.03 (0.94-1.12) 1.04 (0.89-1.22) 
Male 1.03 (0.72-1.49) 1.11 (0.96-1.28) 1.05 (0.90-1.23) 1.01 (0.85-1.21) 1.17 (0.85-1.61) 
Cytogenetic group 4.64 (3.20-6.71) 1.90 (1.65-2.18) 1.65 (1.41-1.94) 1.89 (1.58-2.27) 1.08 (0.78-1.50) 
Secondary 2.29 (1.35-3.91) 1.23 (0.96-1.58) 1.09 (0.79-1.51) 1.10 (0.76-1.59) 1.09 (0.56-2.12) 
FLT3/ITD 1.24 (0.79-1.94) 1.59 (1.34-1.88) 1.69 (1.41-2.03) 2.09 (1.70-2.57) 0.82 (0.54-1.25) 
NPM1-mutant 0.27 (0.17-0.43) 0.46 (0.39-0.55) 0.48 (0.40-0.57) 0.42 (0.34-0.52) 0.69 (0.48-0.99) 
CEBPA-double 
0.54 (0.18-1.61) 
P = .3 
0.53 (0.35-0.81) 
P = .004 
0.60 (0.40-0.91) 
P = .02 
0.57 (0.346-0.93) 
P = .02 
0.74 (0.32-1.70) 
P = .5 
 
*Factors entered into the model were age, sex, type of leukaemia, cytogenetics, WBC, performance status, FLT3/ITD and NPM1 mutant status.  Abbreviations: CR, complete 
remission; OS, overall survival; RFS, relapse-free survival; WBC, white blood cell count 
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4.3.3 Modifying factors for outcome in CEBPA mutant AML 
 
Analyses were performed in order to investigate patient characteristics that could modify the 
beneficial impact of double CEBPA mutations. For these analyses, CEBPA-WT and CEBPA-
single patients were grouped together, as no difference in outcome had been found between 
them. Tests for heterogeneity indicated that the benefit of CEBPA-double mutations was 
predominantly limited to younger patients and female patients (Figure 4.3 A). The impact of 
karyotype was also explored in tests for heterogeneity with patients stratified by cytogenetic 
risk group, with the intermediate-risk patients further divided into those with an NK and 
those with an AK. This analysis showed that the benefit of CEBPA-double mutations was at 
least as great in the intermediate-risk AK patients as those with an NK (P = .7 for OS and P 
= .1 for CIR; Figure 4.3 B). 
 
The interaction between CEBPA mutations and FLT3/ITDs or NPM1 mutations was also 
explored. In terms of interaction with FLT3/ITDs, it was found that the favourable outcome 
of CEBPA-double patients was lost in the presence of a FLT3/ITD, OS for CEBPA-WT, 
CEBPA-single and CEBPA-double was 36%, 35% and 59%, respectively, in FLT3/ITD-
negative (P = .002) and 26%, 21% and 14%, respectively, in FLT3/ITD-positive patients (P 
= .5) (Figure 4.4 A and B). In addition, there was no evidence that the presence of a CEBPA-
single mutation further improved the favourable outcome of an NPM1 mutation, with no 
difference in outcome between NPM1-mutant/CEBPA-WT, NPM1-mutant/CEBPA-single 
and NPM1-WT/CEBPA-double patients: OS was 45%, 44% and 56%, respectively (P =.2; 
Figure 4.4 C). Only two patients were both NPM1-mutant and CEBPA-double and so this 
combination was not analysed. This result was not different if patients were also stratified 
according to FLT3/ITD status, in FLT3/ITD-negative patients OS for NPM1-
mutant/CEBPA-WT, NPM1-mutant/CEBPA-single and NPM1-WT/CEBPA-double was 
55%, 54% and 60%, respectively, (P = .6) and in FLT3/ITD-positive patients 32%, 21% and 
17%, respectively, (P = .8). 
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Figure 4.3 Factors modifying the impact of CEBPA mutant status on clinical outcome. 
Mantel-Byar analyses for CEBPA-double (2 Mutants) cases compared to CEBPA-WT and 
CEBPA-single together (0+1 Mutant) of (A) overall survival stratified by age and sex and 
(B) relapse risk stratified by cytogenetic risk group. Abbreviations: O-E, observed minus 
expected; Var, variance; HR, hazard ratio; CI, confidence interval; OR, odds ratio; NK, 
normal karyotype; NS, not significant.  
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Figure 4.4 Interaction of CEBPA mutations with FLT3/ITD and NPM1 mutations 
Kaplan-Meier curves for overall survival (OS) stratified by CEBPA mutant status in (A) 
FLT3/ITD negative and (B) FLT3/ITD positive patients. (C) OS in patients stratified by 
NPM1 and CEBPA status (0, 1 and 2 mut for CEBPA-WT, CEBPA-single and CEBPA-
double cases, respectively).  
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Figure 4.4 Continued 
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4.4 Discussion 
 
The data presented in this chapter shows an investigation of CEBPA-mutated AML in terms 
of patient characteristics and the impact of mutations on outcome in a large cohort of well-
characterised young adult AML patients with long term follow-up. It was found that 
CEBPA-double, but not CEBPA-single, mutated patients had an improved outcome over 
those without CEBPA mutations, with this benefit being lost in the presence of a FLT3/ITD. 
 
There have been many reports on the characteristics of AML patients with CEBPA 
mutations and, in general, there is a great deal of agreement, both across these different 
reports and with the data presented in this chapter, which is indicative of a strong association 
with particular characteristics in this subgroup of patients. For example, most studies have 
also found no differences between different CEBPA mutation groups for sex or presenting 
WBC (Preudhomme et al, 2002;Barjesteh van Waalwijk van Doorn-Khosrovani et al, 
2003;Frohling et al, 2004;Shih et al, 2006;Marcucci et al, 2008;Wouters et al, 2009;Hou et 
al, 2009;Taskesen et al, 2011) and all studies, including this one, have consistently found an 
association between CEBPA mutations and the M1 and M2 FAB-types,  and with 
intermediate-risk karyotypes, in particular an NK (Tables 4.1 and 4.3). It is of note that no 
CEBPA mutations were detected in 167 patients with a favourable-risk karyotype, which 
may be a reflection of the disruption of C/EBPα activity by alternative mechanisms. For 
instance, C/EBPα protein translation has been shown to be suppressed by the product of the 
oncogenic CBFB-MYH11 fusion in inv(16) AML via a calreticulin-dependent mechanism 
(Helbling et al, 2005). Additionally, in t(8;21) AML the product of the RUNX1-RUNX1T1 
fusion (also known as AML1-ETO) has been shown to suppress CEBPA transcription, 
potentially by inhibition of positive auto-regulation of the CEBPA promoter (Pabst et al, 
2001b). Therefore in patients with these particular chromosomal abnormalities, the 
acquisition of a CEBPA mutation may be functionally redundant.  
 
Whilst there is much agreement between different study groups on the features of CEBPA-
mutated AML, the overall incidence of either CEBPA-single or CEBPA-double mutations is 
relatively rare (3% and 4%, respectively in this cohort), and this means that some features 
may only be discerned when very large numbers of patients have been studied. For instance, 
previous reports found no differences between CEBPA-WT, CEBPA-single and CEBPA-
double patients in terms of age (Wouters et al, 2009;Pabst et al, 2009;Hou et al, 
2009;Dufour et al, 2010), but in this study CEBPA-double cases were found to be 
significantly younger than other patients (P = .003), and this was also noted in a recent 
analysis of 1182 NK cases (Taskesen et al, 2011). However, in contrast with the study of 
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Taskesen et al (2011), which reported that CEBPA-single patients were less likely to have 
NPM1 mutations than those without CEBPA mutations, there were no differences in the 
incidences of FLT3/ITD or NPM1 mutations between CEBPA-WT and CEBPA-single cases 
in the current cohort. By comparison, CEBPA-double patients were significantly less likely 
to have a FLT3/ITD than CEBPA-WT and CEBPA-single patients, and highly unlikely to 
have an NPM1 mutation, which is consistent with other reports (Wouters et al, 2009;Hou et 
al, 2009;Dufour et al, 2010;Taskesen et al, 2011).  
 
Given that, unlike CEBPA-single cases, patients with CEBPA-double mutations generally 
lack mutations in other genes that are commonly mutated in AML, interesting questions are 
raised regarding the sequence of events leading to leukaemic transformation. In patients with 
two CEBPA mutations these could affect the same allele, monoallelic mutations, or different 
alleles, biallelic mutations, with loss of normal allele, and this is explored further in chapter 
5. However, evidence from mouse models suggests that one disrupted CEBPA allele is not 
sufficient for leukaemogenesis. Kirstetter and colleagues (2008) generated a CEBPA allele 
lacking the N-terminus (L), which allowed p30 but not p42 isoform expression and 
mimicked the effect of an N-terminal frame-shifting mutation. Mice homozygous for the L 
allele had GMPs with vastly increased self-renewal capacity and developed a transplantable 
AML with complete penetrance. Heterozygous mice, L/+, did not develop AML and had 
similar haemopoiesis profiles to WT mice. However, there was a decrease in the p42 to p30 
isoform ratio, and myeloid progenitors from the bone marrow were found to have mildly 
increased proliferative capacity compared with those from WT mice. A follow-up study 
(Bereshchenko et al, 2009) combined the p42-null L allele with a K allele containing a 
classic in-frame C-terminal mutation that has been found in a number of AML patients 
(K313dup) in a competitive transplantation model. All mice receiving cells with two 
affected CEBPA alleles (K/K, K/L or L/L) developed a transplantable leukaemia, with the 
most efficient leukaemogenesis in mice receiving K/L cells. The authors hypothesised that 
the efficient leukaemogenesis observed in mice receiving K/L cells was caused by 
premalignant haemopoietic expansion induced by the K allele combined with residual 
myeloid commitment maintained by the L allele, and that this provided a potential 
explanation for the observation of both types of mutation commonly found together in 
patients.  
 
Further evidence that a single CEBPA mutation may be an early step in the process, but not 
leukaemogenic per se, is the observation in familial AML with heterozygous germline 
CEBPA mutations that, at disease presentation, an acquired mutation on the normal allele is 
very common, occurring in 78% of patients (Smith et al, 2004;Nanri et al, 2006;Corbacioglu 
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et al, 2007;Pabst et al, 2008;Renneville et al, 2009b;Taskesen et al, 2011). In addition, there 
can be a long latency before disease on-set of up to 46 years (Pabst et al, 2008). Of note, 
there are no reported patients with germline CEBPA mutations and a family history of AML 
with acquired FLT3/ITD or NPM1 mutations at disease presentation, although one case has 
been described with both KRAS and WT1 mutations (Taskesen et al, 2011). Biallelic CEBPA 
mutations lead to the development of AML in a mouse model with full penetrance indicating 
that, in the mouse at least, further initiating events are not required. However, further 
complexity is likely for leukaemogenesis in human patients and, whilst NPM1 and 
FLT3/ITD mutations are not common in CEBPA-double cases, recent evidence has shown a 
strong specific association with mutations in GATA2, a gene coding for a transcription factor 
that is important for megakaryocytic differentiation and the proliferation and maintenance of 
haemopoietic stem/progenitor cells (Greif et al, 2012). 
 
In terms of patient outcome, as has been historically reported (Preudhomme et al, 
2002;Barjesteh van Waalwijk van Doorn-Khosrovani et al, 2003;Frohling et al, 2004;Bienz 
et al, 2005;Schlenk et al, 2008;Marcucci et al, 2008) it was found that CEBPA-mutant cases 
had a better outcome than CEBPA-WT. However, the benefit seen in the present cohort was 
restricted to CEBPA-double mutant patients, with very similar outcomes between CEBPA-
single and CEBPA-WT cases (Figure 4.2 B). At the time the work presented in this chapter 
was completed, this finding was in agreement with a study from Wouters et al (2009) and a 
report of a smaller cohort (Pabst et al, 2009), but Renneville et al (2009a) had not found this 
clear difference in outcome. Subsequently, there have been three further studies, two 
restricted to only NK patients, that have also found that the benefit for CEBPA-mutations is 
limited to CEBPA-double cases (Hou et al, 2009;Dufour et al, 2010;Taskesen et al, 2011) 
(Table 4.2). It was also important to determine that it was the presence of CEBPA-double 
mutations, and not simply the presence of a particular type of mutation, such as a classic N-
terminal or C-terminal mutation, that was impacting upon outcome. Whilst 90% of CEBPA-
double cases had both types of mutation, only 25% and 58% of CEBPA-single patients had a 
classic N-terminal or C-terminal mutation, respectively. In addition, it has been suggested 
that there may be a difference in outcome between CEBPA-single cases with an N-terminal 
and those with a C-terminal mutation (Taube et al, 2009), and that the GEPs of CEBPA-
single cases with a C-terminal mutation have a tendency to be potentially less distinct from 
GEPs of CEBPA-double cases than do those from CEBPA-single patients with an N-terminal 
mutation (Wouters et al, 2009). However, when the impact of mutation location on outcome 
was investigated in the present cohort, no significant differences were found (Figure 4.2 D), 
and this is in line with a more recent study by Taskesen et al (2011). AML with mutated 
CEBPA has been added as a provisional entry to the updated WHO classification of AML 
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(Swerdlow et al, 2008;Vardiman et al, 2009), however there is now a growing body of 
evidence that, rather than a CEBPA mutation per se defining a separate entity, it is the 
presence of CEBPA-double mutations that defines a group of patients with particular 
characteristics and GEPs (Wouters et al, 2009;Dufour et al, 2010;Taskesen et al, 2011). 
 
Many studies of CEBPA mutations in AML have focussed solely on NK patients (Tables 
4.1. and 4.2), however this excludes intermediate-risk AK patients who accounted for a 
significant proportion of this cohort (273 of 1427, 19%), and in whom a CEBPA-double 
mutation status could be very informative for outcome. In addition, the incidence of CEBPA-
double mutations was similar in intermediate-risk AK and NK patients (5% and 6%, 
respectively). There were, therefore, sufficient intermediate-risk AK cases in this large 
cohort of patients to analyse whether karyotype modified the impact of CEBPA mutations on 
outcome. It was found that the benefit for CEBPA-double mutants was at least as great in 
intermediate-risk AK cases as in NK patients (Figure 4.3 B). This is in contrast to a study on 
ALFA trial patients (Renneville et al, 2009a), where the benefit of CEBPA mutations was 
mostly seen in those with an NK. This difference may be due to the way in which patients 
were grouped for analyses. In the present study the comparison was made between patients 
with and without CEBPA-double mutations, whereas in the study of Renneville et al 
(2009a), CEBPA-mutant patients were divided into three subsets defined by karyotype and 
FLT3/ITD status (NK and FLT3/ITD-negative, NK and FLT3/ITD-positive, and AK) and 
not by the number of CEBPA mutations. 
 
The interaction between different cooperating events in leukaemogenesis and the impact on 
outcome of the particular combination present is important if molecular markers are to be 
used for risk-stratification of patients for therapy. For instance, FLT3/ITD and NPM1 
mutations are, respectively, known adverse and favourable factors for patient prognosis, with 
some controversy over the impact on prognosis if both are present (see chapter 1). The 
impact of FLT3/ITD mutations in CEBPA-mutant AML has been studied previously with 
differing results: either no effect reported (Frohling et al, 2004;Marcucci et al, 2008) or a 
negative impact on outcome (Renneville et al, 2009a). In the present cohort, the benefit in 
outcome for CEBPA-double mutations was completely lost in the presence of a FLT/ITD 
(Figure 4.4 A and B), the first analysis of the impact of FLT3/ITD mutations in this 
subgroup. By contrast with the strong impact of a FLT3/ITD, there was no evidence that a 
CEBPA-single mutation further improved the favourable outcome of NPM1-mutant AML 
(Figure 4.4 C), which has not been reported by others. Only 2 of 1427 (0.1%) patients 
investigated were both CEBPA-double and NPM1 mutated, and therefore this combination 
was not investigated for outcome. In line with this observation and the finding that a 
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FLT3/ITD had a poor impact on outcome regardless of CEBPA genotype (Figure 4.4 A and 
B), a recent large collaborative study of 1182 NK patients found that the outcome of 
CEBPA-single patients was influenced by their FLT3/ITD and NPM1 mutant status 
(Taskesen et al, 2011). However, it was also noted in this report that the outcome for 
CEBPA-single patients was better, although not significantly so, than CEBPA-WT patients 
in all equivalent groups defined by FLT3/ITD and NPM1 status. There was no evidence of 
this in the present cohort, with no difference in outcome seen between CEBPA-single and 
CEBPA-WT patients either in the whole cohort or in groups defined by FLT3/ITD or NPM1 
mutation status. Outcome in CEBPA-mutant AML therefore appears to be dependent on 
what the particular cooperating event(s) may be. Whilst many CEBPA-single cases have an 
additional NPM1 or FLT3/ITD mutation, in the current cohort, 21 of 48 (44%) CEBPA-
single patients lacked either alteration. In these patients alternative factors such as 
cytogenetics and other gene mutations with prognostic implications, such as those in 
DNMT3A and IDH2, may be important. 
 
There are a large number of genes known to be commonly mutated in AML and several of 
them, such as FLT3 and NPM1, are now routinely screened in the diagnostic work-up of new 
cases. As the number of markers increases, some rationalisation will no doubt be required to 
target molecular analyses to cases where knowledge of mutation status would be most useful 
for risk stratification of therapy. The data presented here suggest that CEBPA mutation 
screening could be restricted to intermediate-risk karyotype patients lacking a FLT3/ITD or 
NPM1 mutation, although it should not be limited to just those with an NK. Using such a 
strategy for the current cohort, only a third of patients would have required CEBPA 
screening. 
 
Several studies have suggested that CEBPA mutant-positive patients should be grouped in 
the favourable risk category and should therefore not receive a transplant in first remission 
(Preudhomme et al, 2002;Barjesteh van Waalwijk van Doorn-Khosrovani et al, 
2003;Marcucci et al, 2008;Schlenk et al, 2008). The improved outcome for CEBPA–double 
patients in our cohort was most apparent for OS. Although this may reflect the trend for 
better remission rate in CEBPA-double patents and the reduced relapse rate, it also suggests 
that these patients are more likely to respond to salvage therapy after relapse. This has 
implications for the use of transplantation in these patients and warrants further 
investigation, but, with the relatively low incidence of CEBPA-double patients, this will 
require a meta-analysis of several cohorts. 
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CHAPTER 5: QUANTIFICATION OF CEBPA MUTANT LEVEL 
AND CONFIRMATION OF BIALLELIC MUTATIONS 
 
5.1 Introduction 
 
Mutations in CEBPA were detected in 107 patients in the present cohort and features of 
these alterations are explored further in this chapter. 
 
5.1.1 Mutant level in AML 
 
Mutant level can be defined as the amount of mutant allele present in a DNA sample as a 
proportion of the total alleles, and is therefore a reflection of the overall allelic composition 
of the cells in that sample. There are three main states for a given locus in a cell, 
homozygous, heterozygous and hemizygous. Homozygosity indicates the presence of two 
identical alleles for that locus on both homologous chromosomes, heterozygosity indicates 
different alleles and hemizygosity indicates that only one copy of the locus is present. In a 
genetically identical population of cells, therefore, the mutant level of a homozygous 
mutation or a hemizygous mutation in all cells would be 100%. For a mutation in a 
heterozygous state with wild-type (WT) allele in all cells, the mutant level would be 50%. In 
AML, studies have shown that mutant level can impact on clinical outcome. It may also be 
informative for determining the order of mutation acquisition. 
 
For example, the mutant level of a FLT3/ITD, a mutation which is associated with adverse 
patient outcome, has been shown to be important for prognosis. One early report of 23 
patients with an NK and a FLT3/ITD found that only the cases with more mutant allele than 
WT, as assessed by agarose gel electrophoresis of PCR products, had a significantly poorer 
outcome than NK patients without a FLT3/ITD (Whitman et al, 2001). A second study of 59 
cases with a FLT3/ITD and an intermediate-risk karyotype found that a mutant level higher 
than the median level of 44% was associated with an adverse prognosis, while patients with 
a FLT3/ITD mutant level less than this had a similar outcome to FLT3/ITD-negative cases 
(Thiede et al, 2002). A report from our own group on a large cohort of 354 FLT3/ITD-
positive cases from the MRC AML 10 and 12 trials split patients into those with a low (less 
than 25%), intermediate (25% to 50%) or high (greater than 50%) mutant level. In line with 
the two smaller studies, the poorest patient outcomes were found in those with a high level 
FLT3/ITD mutant level. However, prognosis was still significantly worse than FLT3/ITD-
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negative cases in those with an intermediate level mutation and, even in the low mutant level 
group, relapse risk was still significantly higher (Gale et al, 2008). 
  
Data on mutant levels can be used to infer something about the biology and order of 
mutation acquisition in leukaemogenesis. One of the hallmarks of AML is the clonal 
expansion of abnormal myeloid cells, however, there is a general consensus that 
leukaemogenesis, as with other malignancies, probably requires several genetic hits over a 
period of time (Kelly & Gilliland, 2002;Ashworth et al, 2011). The sequencing of individual 
cancer genomes has revealed large numbers of somatically acquired mutations, from less 
than 1,000 in some cancers to more than 100,000 in others, and these may be divided into 
driver and passenger mutations (see chapter 1) (Stratton et al, 2009). The number of driver 
mutations within an individual cancer probably varies between cancer types and it has been 
suggested it may be around 5 to 7, or as many as 20 (Stratton et al, 2009). These cancer-
associated mutations may confer a selection advantage by alteration of a number of different 
cellular pathways, such as by increasing proliferation or evasion of normal apoptosis 
processes. This accumulation of genetic damage results in a transformed phenotype, with 
cells of that clone out-growing normal cells. However, the linear acquisition of mutations in 
a single clone is an over-simplification, with several lines of evidence for intra-tumour 
genetic heterogeneity, both in leukaemias and other malignancies (Greaves & Maley, 
2012;Ding et al, 2012;Gerlinger et al, 2012). As depicted in Figure 5.1, some genetic hits 
may occur as early or primary events in leukaemogenesis and, as such, are present in the 
majority of blast cells at disease presentation. Other hits may be acquired in only a sub-clone 
of cells at a later stage of the evolution of the leukaemia. Whilst these hits confer a selection 
advantage to that sub-clone in the environmental conditions pertaining at that time, it is 
likely that at disease presentation the secondary hit will only be present in a minority of blast 
cells, which will be reflected in the mutant level. 
 
The use of mutant levels in making inferences about the order of mutation acquisition can be 
exemplified by the combination of FLT3/ITD and NPM1 mutations. In the study of the MRC 
AML 10 and AML 12 trial patients, the NPM1 mutant level of 503 NPM1-mutant cases 
clustered quite tightly around the median mutant level of 43%, with only 8% of cases having 
a low level (less than 25%) and just 3% a high level (greater than 50%) mutant (Gale et al, 
2008). Therefore, in the majority of NPM1-mutant patients the mutation was present in 
between   
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Figure 5.1 Multi-step pathogenesis of leukaemia and the biological basis of mutation 
level. In this example, at disease presentation, mutations A and B are present in nearly all 
cells and mutation C is only present in a small proportion of the population. In genomic 
DNA extracted from this cell population, and assuming all mutations are heterozygous, 
mutations A and B would have an intermediate mutant level of 39% and 44%, respectively. 
Mutation C would have a low mutant level of 17%. 
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25% and 50% of alleles (intermediate level), which is consistent with a heterozygous 
mutation present in most of the cells, indicating that the acquisition of the NPM1 is likely to 
be an early event in leukaemogenesis.  
 
By contrast, the FLT3/ITD level in the 354 FLT3/ITD-positive patients studied varied 
widely between individuals. Although the median total mutant level was 35%, this ranged 
between 1% and 96%, with 29% of cases classified as low, 56% as intermediate and 15% as 
high level mutant. In 208 patients with both a FLT3/ITD and an NPM1 mutation, 
quantification of both mutant levels showed no correlation between the two. For the 53 
patients with a high level FLT3/ITD, a mutant level above 50% indicated the presence of the 
FLT3/ITD in the majority of cells, with a loss of the WT allele in at least some of the cells. 
In previous reports, fluorescence in-situ hybridisation (FISH) analysis has found no loss or 
gain of chromosomal material at the FLT3 locus on chromosome 13, however loss of 
heterozygosity as a result of uniparental disomy (UPD) has been indicated by SNP array data 
and analysis of short tandem repeats, consistent with a homozygous, rather than hemizygous, 
mutation (Thiede et al, 2002;Raghavan et al, 2005;Griffiths et al, 2005). For patients with an 
intermediate level FLT3/ITD, there are several alternatives for the allelic composition of the 
cell population. For example, a 50% mutant level could be the result of a heterozygous 
mutation in all cells, a homozygous mutation in half of the cells, or a mixed population of 
both. Further study of 34 of the intermediate mutant level cases was carried out using a 
polymorphism to investigate the genetic composition in more detail (Green et al, 2008). In 
32 (94%) of 34 cases, no evidence of a homozygous mutation could be detected, consistent 
with the presence of a heterozygous mutation in most cells. In only two cases, mutant 
homozygosity in at least some cells was indicated, with one patient having more 
homozygous than heterozygous mutant cells. A low level FLT3/ITD suggested that less than 
half of the cells in the sample had a heterozygous mutation. In most of these low level 
FLT3/ITD cases it could be shown, by either X-chromosome inactivation pattern analysis for 
a clonal population or presence of an NPM1 mutation at greater than 25% of total NPM1 
alleles, that a low FLT3/ITD level was not the result of the leukaemic cells comprising only 
a small proportion of the total cells analysed. Therefore, in some patients, the FLT3/ITD 
mutation was occurring in only a sub-clone of the leukaemia. In addition, a low-level 
FLT3/ITD was frequently found in combination with an intermediate-level NPM1 mutation 
suggesting that, while most of the leukaemic cells carried the NPM1 mutation, only a sub-
clone also had the FLT3/ITD. This indicated that the FLT3/ITD was probably acquired after 
the NPM1 mutation. 
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5.1.2 CEBPA mutant level 
 
There is very little information available in the literature on mutant level in CEBPA. One 
study of 8 CEBPA-mutant cases reported only that the mutant level ranged between 33% and 
60%, with no further information available on individual levels or methodology (Pabst et al, 
2001b). In addition, although a number of groups have used a screening method for CEBPA 
length mutations that would give quantitative data, only details of the detected CEBPA 
mutations were reported, with no information on the mutant level in these patients (Lin et al, 
2006;Juhl-Christensen et al, 2008;Benthaus et al, 2008). The level of CEBPA mutations is of 
interest as the mutations are generally considered to be early events in leukaemogenesis due 
to their presence in the germline of some pedigrees with familial AML and their relative 
stability as a marker of disease (chapter 3), and would therefore be predicted to be present at 
around the 50% level. However, there has been no comprehensive validation of this 
hypothesis and it is unknown whether this is true for all CEBPA-mutant cases, and further 
investigation is required. 
 
As described in chapter 3, two different heterozygous mutations can be detected in 
approximately half of CEBPA-mutant patients, and there are interesting questions regarding 
the allelic and cellular context of the mutations in these cases. In genes where two different 
heterozygous mutations can be detected, they may either affect the same allele (monoallelic) 
or different alleles (biallelic). Figure 5.2 depicts the three possible allelic compositions for a 
population of leukaemic cells in a patient with two mutations, each with a mutant level of 
50%. First, the different mutations could be in different cells, therefore each mutation would 
need to be homozygous in half of the cells in order to constitute 50% of the total alleles. 
Additionally, all cells could have both mutations, either monoallelically, on the same allele, 
or biallelically, on different alleles. Mutant level quantification in isolation would not be 
sufficient to confirm which is the case, and cloning of alleles is required to determine if the 
different mutations are on the same, or different, alleles (section 5.1.4). 
  
5.1.3 Techniques for quantifying CEBPA mutant level 
 
There are several different techniques that could be used to quantify CEBPA mutant level, 
one of which is fragment analysis of fluorescently-labelled PCR products. Although there is 
a lack of reported data on CEBPA mutant level, nevertheless, as mentioned earlier, several 
groups have successfully used this method to detect CEBPA length   
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Figure 5.2 Possible allelic composition of cells in a CEBPA-double case.  
Each mutation constitutes 50% of the total CEBPA alleles. Cellular composition if the 
different mutations occur in (A) different cells and (B) the same cell. Note, a combination of 
these options could also occur. For simplicity, the possibility of cells without a CEBPA 
mutation, either normal or leukaemic, has been excluded.  
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mutations (Lin et al, 2006;Juhl-Christensen et al, 2008;Benthaus et al, 2008). This technique 
can give a quantitative assessment of mutant level by using the area under the relevant peaks 
in the chromatogram to calculate the mutant allele as a percentage of the total alleles, or by 
calculating the ratio of the mutant peak to the WT peak. The sensitivity of the technique for 
detecting a mutant allele has been assessed in two reports by serially diluting a sample from 
a known CEBPA-mutant patient with a WT sample, before PCR amplification and fragment 
analysis. From these experiments it was found that mutations could be detected when they 
were approximately 5% of the total alleles, and that the observed mutant level was highly 
correlated with the expected level from the mixes (Lin et al, 2006;Benthaus et al, 2008). One 
disadvantage of this technique is that point mutations and indels not affecting overall length 
cannot be detected or quantified. This problem can be overcome when quantifying known 
point mutations, by digesting the labelled PCR product with a restriction enzyme that will 
digest either the WT or the mutant alleles, allowing them to be separated by size. However, 
this is time consuming as a new assay needs to be designed specifically for each individual 
mutation and may not be possible for all mutations due to the difficulty of designing a 
specific digestion for homopolymers of Cs and Gs, which are both common in the CEBPA 
sequence and frequently mutated. 
 
Pyrosequencing (QIAGEN, Crawley, UK) is another technique enabling sensitive 
quantification of mutant level in patient samples. Unlike fragment analysis, pyrosequencing 
allows direct quantification of point mutations as well as insertions or deletions. However, 
the PCR products that can be analysed in a single assay are relatively small, at less than 100 
bp. Therefore, to quantify mutations across CEBPA, more than 10 different overlapping PCR 
amplicons would need to be designed and optimised, which would be challenging given the 
GC-rich nature of this gene. In addition, the individual nature of the mutations present in 
different patients would require optimisation of the pyrosequencing assay for each one, 
making this technique unsuitable for this application. Quantitative real-time polymerase 
chain reaction (Q-PCR) based assays could also be utilised to quantify the relative levels of 
WT and mutant alleles in a DNA sample. However, as with pyrosequencing, the individual 
nature of the different mutations would require a significant amount of optimisation.  
 
Therefore, fragment analysis was selected as the method to quantify mutant level in this 
study, as it has been shown to be both a sensitive and relatively straightforward technique for 
detecting CEBPA mutations. In addition, it is a quantification method that has been 
successfully used in the department for other genes, even for point mutations such as most 
FLT3/TKD mutations (Mead et al, 2007;Gale et al, 2008). 
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5.1.4 Allelic distribution of CEBPA mutations 
 
As introduced above, it is possible that CEBPA-double patients with two different alterations 
have either monoallelic or biallelic mutations. There are a number of groups that have 
cloned the entire CEBPA coding sequence of such patients and sequenced clones to 
determine whether the mutations were present on the same allele. Of 72 cases with two 
different mutations that have been investigated, 52 (72%) were found to have different 
mutations on different alleles and, therefore, classified as biallelic CEBPA mutations 
(Preudhomme et al, 2002;Barjesteh van Waalwijk van Doorn-Khosrovani et al, 
2003;Frohling et al, 2004;Lin et al, 2005;Shih et al, 2006;Dufour et al, 2010). The majority 
of clones from a further 17 (24%) patients were also found to bear mutations on different 
alleles, however one or two clones were additionally found with both mutations (Lin et al, 
2005;Shih et al, 2006). In the remaining 3 (4%) patients, the mutations were carried on the 
same allele (Preudhomme et al, 2002;Frohling et al, 2004). Therefore, the general consensus 
is that the vast majority of CEBPA-double patients have biallelic disease. Indeed, 
competitive transplantation models of CEBPA mutations in mice have found that only mice 
who receive cells with two affected CEBPA alleles develop AML (Bereshchenko et al, 
2009), suggesting a requirement for complete loss of the WT allele.  
 
The data presented in chapter 4, in line with other published studies, showed that the benefit 
of a CEBPA mutation is restricted to CEBPA-double cases, with no impact on outcome for a 
single CEBPA mutation. If mutant status is to be used for the risk-stratification of patients it 
is, therefore, important to correctly classify those with CEBPA mutations as CEBPA-single 
or CEBPA-double. Standard screening techniques, such as dHPLC or direct nucleotide 
sequencing, are effective at detecting the presence of mutations, but if two heterozygous 
mutations are detected in the same patient then these methods give no information regarding 
the allelic distribution. 
 
This chapter presents data on the quantification of mutant level by fragment analysis of 
fluorescently-labelled PCR products in the cohort of CEBPA-mutant cases described in 
chapter 3. The allelic distribution of mutations in CEBPA-double cases will be investigated 
by cloning of the entire coding sequence in order to determine whether mutations are 
biallelic and, by implication, whether the favourable impact on prognosis is related to the 
presence of two CEBPA mutations per se, or the presence of biallelic mutations. 
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5.2 Materials and Methods 
 
5.2.1 Quantification of CEBPA mutant level by fragment analysis 
 
As described in chapter 3, the entire coding sequence of CEBPA was divided into three 
overlapping fragments called fragments 1, 2 and 3 (see section 3.2.1). The primer pairs used 
to amplify each fragment were CEBPA/1F and CEBPA/1R3, CEBPA/2F and CEBPA/2R, 
and CEBPA/3F and CEBPA/3R, respectively (Appendix Table 1). For the quantification 
assay, the forward primer in each pair was labelled at the 5′ end with a fluorescent dye, D4 
(WellRED oligos, Sigma-Aldrich Company Ltd., Poole, UK). Addition of the fluorescent 
label and the sensitivity of the technique necessitated adjustment of both the PCR reaction 
mix and the cycling conditions used in the standard BIOTAQ DNA Polymerase protocol 
given in section 2.1.2. The concentration of each primer was reduced from 0.5µM to 
0.25µM and 5% DMSO was also included to aid in amplification of the GC-rich sequence. 
With regard to the cycling conditions, all 3 steps of each cycle were extended to 1 minute 
and the temperature ramping of the thermocycler block was set at 0.5°C/second. Only 28 
cycles of amplification were performed, instead of 35, in order to limit the amount of PCR 
product generated and prevent saturation of the fluorescence detector during fragment 
analysis. The final extension step at 72°C was also extended from 5 minutes to 15 minutes to 
ensure all PCR products were fully extended. Table 5.1 summarises the primer pairs, 
annealing temperatures and expected amplicon sizes for each fragment.  
 
Post-cycling, PCR products were diluted 1 in 20 in a formamide sample loading solution 
containing a DNA size standard ladder (DNA Size Standard Kit – 600, Beckman Coulter, 
High Wycombe, UK) and analysed by capillary electrophoresis using the CEQ 8000 Genetic 
Analysis System (Beckman Coulter). For reference, all runs included a PCR product 
amplified from a cell line with known WT CEBPA, such as HL60 or NB4, and this was used 
to identify the WT peak in patient samples. Mutant peaks representing insertion or deletion 
mutations were identified by their larger or smaller fragment sizes and the area under
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Table 5.1 Summary of PCR protocols for fragment analysis 
 
Fragment Forward primer Reverse primer 
Annealing 
Temperature 
Expected WT 
fragment size, bp 
Observed WT 
fragment size* 
(bp ±2SD) 
Observed – 
Expected (bp) 
1 D4-CEBPA/1F CEBPA/1R3 62°C 548 524 ±4.37 -24 
2 D4-CEBPA/2F CEBPA/2R 62°C 463 447 ±2.19 -16 
3 D4-CEBPA/3F CEBPA/3R 64°C 424 410 ±2.28 -14 
 
* Observed WT fragment size is the mean fragment size of between 5 and 8 separate fragment analysis runs of a PCR product from NB4 cell line DNA, a 
known CEBPA-WT. Abbreviations: bp, base pairs; SD, standard deviation; D4, 5’ fluorescent label; WT, wild-type. 
 
127 
 
WT and mutant peaks was determined by the instrument software. The mutant level was 
defined as the area under the mutant peak as a percentage of the total alleles, and was 
calculated using the following formula: area under mutant peak / (area under mutant peak + 
area under WT peak) x 100. The size of the insertion or deletion was calculated from the 
difference in fragment size between the WT and mutant peaks, with fragment size called by 
the instrument software. 
 
5.2.2 Quantification of mutant level by restriction enzyme digestion 
 
There were three patients where homozygous CEBPA-mutations were detected, however, 
none of these mutations, two missense and one indel, affected the overall length (patients 91, 
101 and 102, Appendix Table 2). One case was selected for quantification, patient 102 
containing the homozygous 962A>G change, so that the level of any remaining WT allele, 
which was not visible on the sequencing chromatogram, could be quantified. An assay was 
designed so that PCR amplification with a mismatch reverse primer created a restriction 
enzyme recognition site in WT, but not mutant, alleles, enabling separation of WT and 
mutant alleles by size. Amplicons of 243 bp were generated using primers D4-CEBPA/3F 
and CEBPA/G964T/R(MM), and 8µl of each PCR product was digested at 65°C for 3 hours 
in a reaction mix with 1µl Tsp509I and 1µl of manufacturer’s buffer 1 (New England 
Biolabs, Hitchin, UK). After digestion, 2µl of the reaction was analysed as described above 
(section 5.2.1) on the CEQ 8000 Genetic Analysis System. WT alleles were digested to a 
213 bp fragment and 962A>G mutant alleles were not digested giving a 243 bp fragment. 
 
5.2.3 Analysis of full-length clones of the CEBPA coding sequence 
 
Of the 59 CEBPA-double cases in this cohort, 13 were selected for analysis of the presence 
of biallelic mutations, and details of the mutations in these patients are given in Table 5.2.  
 
5.2.3.1 Cloning of the CEBPA coding sequence 
 
In each case, PCR products of 1201 bp containing the entire coding sequence of CEBPA 
were generated using genomic DNA with primers CEBPA/1F and CEBPA/3R and the 
standard BIOTAQ DNA polymerase reaction mix (see section 2.1.2), with 5% DMSO as an 
additive, in a total volume of 20µl. Cycling conditions were 35 cycles of 95°C for 60 
seconds, 62°C for 60 
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Table 5.2 Details of 13 cloned CEBPA-double cases and technique used to screen clones 
 
 Mutation 1
1
 Mutation 2 
Patient 
no.
2
 
DNA change 
Predicted 
size change 
(bp) 
Screening 
method 
DNA change Fragment 
Predicted 
size change 
(bp) 
Screening 
method 
12
3
 86_94delinsT -8 Fragment analysis 943_945dup 3 +3 Fragment analysis 
13
3
 98_116del -19 Fragment analysis 977_978ins66nt 3 +66 Agarose gel 
15 107_113del -7 Fragment analysis 543C>A 2 None RED 
24
3
 126_132del -7 Fragment analysis 934_936dup 3 +3 Fragment analysis 
30 155dupT +1 MM primer + RED 499dupG 2 +1 RED 
37
3
 184_186delinsG -2 RED 986_987ins105nt 3 +105 Agarose gel 
39 191_194dup +4 Fragment analysis 949_950insGTC 3 +3 Fragment analysis 
44 230_233del -4 Fragment analysis 917_934del 3 -18 Fragment analysis 
47 230_231dup +2 
Fragment analysis 
spiked with WT 
927_986dup 3 +60 Agarose gel 
49 245_246insGTGTT +5 Fragment analysis 909_923dup 3 +15 Fragment analysis 
60 296_299dup +4 Fragment analysis 934_936dup 3 +3 Fragment analysis 
64 326_327insTA +2 RED 934_936dup 3 +3 Fragment analysis 
65 339_342del -4 Fragment analysis 934_936dup 3 +3 Fragment analysis 
 
1
All mutations were in fragment 1.
 2
Patient number relates to Appendix Table 2. 
3
Cases were also heterozygous for one of the common polymorphisms: G/T 
SNP at nucleotide 690 (patients 12, 24 and 37) or H195_P196dup (patient 13). Abbreviations: ins, insertion; del, deletion; dup, duplication; nt, nucleotide; 
MM, mismatch; RED, restriction enzyme digestion; WT, wild-type. 
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seconds and 72°C for 90 seconds followed by a final extension at 72°C for 10 minutes, with 
a temperature ramping speed of 0.5°C/second. Products were checked on a 1.5% agarose gel 
stained with ethidium bromide. PCR products were cloned into the pCR2.1-TOPO vector 
using the TOPO TA Cloning Kit (Invitrogen Life Technologies, Paisley, UK), and the 
TOPO cloning reaction was used to transform One Shot MAX Efficiency DH5α-T1 
chemically competent E. coli (Invitrogen Life Technologies), as described in sections 2.1.8 
and 2.1.9. Bacteria were spread on LB agar plates containing 100µg/ml carbenicillin, which 
were pre-coated with 40µl of a 40mg/ml X-gal solution to allow blue/white colony 
screening, as detailed in section 2.1.9, and incubated overnight at 37°C. At least 14 white 
colonies per patient were picked, seeded into 96-well plates and incubated overnight at 
37°C, as described in section 2.1.10. 
 
5.2.3.2 Detection of mutations 
 
For each case, the two mutated CEBPA fragments were amplified by PCR from each clone 
and analysed for the presence or absence of the appropriate mutation. All PCRs, regardless 
of the downstream detection method, used BIOTAQ DNA Polymerase to amplify the 
required fragment from 1µl of the bacterial culture in a reaction mix supplemented with 5% 
DMSO, and were preceded with a hot start of 5 minutes at 95°C in order to ensure lysis of 
the bacteria. An appropriate technique was selected to detect each individual mutation and 
this information is given in Table 5.2.  
 
Of the 23 different mutations in the 13 cases, 3 were large insertions of at least 60 bp in 
fragment 3.  For these, amplification from primers CEBPA/3F and CEBPA/3R and agarose 
gel electrophoresis size separation of the PCR products easily identified the large insertions. 
A further 14 mutations caused size changes of between 3 and 19 bp, which were identifiable 
by fragment analysis of the appropriate fragment following the method given in section 
5.2.1, apart from the initial hot start before cycling. One case had a 2 bp insertion, which was 
difficult to distinguish confidently from WT clones by fragment analysis, due to the 
variability in fragment size called by the instrument software (see section 5.3.2), an issue 
exacerbated by the very large amount of PCR product produced from bacterial clones versus 
that from genomic DNA. Therefore, PCR product from the bacterial clone was mixed 1:1 
with PCR product from a known CEBPA-WT sample and the fragment analysis 
chromatograms of the “mixed” and “unmixed” clone were compared. A double peak in the 
mixed sample compared to the unmixed sample identified mutant clones. Of the remaining 5 
mutations, 4 caused size changes of 1 or 2 bp and one was a point mutation, and for these, 
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PCR products were generated from the primers specified in Table 5.3. In 4 of these cases, 
direct digestion of PCR products with a restriction enzyme followed by agarose gel 
electrophoresis discriminated between WT and mutant clones. In the remaining case, a 
mismatch primer was designed to introduce a restriction site in PCR products from WT, but 
not mutant, clones. The restriction enzymes used and the resultant fragment sizes for WT or 
mutant clones are given in Table 5.3. 
 
5.2.3.3 Detection of common polymorphisms 
 
Of the 13 patients where full-length CEBPA products were cloned, 4 were also heterozygous 
for one of the two common polymorphisms, G/T at nt 690 or H195_P196dup. The 
polymorphism status of the clones from these patients was determined using either PCR with 
a mismatch primer and SgrAI digest for the G/T at nt 690 or fragment analysis for the 
H195_P196dup. The methods used were as detailed in section 3.2.5, apart from the use of 
1µl of bacterial culture as a template and an initial hot start step of 5 minutes at 95°C. 
 
 
5.3 Results 
 
By fragment analysis assays of all three CEBPA fragments, it was found that the size of a 
PCR product from a known CEBPA WT sample, as called by the instrument software, was 
smaller than the expected product size, with a reduction of 24 bp (4%), 16 bp (3%) and 14 
bp (3%) for fragments 1, 2 and 3, respectively (Table 5.1). However, nucleotide sequencing 
of PCR products in both directions confirmed that the complete expected sequence was 
present. There are two other reports that have also found the observed WT fragment size to 
be smaller than the expected WT fragment size (Benthaus et al, 2008;Juhl-Christensen et al, 
2008). In both of these studies, the CEBPA coding sequence was divided into four 
amplicons, with a reduction of between 12 bp (4%) and 18 bp (4%) in one study (Benthaus 
et al, 2008), and between 8 bp (2%) and 22 bp (4%) in the other (Juhl-Christensen et al, 
2008). This phenomenon may be due to by the GC-rich nature of the CEBPA sequence 
causing secondary structure formation, which interferes with electrophoresis of fragments 
(Benthaus et al, 2008). However, the inclusion of a known WT control in all runs enabled 
easy identification of the WT fragment in fragment analysis of patient samples. 
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Table 5.3 Screening of full-length clones by restriction enzyme digestion 
 
       
Fragment sizes 
post-RED (bp) 
Patient 
No.
1
 
DNA Change Fragment 
Forward  
primer 
Reverse 
primer 
Amplicon 
size (bp) 
Restriction 
enzyme 
WT MUT 
15 543C>A 2 CEBPA/2F2 CEBPA/2R 333 MseI 333 70 + 263 
30 155dupT 1 CEBPA/1F 
CEBPA/G157A 
/R(MM) 
215 DdeI 31 + 184 215 
 499dupG 2 CEBPA/2F2 CEBPA/2R 333 BseRI 31 + 302 333 
37 184_186delinsG 1 CEBPA/1F CEBPA/1R 443 BspEI 443 211 + 230 
64 326_327insTA 1 CEBPA/1F CEBPA/1R3 548 BfaI 548 192 + 356 
 
1
Patient number relates to Appendix Table 2. Abbreviations: ins, insertion; del, deletion; dup, duplication; MM, mismatch; RED, restriction enzyme digestion; 
WT, wild-type; MUT, mutant; bp, base pairs. 
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Mutations in CEBPA causing length changes that were 2 bp or more were detected easily by 
fragment analysis of fluorescently labelled PCR products. However, single base pair 
insertions or deletions could not be distinguished from the WT peak. A number of changes 
to the protocol were tested in an attempt to solve this issue, for example new primers were 
designed to generate smaller PCR products, the fluorescent label was tested on the reverse 
rather than the forward primer, and products were electrophoresed at a lower voltage over a 
longer period on the CEQ 8000 Genetic Analysis System. However, the expected mutant 
peak could not be resolved from the WT fragment peak. Therefore, direct mutant level 
quantification by fragment analysis was not possible in 39 (23%) of the 166 CEBPA 
mutations detected in 107 patients. 
 
5.3.1 Quantification of H195_P196dup polymorphism allele level by fragment analysis 
 
To assess the use of fragment analysis for the quantification of the proportion of alleles with 
size changes in CEBPA, the level of the known polymorphism H195_P196dup was 
determined in 65 of the 68 (96%) patients in the cohort who were identified as heterozygotes 
for this change. PCR products could not be obtained in the remaining three cases. This 6 bp 
insertion was clearly identifiable by fragment analysis of fragment 2 (Figure 5.3 A), and 
although levels ranged between 39% and 64%, the median level of H195_P196dup in these 
cases was 50% ±8% (median ±2SD), with a very tight distribution around the median level 
(Figure 5.3 B). In addition, the size of the insertion was, to the nearest integer, the expected 
6 bp for all samples tested, with a median difference in size between the WT and 
H195_P196dup peaks of 5.97 ±0.23 bp. These results were consistent with the level and 
insertion size expected for a heterozygous 6 bp insertion present in every cell, and gave 
confidence that fragment analysis was a suitable method for quantifying the level of size 
changes in CEBPA. 
 
5.3.2 Quantification of CEBPA mutant level by fragment analysis 
 
Quantification of the mutant level of both insertion and deletion mutations causing changes 
greater than or equal to 2 bp was straightforward for all CEBPA fragments. Examples of 
fragment analysis chromatograms for a 2 bp insertion in fragment 1 and a 12 bp deletion in 
fragment 2 are shown in Figure 5.4 A and B. These mutations each constituted nearly 50% 
of the total alleles (46% and 47%, respectively), however the technique also detected low 
level mutations, with one mutant quantified at 9% of the sample (Figure 5.4 C). 
.   
133 
 
 
 
Figure 5.3 Quantification of H195_P196dup polymorphism allele level by fragment 
analysis. A. Fragment analysis chromatogram of CEBPA fragment 2 for an H195_P196dup 
heterozygote. Blue-labelled peaks represent PCR products and red peaks are a size standard 
ladder. The proportion of the total alleles with the H195_P196dup was 50% in this case.  
B. Distribution of the level of H195_P196dup alleles in 65 cases.
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Figure 5.4 Detection and quantification of CEBPA mutant level by fragment analysis. Fragment analysis chromatograms of (A) Fragment 1 from patient 
64 showing the expected 2 bp insertion, (B) Fragment 2 from patient 76 with a 12 bp deletion, (C) Fragment 3 from patient 88 showing a low level mutation. 
The size of the insertion by fragment analysis was 48 bp, the expected size from nucleotide sequencing was 49 bp, (D, E) CEBPA/3F* to 
CEBPA/G964T/R(MM) products from a WT control and patient 102 pre- (D) and post-Tsp509I digestion (E), which discriminated between alleles with or 
without the 962A>G mutation. Blue-labelled peaks represent PCR products and red peaks are a size standard ladder. 
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Figure 5.4 continued 
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Of the 100 mutations causing a 2 bp or more size change that were analysed, it was found in 
19 (19%) that the size of the insertion or deletion was incorrectly called by the instrument 
software, by between 1 and 4 bp, when compared to the size change expected from 
nucleotide sequencing This is likely to be a mutation-specific effect due to the GC-rich 
sequence causing secondary structure, which may interfere with the capillary 
electrophoresis. 
 
Of the 166 CEBPA mutations detected in 107 patients, 23 (14%) could not be directly 
detected by fragment analysis as they were either point mutations (n = 21) or indels that did 
not change the overall sequence length (n = 2). Each of the 20 different mutations would 
have required an individual assay to be designed using a specific digest or mismatch primers 
for amplification followed by a specific digest. Therefore a specific assay was designed for 
only one of these cases with a missense mutation (patient 102, 962A>G) only identified by 
dHPLC analysis of patient PCR product mixed with that from a known WT sample, and no 
WT allele was visible on the sequencing chromatogram. It was again found that the observed 
fragment sizes, for both digested and undigested alleles, were smaller than those expected. 
However, comparison of the digestion pattern for a known CEBPA-WT with that from 
patient 102 (Figure 5.4 D and E) allowed quantification of the mutation as 97%. This is 
consistent with either a homozygous or hemizygous mutation, and while UPD has not been 
confirmed in this case it is known to be a common cause of homozygous CEBPA mutations 
(Fitzgibbon et al, 2005;Wouters et al, 2007c), and therefore classification of this change as 
homozygous was appropriate. 
  
5.3.3 CEBPA mutant level 
 
In total, 101 mutations from 75 CEBPA-mutant cases (22 CEBPA-single, 53 CEBPA-double) 
were quantified and the median mutant level was 44% (range 9% to 97%). The distribution 
of CEBPA mutant level is shown in Figure 5.5 A. Quantification of the H195_P196dup 
polymorphism had allowed an approximation of the technical limits of fragment analysis 
when quantifying the level of a heterozygous size change known to be present in all cells. If 
the range of levels set by quantification of the H195_P196dup polymorphism was applied to 
the CEBPA mutations, 77 mutations (76%) from 58 patients had a level of between 39% and 
64%, consistent with the presence of a heterozygous mutation in all, or at least most, cells. 
While nearly a quarter of mutations quantified (23%) were less than the 39% lower limit, the 
mutant level was less than 25% (i.e. consistent with a heterozygous mutation in less than 
half of cells) for just 5 mutations from 5 different patients (3 CEBPA-single, 2 CEBPA-
double). One of these cases (CEBPA-mutant level 13%) also had an NPM1 mutation 
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Figure 5.5 CEBPA mutant level 
A. Distribution of CEBPA mutant level of 101 mutations from 75 patients. 
B. Paired mutant levels in 26 CEBPA-double cases. 
C. Comparison of CEBPA and FLT3/ITD mutant level in 11 cases positive for both 
mutations. For the 5 CEBPA-double cases with both mutations quantified, the mean of the 
two levels is plotted.  
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of 49%, suggesting that the CEBPA mutation was a secondary event. Additional markers 
were not available in the other cases.  
 
In 26 CEBPA-double cases it was possible to quantify the level of both mutations (Figure 
5.5 B). All patients had at least one mutation constituting more than 25% of alleles, and the 
paired levels were highly correlated (P = .0002, paired t-test), with an average difference of 
7% (range 0 to 21%) in the level of the different mutations from the same patient. This 
suggested that both mutations were present in the same cell. At least one CEBPA mutation 
was quantified in 11 FLT3/ITD-mutant patients.  Nearly all of the CEBPA mutant levels in 
these cases were consistent with the presence of a heterozygous mutation in most cells, with 
the level in 10 cases (91%) quantified as between 41% and 53%. However, the level of the 
FLT3/ITD varied widely (3% to 45%, Figure 5.5 C), suggesting that acquisition of a CEBPA 
mutation could precede a FLT3/ITD. 
 
5.3.4 Confirmation of biallelic mutations by cloning 
 
There were 13 CEBPA-double cases where the entire CEBPA coding sequence was cloned 
and between 14 and 33 clones per patient were screened for the presence of each mutation. 
Overall, most clones (87%) had one mutation, 9% were WT and 4% had both mutations 
(Table 5.4). This indicated that, in these patients, the two mutations predominantly occurred 
on different alleles.  
 
Four of these cases were also heterozygous for one of the two common polymorphisms, and 
in these patients the clones with one mutation were additionally screened to determine the 
polymorphism status of the cloned allele. Results were obtained on 77 clones and this data is 
given in Table 5.5. In patients 12, 13 and 37, there was an association between the 
polymorphism allele and the CEBPA mutation, with the N-terminal and C-terminal 
mutations associated with the same polymorphism allele in every clone. Moreover, the 
different mutations were associated with different polymorphism alleles. For example, of the 
15 clones analysed from patient 37, a heterozygote for the G/T SNP at nt 690, all 10 clones 
with the N-terminal mutation had a G at nt 690, while all 5 with the C-terminal mutation had 
a T at nt 690. In the remaining case (patient 24), 24 (92%) of the 26 clones with one 
mutation screened also followed this pattern, however 2 clones were found where the 
mutation was on the opposite polymorphism allele from the other clones with the same 
mutation. It was also noted that, for each of these 4 cases, there was a preponderance
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Table 5.4 Screening of full-length clones in 13 CEBPA-double cases. 
 
Patient 
No.
1
 
Mutation 1 
% 
Mutation 
1 
Mutation 2 
% 
Mutation 
2 
Number of 
clones 
screened 
Clones 
with one 
mutation, 
n (% of 
clones) 
Clones 
with both 
mutations, 
n (% of 
clones) 
Wild-type 
clones, 
n (% of 
clones) 
12
2
 86_94delinsT 59 943_945dup 50 19 14 (74) 3 (15) 2 (11) 
13
2
 98_116del 49 977_978ins66nt 40 32 26 (82) 2 (6) 4 (12) 
15 107_113del 49 543C>A N/A 27 27 (100) 0 0 
24
2
 126_132del 59 934_936dup 45 33 26 (79) 2 (6) 5 (15) 
30 155dupT N/A 499dupG N/A 19 15 (79) 1 (5) 3 (16) 
37
2
 184_186delinsG 52 986_987ins105nt 31 17 15 (88) 0 2 (12) 
39 191_194dup 43 949_950insGTC 29 30 27 (90) 2 (7) 1 (3) 
44 230_233del 44 917_934del 47 19 15 (79) 0 4 (21) 
47 230_231dup 39 927_986dup 28 14 14 (100) 0 0 
49 245_246insGTGTT 50 909_923dup 46 19 19 (100) 0 0 
60 296_299dup 45 934_936dup 42 20 17 (85) 0 3 (15) 
64 326_327insTA 46 934_936dup 48 15 12 (80) 1 (7) 2 (13) 
65 339_342del 51 934_936dup 48 21 20 (95) 1 (5) 0 
         
    TOTAL 285 247 (87) 12 (4) 26 (9) 
 
1
Patient number relates to Appendix Table 2. 
2
Cases were also heterozygous for one of the common polymorphisms: G/T SNP at nucleotide 690 (patients 12, 
24 and 37) or H195_P196dup (patient 13). Abbreviations: ins, insertion; del, deletion; dup, duplication; nt, nucleotide; N/A, not available.  
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Table 5.5 Polymorphism analysis in full-length clones with only one mutation in four CEBPA-double cases. 
 
  Mutant level, %  
No. of clones with 
N-terminal mutation 
No. of clones with 
C-terminal mutation 
Patient 
no.
1
 
Polymorphism 
N-terminal 
mutation 
C-terminal 
mutation 
Total no. 
of clones 
screened 
Total 
no. 
Major 
allele
2
 
Minor 
allele
2
 
Total 
no. 
Major 
allele
2
 
Minor 
allele
2
 
12 G/T nt 690 59 50 14 12 12 0 2 0 2 
13 H195_P196dup 49 40 22
3
 19 19 0 3 0 3 
24 G/T nt 690 59 45 26 17 16 1 9 1 8 
37 G/T nt 690 52 31 15 10 10 0 5 0 5 
   TOTAL 77       
 
1
Patient number relates to Appendix Table 2. 
2
Major allele denotes G at nt 690 or non-H195_P196dup, minor allele denotes T at nt 690 or presence of 
H195_P196dup as appropriate. 
3
The polymorphism status was not determined for 4 clones with one mutation from patient 13. Abbreviations: nt, nucleotide; 
WT, wild-type; dup, duplication. 
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of clones with N-terminal mutations (58 of 77, 75%) as compared to clones with C-terminal 
mutations (19 of 77, 25%) (Table 5.5). The cause of this imbalance is unknown but may, in 
part, be the result of both the relatively small number of alleles studied per patient and a 
higher mutant level of the N-terminal compared to the C-terminal mutation, of between 9% 
and 21%, in each case (Table 5.5). 
 
 
5.4 Discussion 
 
The data presented in this chapter shows quantification of CEBPA mutant level in the same 
cohort of CEBPA-mutant patients determined in chapter 3 and confirmation of biallelic 
mutations in selected CEBPA-double cases by cloning of the entire coding sequence. 
Together, this information can be used to examine the allelic composition of the population 
of leukaemic cells at disease presentation. 
 
The technique selected to quantify mutant level was fragment analysis of fluorescently 
labelled PCR products as there have been several reports showing that this method could 
successfully detect CEBPA length mutations in a sensitive manner (Lin et al, 2006;Juhl-
Christensen et al, 2008;Benthaus et al, 2008). Indeed, when used in this study, fragment 
analysis was found to be a straightforward technique for size changes of two base pairs or 
more, with detection and quantification of mutations of this type even when the mutant 
constituted less than 10% of the total alleles (Figure 5.4 C). Additionally, quantification of 
the known polymorphism H195_P196dup in 65 cases gave a median allele level of 50% 
(range 39% to 64%), with a tight distribution around this figure (Figure 5.3 B), which is the 
level expected for a heterozygous polymorphism present in all cells. These results indicated 
that the use of fragment analysis for quantification in this context was appropriate. However, 
unlike previous reports (Lin et al, 2006;Juhl-Christensen et al, 2008;Benthaus et al, 2008), 
insertions or deletions of just a single base pair could not be detected in this study, despite 
attempts at optimisation of the method. This difference may be because an Applied 
Biosystems Genetic Analyzer was used in each of those reports, rather than the CEQ 8000 
Genetic Analysis System (Beckman Coulter) that was available for this study. However, 
both instruments had the same issue with regards to the reduced WT fragment sizes called 
by the instrument software versus those expected (Table 5.1) (Benthaus et al, 2008;Juhl-
Christensen et al, 2008). In addition, in this study the size of the insertion or deletion, as 
calculated from the called fragment sizes, was not accurately determined in nearly one fifth 
of mutations, when compared with the nucleotide sequence. Both of these observations are 
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probably due to the GC-rich nature of the CEBPA gene, causing secondary structure, which 
affected how the PCR product electrophoresed. This secondary structure may not have been 
completely removed by the denaturation step performed by the instrument before the 
electrophoresis, which involved heating the PCR product in a sample loading solution 
containing de-ionised formamide, a stabiliser of single-stranded DNA molecules. However, 
neither issue appeared to significantly impact upon quantification of mutant level, as 
indicated by analysis of H195_P196dup polymorphism alleles. 
 
Of the 166 CEBPA mutations detected in 107 patients by WAVE analysis, most (n = 104, 
63%) caused a size change of 2 bp or more and could be quantified directly by the selected 
method. A further 39 mutations (23%) caused 1 bp length alterations and 23 (14%) were 
point mutations or indels that did not affect overall length. Therefore, 37% of the known 
mutations could not be directly quantified by fragment analysis in this study. In one 
particular case with a homozygous point mutation, a mismatch primer was used for 
amplification followed by allele-specific restriction enzyme digestion of WT, but not 
mutant, alleles allowing separation by size. Overall, 101 mutations from 75 patients were 
quantified, which was considered sufficient to explore the distribution of CEBPA mutant 
levels in AML patients. 
 
The median mutant level of the 101 mutations quantified was 44% (range 9% to 97%) 
(Figure 5.5 A). Approximately three quarters of the mutations quantified were of a level 
consistent with that of the known H195_P196dup polymorphism and were suggestive of the 
presence of a heterozygous mutation in most cells in most cases. There is only one other 
published brief report on CEBPA mutant level, in which it was stated that the mutant level of 
8 CEBPA-mutant cases ranged between 33% and 60% (Pabst et al, 2001b), which is 
consistent with the data from this, much larger, study. The CEBPA mutant levels in the 
present cohort are therefore in agreement with the concept of CEBPA mutations as early 
events in leukaemogenesis, as suggested by their relative stability in disease progression and 
occurrence as germline mutations in familial AML (chapter 3). In further support of this is 
the finding that in 10 of the 11 CEBPA-mutant cases with a FLT3/ITD mutation where 
quantification was performed, the CEBPA level was more than 40%, while the FLT3/ITD 
level was variable, even down to 3% (Figure 5.5 C), suggesting that, in at least some cases, 
the FLT3/ITD was acquired after the CEBPA mutation. The CEBPA mutant level was low 
(less than 25%) in a small number of cases, which could be due to the presence of either 
normal or leukaemic CEBPA-WT cells in the sample. Blast counts were not available for 
this study, however, one of these cases also had an NPM1 mutation of 49%, indicating a 
CEBPA mutation is not always an early event. 
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In the cohort described in chapter 3, there were 56 patients where two different CEBPA 
mutations were detected, accounting for 95% of those classified as CEBPA-double. These 
patients had a favourable prognosis provided that a FLT3/ITD mutation was not also present 
(chapter 4). The level of both mutations could be quantified in 26 of these cases, and in all 
cases one, or both, of the mutations constituted at least a quarter of total alleles, and the 
paired levels were highly correlated (P = .0002, paired t-test, Figure 5.5B). There are at least 
three different allelic and cellular distributions possible for two intermediate-level mutations 
in the same patient, including different mutations in different cells and different mutations in 
the same cell, either on the same, or different, alleles (Figure 5.2), and the paired mutant 
levels were suggestive of the presence of both mutations in the same cells. To investigate the 
allelic distribution, the entire coding sequence was therefore cloned in 13 of the 56 (23%) 
CEBPA-double cases with two different mutations, and clones were screened for the 
presence of each mutation. The presence of biallelic mutations was confirmed in all 13 
cases. This is in line with evidence from other reports which confirmed the presence of 
biallelic CEBPA mutations in 69 (96%) of 72 cases with two different mutations 
(Preudhomme et al, 2002;Barjesteh van Waalwijk van Doorn-Khosrovani et al, 
2003;Frohling et al, 2004;Lin et al, 2005;Shih et al, 2006;Dufour et al, 2010). The vast 
majority of clones (87%) had just one mutation, consistent with the mutations being on 
different alleles, although a small number of clones (4%) from 7 different cases were found 
with both mutations. This has been described in other reports (Lin et al, 2005;Shih et al, 
2006), but it is not clear whether this is a true result or a technical error. It is possible that 
these double-mutant clones are the result of a PCR artefact caused by primers bound to 
partially annealed, mismatched templates leading to strand displacement and the formation 
of chimeric PCR products, as has been proposed for the JAK2 gene (Beer et al, 2010). 
However, it is also possible that a recombination event had occurred within the CEBPA gene 
in a small subclone of the leukaemic cells so that both mutations were on the same allele. 
Evidence from mouse models suggests that one affected CEBPA allele is not sufficient for 
leukaemogenesis (Kirstetter et al, 2008;Bereshchenko et al, 2009), and therefore cells with 
both mutations on the same allele may not have a selection advantage and would remain a 
low proportion of the population. Despite this uncertainty regarding the double-mutant 
clones, it is clear that, in all 13 cases analysed, single-mutant clones predominated. This 
indicates that the different mutations are on different alleles, but does not rule out the 
possibility that the mutations could be in different cells (Figure 5.2, option A). Therefore, 
the polymorphism status of clones from 4 of the cloned CEBPA-double cases with an 
informative polymorphism was investigated. This found an association between the 
polymorphism allele and the CEBPA mutation, with the N-terminal and C-terminal 
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mutations associated with different polymorphism alleles in clones from the same patient 
(Table 5.5). Of the 77 clones examined, only 2 clones from one patient did not follow this 
pattern, and the mutation was on the opposite polymorphism allele from other clones with 
the same mutation. Similarly to the clones with both mutations, it is possible that this was 
caused by a recombination event in a cell or is a PCR artefact. In either case, this was clearly 
a rare event (3%) and the dominant pattern found was that the different mutations were each 
on a different polymorphism allele. Given that mutation levels in these 4 patients were all 
between 31% and 59%, the polymorphism status of the clones showed it was most likely 
that the different mutations were in the same cell (Figure 5.2, option B.ii). 
 
The data presented in this chapter has shown that CEBPA mutant level is consistent with a 
heterozygous mutation present in most cells and that in CEBPA-double cases both alleles are 
mutated, with loss of WT CEBPA. Acquisition of a CEBPA mutation(s) is, therefore, 
probably an early event in leukaemogenesis in most, but not all, CEBPA-mutant cases. In 
addition, the data indicates that biallelic CEBPA mutations, and therefore loss of normal 
CEBPA, are associated with a favourable clinical outcome in FLT3/ITD-negative patients. 
Unlike CEBPA-double patients, the prognosis of CEBPA-single patients was not found to be 
significantly different from CEBPA-WT cases in the present cohort (chapter 4), and it is, 
therefore, important to correctly classify CEBPA-mutant patients as either CEBPA-single or 
CEBPA-double. This can be challenging if the type of mutation(s) detected does not fall into 
either the “classic” N-terminal or C-terminal mutation categories, and exploring these non-
classical mutations is the subject of chapter 6. 
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CHAPTER 6: TRANSACTIVATION POTENTIAL OF  
NON-CLASSICAL CEBPA MUTATIONS 
 
6.1 Introduction 
 
Mutations in CEBPA in AML patients can be detected across the whole gene and a variety of 
alterations have been identified, including missense, nonsense and in-frame or out-of-frame 
size changes. The data presented in chapter 4 shows that CEBPA-double patients lacking a 
FLT3/ITD have a favourable outcome compared to CEBPA-single or CEBPA-WT cases. 
However, if this information is to be used to aid clinical management decisions, it will be 
necessary to correctly classify patients as CEBPA-WT, CEBPA-single or CEBPA-double, 
requiring decisions as to whether individual DNA sequence alterations are functionally 
relevant mutations or non-pathogenic changes, whether germline or acquired. Whilst a role 
in leukaemogenesis has been established for the classical CEBPA mutations, this is less clear 
for the non-classical alterations and further investigation is required.  This is of particular 
importance for CEBPA-double patients with a classical mutation in combination with a non-
classical sequence change, who may be more correctly classified as CEBPA-single if the 
latter alteration was non-pathogenic. 
 
6.1.1 Impact of CEBPA mutations on protein function 
 
As introduced in chapter 3 (see section 3.1.2), mutations in CEBPA in AML patients were 
first reported by Pabst and colleagues in 2001, and they performed in vitro assays to explore 
the impact of these patient-derived mutations on C/EBPα protein function (Pabst et al, 
2001b). Since that report, there have been several comprehensive functional studies of 
CEBPA mutations, both in vitro and in vivo, and these data are introduced briefly below in 
sections 6.1.1.1 and 6.1.1.2. The focus has been on modelling the effects of out-of-frame 
insertions/deletions or nonsense mutations in the N-terminus (classical N-terminal 
mutations) and/or in-frame insertions/deletions in the DNA binding (DBD) or leucine zipper 
(LZD) domains (classical C-terminal mutations), as these are the most common types of 
mutations identified in patients. Indeed, 121 (74%) of 163 mutations in the present cohort 
were heterozygous classical N- or C-terminal mutations. However, there remains a 
significant minority of mutations that do not fall into either of these categories. 
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6.1.1.1 In vitro studies of classical N- and C-terminal CEBPA mutations 
 
The major observation made with regard to classical N-terminal mutations has been that they 
cause loss of p42 isoform expression and a concomitant increase in p30 C/EBPα (Pabst et al, 
2001b), an isoform that lacks the first transactivation domain (TAD1), but retains the DBD 
and LZD. Porse et al (2001) found that full-length p42 isoform expression was associated 
with an arrest in mitotic growth, thought to be mediated by repression of E2F-dependent 
transcription, which required the amino terminus of C/EBPα (Porse et al, 2001). In line with 
this, the p30 isoform has been found to lack both the ability to inhibit cell growth and to 
induce terminal differentiation in adipocyte and haemopoietic cell lines (Lin et al, 
1993;D'Alo' et al, 2003;Kato et al, 2011). However, these findings have not been confirmed 
in all studies, which may be related to the experimental system used. For instance, 
expression of the p30 isoform in a murine cell line had an anti-mitotic effect (Cleaves et al, 
2004), but expression of an N-terminal mutant in human haemopoietic progenitors did not 
reduce cell proliferation (Quintana-Bustamante et al, 2012).  
 
Whilst both p30 and p42 C/EBPα regulate a number of common genes, there are several 
targets restricted to only one isoform, for example MPP11, p84N5 and SMYD2 are all 
downregulated by p30 isoform expression but not p42 (Wang et al, 2007) and p42, but not 
p30, upregulates transcription of the G-CSF receptor (D'Alo' et al, 2003). Analysis of 
isoform-specific targets has also revealed mechanisms of cross-talk between p30 and p42. 
For instance, the expression of the p30 but not p42 isoform in K562 and primary AML cells 
was associated with upregulated Ubc9, leading to sumoylation of p42 C/EBPα, which 
impaired the transcriptional activity of the p42 protein (Geletu et al, 2007).  
 
The p30 isoform is expressed together with p42 C/EBPα in normal cells and changes in the 
p42/p30 isoform ratio have been observed in cell processes, such as adipocyte differentiation 
(Lin et al, 1993;Calkhoven et al, 2000). It has been hypothesised that regulation of the 
p42/p30 ratio enables cells to respond to extracellular conditions. In nutrient- or growth 
factor-rich conditions, p30 isoform expression is increased, probably mediated by increased 
eukaryotic translation initiation factors such as eIF2α and eIF4E, thereby promoting cell 
proliferation and delaying terminal differentiation (Calkhoven et al, 2000;Nerlov, 2004). In 
AML with N-terminal CEBPA mutations, the increase in p30 and concomitant decrease in 
p42 isoform expression is hypothesised to cause a loss of regulation of the p42/p30 ratio, 
thereby increasing cell proliferation and reducing differentiation (Nerlov, 2004). 
  
147 
 
Wild-type p42, hereafter called WT, can bind to target DNA sequences and activate 
transcription of genes, such as those coding for the G-CSF receptor and neutrophil elastase. 
Therefore, the functional impact of classical mutations on this transactivation (TA) activity 
has been explored by several groups using in vitro luciferase reporter assays, where human 
or murine cell lines have been transiently transfected to exogenously express C/EBPα (Pabst 
et al, 2001b;Gombart et al, 2002;Cleaves et al, 2004;Pabst et al, 2009;Kato et al, 2011). In 
assays transfecting a single C/EBPα construct into cells, C/EBPα with either a classical N-
terminal mutant or the p30 isoform had lower TA activity than the WT control (Pabst et al, 
2001b;Gombart et al, 2002;Cleaves et al, 2004;Kato et al, 2011). This reduction was 
significant in all reports, and activity was quantified at between 21% and 16% of the WT 
activity in one study (Pabst et al, 2001b) and reduced from 40-fold activation for WT over 
vector alone to 5-fold for the p30 isoform in another (Cleaves et al, 2004). N-terminal 
mutants or the p30 isoform have also been co-expressed with a WT C/EBPα construct in 
luciferase reporter assays and reduced TA activity was still observed. In one such study, TA 
activity was 28% of the WT activity (Pabst et al, 2009), and in another TA activity was 
similar for an N-terminal mutant construct or a p30 isoform construct when expressed either 
singly or co-expressed with WT (Pabst et al, 2001b). Indeed, the p30 isoform has been 
described as having a dominant negative effect over WT in several reports (Pabst et al, 
2001b;Gombart et al, 2002;Cleaves et al, 2004;Pabst et al, 2009). The mechanism(s) for the 
reduction in TA activity seen for the p30 isoform are unclear and may be related to a lack of 
TAD1 and/or a loss of DNA binding. When the ability to bind a target DNA sequence has 
been assessed by electrophoretic mobility shift assays (EMSAs), classical N-terminal 
mutants or the p30 isoform have variously been reported to have slightly reduced (Kato et al, 
2011), significantly reduced (7-fold reduction compared with WT) (Pabst et al, 2001b) or 
nearly complete absence of DNA binding ability (D'Alo' et al, 2003). There is also some 
evidence that the p30 isoform may differentially bind to specific promoters, losing affinity 
for the G-CSF receptor promoter but retaining it for the neutrophil elastase and PU.1 gene 
promoters (Cleaves et al, 2004). 
 
Wild-type C/EBPα promotes myeloid differentiation and cell-cycle arrest but, in in vitro 
studies, expression of classical N-terminal mutant or the p30 isoform in human and murine 
cell lines has been shown to cause a loss of myeloid differentiation (Pabst et al, 
2001b;D'Alo' et al, 2003;Cleaves et al, 2004;Kato et al, 2011). However, exogenous 
overexpression of classical N-terminal mutant C/EBPα in primary human haemopoietic 
progenitor cells has been reported to cause a loss of myeloid differentiation (Schwieger et al, 
2004), as well as to favour it at the expense of erythroid differentiation (Quintana-
Bustamante et al, 2012). Similarly, a consensus has not been reached on the impact of a 
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classical N-terminal mutant or the p30 isoform on cell growth, cell cycling and self-renewal 
potential, as tested by colony formation assays, re-plating efficiency and cell-cycle analysis 
of transduced human or murine cell lines and primary haemopoietic cells. This variation may 
be due to different experimental conditions, in particular differences between human and 
murine systems (D'Alo' et al, 2003;Cleaves et al, 2004;Schwieger et al, 2004;Kato et al, 
2011;Quintana-Bustamante et al, 2012). 
 
Classical C-terminal mutations have also been shown to strikingly reduce TA activity as 
compared to WT C/EBPα in luciferase reporter assays when individually transfected into 
cell lines, with 2% and less than 20% of the WT activity reported for several different 
mutations (Pabst et al, 2001b;Gombart et al, 2002;Kato et al, 2011). In assays co-expressing 
a C-terminal mutant with WT C/EBPα, 36% of the WT TA activity was reported in one 
study (Pabst et al, 2009), but no impact on activity was observed in two others (Gombart et 
al, 2002;Kato et al, 2011), and a dominant negative activity for C-terminal mutant over WT 
C/EBPα has not been identified (Pabst et al, 2001b). The lack of TA activity in the single 
construct transfection assays is associated with nearly complete loss of DNA binding for all 
classical C-terminal mutants, as tested by EMSA (Pabst et al, 2001b;Gombart et al, 
2002;Kato et al, 2011). This is consistent with the finding that expression of a C-terminal 
mutant in both a murine cell line and human haemopoietic progenitor cells caused a loss of 
myeloid differentiation (Kato et al, 2011;Quintana-Bustamante et al, 2012). Both classical 
N- and C-terminal mutants are reported to retain their nuclear subcellular location (Pabst et 
al, 2001b;Gombart et al, 2002), however the p30 isoform localised on the chromosome 
during the mitotic phase, whilst a C-terminal mutant C/EBPα did not (Kato et al, 2011). 
 
6.1.1.2 In vivo studies of classical N- and C-terminal CEBPA mutations 
 
A number of different mouse models have been developed to explore the impact of classical 
N- and C-terminal C/EBPα mutants in vivo. The first was a knock-in model that combined 
the p30 isoform, called the L allele, and a classical C-terminal mutation (K313dup, the K 
allele), which were expressed from the endogenous cebpa promoter (Bereshchenko et al, 
2009). In this study, due to the lethality associated with the mutation of both cebpa alleles, 
foetal liver cells from K/K, K/L and L/L mice were competitively transplanted into lethally 
irradiated syngeneic mice (Kirstetter et al, 2008). All mice transplanted with K/K, K/L or 
L/L cells developed leukaemia, however those receiving K/L cells had significantly shorter 
survival than those receiving K/K or L/L cells. Moreover, K/L and L/L tumours were nearly 
always granulocytic, and fractionation of the leukaemic cells by immunophenotype and 
transplantation into secondary recipients demonstrated that the leukaemia initiating cell(s) 
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was found in the myeloid progenitor compartment (Kirstetter et al, 2008;Bereshchenko et al, 
2009). By contrast, approximately only one quarter of K/K tumours could be classified as 
myeloid, while the remainder were characterised by an immature erythroid phenotype. 
However, the frequency of phenotypic HSCs was increased in mice that received K/K or 
K/L cells, but not L/L cells. The authors therefore hypothesised that the p30 isoform and the 
C-terminal mutant had different roles in leukaemogenesis, with the C-terminal mutation 
causing pre-malignant haemopoietic expansion whilst the p30 isoform maintained residual 
myeloid commitment (Bereshchenko et al, 2009).  
 
In a second model, Kato and colleagues transduced murine BM mononuclear cells with 
retroviral C/EBPα expression construct(s) to induce overexpression of a C-terminal mutant 
(K304_R323dup), an N-terminal mutant (T60fs), or both, and these cells were then 
transplanted into irradiated syngeneic mice (Kato et al, 2011). Nearly all mice receiving 
cells transduced with the C-terminal mutant construct developed AML within 4 to 12 
months after transplantation, however most mice receiving an N-terminal mutant remained 
healthy for at least a year, with a minority developing a B-cell acute lymphoid leukaemia. As 
with the knock-in model, co-expression of the N- and C-terminal mutants shortened the 
latency of AML development to 3 to 5 months (Kato et al, 2011). However, contrasting 
results were reported by Quintana-Bustamante et al (2012), who transduced human 
haemopoietic progenitor cells with a lentiviral C/EBPα expression construct for WT, an N-
terminal mutant, a C-terminal mutant or both the N- and C-terminal mutant constructs 
(Quintana-Bustamante et al, 2012). Whilst initial engraftment was observed for all 
constructs, by 8 weeks all or almost all of the graft had been lost. These data indicated that 
all constructs caused loss of re-populating capacity and suggested that further events were 
required for the transformation of normal human haemopoietic stem/progenitors. 
 
6.1.1.3 Functional impact of non-classical CEBPA mutations 
 
Predicting the impact on protein function of a specific DNA sequence alteration can be 
difficult. As indicated above, functional studies of mutated C/EBPα have largely focussed on 
the two most common types of mutations, and the evidence suggests that all p30-causing 
CEBPA mutations and all classical C-terminal mutations so far evaluated generate a protein 
lacking some of the functional activities of normal p42 protein. However, a significant 
proportion of the mutations in the present cohort (42 of 163, 26%) were identified as neither 
of the classical mutations, and only a few individual non-classical alterations identified in 
patients have been tested in in vitro assays. Pabst et al (2001b) assayed three non-classical 
mutations for their impact on TA activity in a luciferase reporter assay, an N-terminal 
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missense mutation that did not cause an increase in the p30 isoform expression (H84L), a 
frame-shift in the middle of the gene that caused a complete loss of the C-terminus for both 
the p30 and the p42 isoforms (R165fs), and a frame shift in the C-terminus that slightly 
truncated both isoforms (V351fs). These mutants varied widely in their TA activity as 
compared with WT, with no difference seen for H84L, a reduction in activity for V351fs 
C/EBPα, and a large increase in activity for the R165fs mutant (Pabst et al, 2001b). The 
findings that H84L mutant C/EBPα did not impair TA activity and the V351fs mutant 
decreased activity are predictable given the known functional consequences of the classical 
mutations. However, the observation that R165fs mutant C/EBPα strongly increased TA 
activity is unexpected and was not explained. 
 
In the patient cohort described in chapter 3, 22 (13%) of the 163 mutations detected were 
nonsense mutations or frame-shift/truncating insertions/deletions after the p30 isoform 
translation initiation site (15 in CEBPA-single and 7 in CEBPA-double cases). These are 
predicted to cause loss of some or all of the C-terminal DBD and LZD and could be 
expected to cause a loss of C/EBPα TA activity similar to that of classical C-terminal 
mutants. In addition, in the middle region of CEBPA there were six missense mutations, of 
which five were in CEBPA-single cases, and three in-frame insertions/deletions, all in 
CEBPA-single cases. The functional significance of these mutations is not clear. Unless this 
region is a “hotspot” for random mutations it is likely that their presence causes a selection 
advantage. In theory they could, by unknown mechanisms, lead to reduced TA activity and 
may act as a classical N-terminal mutation, with dominant-negative activity over the WT 
protein. Alternatively, they might not affect TA activity, as determined in in vitro assays, 
and have a different role in leukaemia pathogenesis. Therefore, to further explore the role of 
these atypical mutations an assay to determine the TA activity of C/EBPα mutants was 
developed. 
 
6.1.2 Quantifying C/EBPα transactivation activity by luciferase reporter assay 
 
As described above, luciferase reporter assays have been employed in several different 
reports as a technique for determining the TA activity of C/EBPα. In these assays, a 
luciferase reporter construct is generated that contains copies of a C/EBPα target sequence, 
such as the binding sequence in the CSF3R gene promoter (G-CSF receptor), upstream of a 
luciferase gene, and this is then co-transfected into cells together with a construct containing 
the required CEBPA sequence (Figure 6.1). C/EBPα that can recognise the target sequence 
in the reporter construct and bind to the DNA as a dimer activates transcription of the 
luciferase gene (Figure 6.1 A). C/EBPα variants that are deficient in DNA binding and/or 
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transcriptional activation activity will result in reduced levels of luciferase transcription 
(Figure 6.1 B and C). The amount of luciferase generated can then be assessed by cell lysis, 
addition of the luciferase substrate luciferin, and measurement of the luminescence in a 
luminometer. This system can also be utilised to explore the interaction between different 
C/EBPα proteins by co-transfection of more than one CEBPA construct. This is important 
because patients with CEBPA mutations may co-express either mutant and WT C/EBPα 
(CEBPA-single) or two different mutant proteins (CEBPA-double). 
 
This chapter presents the results of an investigation into the impact of non-classical CEBPA 
mutations on C/EBPα TA activity using a luciferase reporter assay.
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Figure 6.1 Principles of testing C/EBPα transactivation activity using a luciferase reporter assay. A luciferase reporter construct containing C/EBPα 
binding sites is co-transfected into cells with one or more CEBPA constructs. Wild-type p42 C/EBPα (A) can recognise its target sequence, bind to DNA, 
dimerise and activate transcription of the luciferase gene. The p30 isoform (B), retains the DNA binding and leucine zipper domains (DBD and LZD), but 
lacks the first transactivation domain, reducing transcription of the luciferase gene. C/EBPα with a DBD or LZD mutation (C) may be deficient in binding to 
DNA or dimerisation, thereby reducing luciferase transcription. The relative amounts of active firefly luciferase are determined by addition of the substrate, 
luciferin, and measuring luminescence. For simplification, C/EBPα dimers and mixtures are not shown here. 
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6.2 Materials and Methods 
 
To study the TA activity of non-classical CEBPA mutations, a number of C/EBPα 
expression constructs (section 6.2.1) were made by PCR amplification of the required 
CEBPA sequence from genomic DNA (section 6.2.2) that was cloned into murine stem cell 
virus (MSCV) vectors containing a fluorescent marker gene and used to transform bacteria 
(section 6.2.3). Bacterial clones were analysed to identify constructs containing the desired 
CEBPA insert (section 6.2.4). C/EBPα expression vectors were then co-transfected into 
293T cells with a Renilla luciferase expression plasmid supplied by Promega and a 
luciferase reporter construct, pTK81-CSF3R-luc, which was kindly donated by Thomas 
Pabst of the University of Bern, Switzerland with the permission of Daniel Tenen of the 
Beth Israel Deaconess Medical Center, Harvard, USA, and has been described previously 
(Pabst et al, 2001b) (section 6.2.5). The TA activity was then determined using the Dual-
Luciferase Reporter Assay System from Promega (section 6.2.6). 
 
6.2.1 Selection of C/EBPα controls and mutants 
 
Overall, 16 different CEBPA sequences were cloned into MSCV vectors (Table 6.1). All 
constructs contained the entire CEBPA coding sequence except one, p30, which only 
included the sequence for the p30 isoform and was utilised as a control for immunoblotting. 
Three were control constructs containing WT CEBPA, a classical N-terminal or a classical 
C-terminal mutation. The N-terminal mutant control (hereafter called N), Q83fs, was 
detected in three cases in the cohort presented in chapter 3, two CEBPA-double and one 
CEBPA-single (Table 6.2), and was predicted to cause loss of full-length p42 isoform and an 
increase of p30 translation. The C-terminal mutant control (hereafter called C) was 
K313dup, a duplication in the LZD that has been investigated previously in both in vitro and 
in vivo studies (Carnicer et al, 2008;Bereshchenko et al, 2009) and was detected in six cases 
in the cohort (4 CEBPA-double, 2 CEBPA-single, Table 6.2). A second classical C-terminal 
mutation that was in the DBD (K304_Q305insL) identified in three CEBPA-double cases 
and the known 6 bp polymorphism (H195_P196dup, see section 3.1.2) were investigated as 
additional controls.  
 
The remaining 10 CEBPA sequences were selected from the non-classical mutations 
identified in the patient cohort. Of the 115 mutations detected in 59 CEBPA-double patients, 
14 (12%) were neither classical N-terminal nor classical C-terminal mutations. For the 
purposes of this study homozygous mutations were considered non-classical. They included 
four out-of-frame insertions/deletions, one nonsense and one missense mutation in the
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Table 6.1 CEBPA constructs generated 
 
Construct Type 
Nucleotide 
change 
Amino acid 
change 
Method used to 
screen clones
1
 
Controls:    
WT / Kozak-WT None None Sequencing 
Kozak-p30 1_357del M1_V119del Sequencing 
6 bp polymorphism 584_589dup H195_P196dup 
Fragment analysis  
D4-CEBPA/2F + CEBPA/2R 
Δ = +6 bp 
Classic N-terminal 247delC Q83fs Sequencing 
Classic C-terminal (LZD) 937_939dup K313dup Sequencing 
Classic C-terminal (DBD) 912_913insTTG K304_Q305insL 
Fragment analysis 
D4-CEBPA/3F + MSCV/R2 
Δ = +3 bp 
Atypical mutations from CEBPA-doubles cases:  
Out-of-frame del in middle 625delC Q209fs Sequencing 
Out-of-frame ins in middle 707_708insT A238fs 
CEBPA/2F2 + CEBPA/2R 
FokI digestion 
WT = 35+298 bp 
MUT = 35+93+205 bp 
Out-of-frame ins in LZD 938_939insTA K313fs Sequencing 
Missense in DBD 883G>C A295P 
CEBPA/3F + MSCV/R2 
FokI digestion 
WT = 400 bp 
MUT = 136+264 bp 
Missense in middle 827A>G K276R 
CEBPA/3F + MSCV/R2 
MnlI digestion 
WT = 42+358 bp 
MUT = 39+42+319 bp 
Atypical mutations from CEBPA-singles cases:  
Deletion in middle 558_566del P187_P189del 
Fragment analysis 
D4-CEBPA/2F + CEBPA/2R 
Δ = -9 bp 
Deletion in middle 578_589del H193_P196del 
Fragment analysis 
D4-CEBPA/2F + CEBPA/2R 
Δ = -12 bp 
Missense in middle 548C>A P183Q 
CEBPA/2F2 + CEBPA/2R 
BbvI digestion 
WT = 47+50+89+147 bp 
MUT = 33+47+50+ 
80+114 bp 
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Table 6.1 Continued 
 
Construct Type 
Nucleotide 
change 
Amino acid 
change 
Method used to 
screen clones
1
 
Atypical mutations from CEBPA-single cases continued:  
Missense in middle 698C>G P233R 
CEBPA/2F2 + CEBPA/2R  
FspI digestion 
WT = 333 bp 
MUT = 106+227 bp 
Missense in middle 724G>A G242S 
CEBPA/2F2 + CEBPA/2R 
DdeI digestion 
WT = 333 bp 
MUT = 82+251 bp 
 
 
1
 Clones containing the desired CEBPA sequence were identified by either sequencing 
plasmid DNA from MSCV/F2 and MSCV/R2 or by PCR amplification with the indicated 
primers and subsequent fragment analysis or specific restriction enzyme digestion. 
All primer sequences are given in Appendix Table 1. Abbreviations: del, deletion; ins, 
insertion; dup, duplication; DBD, DNA-binding domain; LZD, leucine zipper domain; bp, 
base pairs; Δ, difference in fragment size between WT and mutant clones; WT, wild-type 
clones; MUT, mutant clones. 
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Table 6.2 Patients identified with the mutations used in the constructs 
 
CEBPA construct Patient(s) identified with mutation 
Type 
Amino acid 
change 
Single 
or Double
1
 
Second mutation 
(location in gene
2
) 
No.
3
 
     
Controls:     
WT / Kozak-WT None    
Kozak-p30 M1_V119del    
6 bp polymorphism H195_P196dup    
Classic N-terminal Q83fs 
Single 
Double 
Double 
NA 
R300_Q312dup (C) 
K313dup (C) 
50 
51 
52
4
 
Classic C-terminal (LZD) K313dup 
Double 
Double 
Double 
Double 
Single 
Single 
G53fs (N) 
I68fs (N) 
L78fs (N) 
Q83fs (N) 
NA 
NA 
29 
43 
48 
52
4
 
96 
97 
Classic C-terminal (DBD) K304_Q305insL 
Double 
Double 
Double 
P23fs (N) 
H24fs (N) 
G99fs (N) 
5 
8 
59 
Atypical mutations from Doubles:    
Out-of-frame del in middle Q209fs Double H24fs (N) 7 
Out-of-frame ins in middle A238fs Double V95fs (N) 56 
Out-of-frame ins in LZD K313fs Double G38fs (N) 21 
Missense in DBD A295P Double A44fs (N) 25 
Missense in middle K276R 
Double 
Single 
L178fs (Middle) 
NA 
71 
86 
Atypical mutations from Singles:    
Deletion in middle P187_P189del 
Single 
Single 
NA 
NA 
74 
75 
Deletion in middle H193_P196del Single NA 76 
Missense in middle P183Q Single NA 73 
Missense in middle P233R Single NA 79 
Missense in middle G242S 
Single 
Single 
NA 
NA 
80 
81 
 
1
Patient classified as CEBPA-single (Single) or CEBPA-double (Double). 
2
Location in gene 
refers to either the N-terminus (N, from p42 ATG to p30 ATG), middle (between the p30 
ATG and the DBD) or C-terminus (C, DBD or LZD).
 3
Patient number relates to Appendix 
Table 2. 
4
Mutations not present in CR sample. Abbreviations: NA, not applicable; del, 
deletion; ins, insertion; dup, duplication; DBD, DNA-binding domain; LZD, leucine zipper 
domain. 
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middle region, and three missense, three homozygous and two out-of-frame 
insertions/deletions in the C-terminus (Table 3.3). Of these atypical mutations, five 
representative alterations were chosen: an out-of-frame deletion in the middle of the gene 
(Q209fs), an out-of-frame insertion in the middle (A238fs) and one in the LZD (K313fs), all 
predicted to truncate both the p30 and the p42 isoforms, and two missense mutations, one 
just upstream of and one within the DBD (K276R and A295P, respectively). One of these, 
K276R, occurred in both a CEBPA-single and a CEBPA-double case (Table 6.2) and it was 
unknown if either missense mutation would impact on the TA activity of C/EBPα. 
 
Of the 48 CEBPA-single cases identified in the cohort, 28 (58%) had atypical CEBPA 
mutations (Table 3.3), including 11 cases with out-of-frame insertions/deletions and one 
with a nonsense mutation in the middle of the gene, and three with out-of-frame 
insertions/deletions in the C-terminus, all predicted to cause a truncated protein for both 
isoforms. In addition, ten patients had missense mutations (five in the middle and five in the 
C-terminus) and three cases had in-frame deletions in the middle. Five representative 
mutations were selected for further analysis: two in-frame deletions (H193_P196del and 
P187_P189del) that were detected in one and two cases respectively and affected similar 
residues to the 6 bp polymorphism (H195_P196dup), and three missense mutations in the 
middle (P183Q, P233R, G242S) of unknown significance (Table 6.1 and Table 6.2). 
 
6.2.2 CEBPA amplicons for insertion into MSCV vectors 
 
There were three different primer pairs used in PCRs to amplify the required CEBPA 
sequences for insertion into MSCV vectors (Figure 6.2). All primer sequences are given in 
Appendix Table 1. First, amplicons of the entire CEBPA coding sequence were amplified 
from known CEBPA-WT genomic DNA (gDNA) using primers CEBPA/Clone/F and 
CEBPA/Clone/R to generate a 1125 bp product (Figure 6.2 A). For both primers, the 22 
nucleotides at the 3′ end were complementary to the indicated CEBPA sequence, and the 
sequence towards the 5′ end contained a restriction enzyme recognition site for cloning 
purposes, EcoRI in the forward and XhoI in the reverse primer, with an additional 12 
nucleotides at the 5′end to enable efficient digestion. In addition, the forward primer 
sequence included a Kozak consensus sequence directly upstream of the translation initiation 
codon for the p42 isoform, and therefore this amplicon was termed Kozak-WT (Figure 6.2 
A). 
 
Second, primers CEBPA/Clone-p30/F and CEBPA/Clone/R were used to generate a 768 bp 
PCR product containing only the p30 isoform sequence from a known CEBPA-WT gDNA 
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Figure 6.2 Generation of CEBPA constructs. The required CEBPA coding sequence was 
amplified from genomic DNA using primers that included a 3′ end complementary to the 
CEBPA sequence and a 5′ end that incorporated a restriction enzyme recognition site (EcoRI 
or XhoI) to enable cloning into the vector. Three different primer pairs were used: A. 
CEBPA/Clone/F and CEBPA/Clone/R were used to amplify the entire WT CEBPA coding 
sequence. The forward primer incorporated a Kozak consensus sequence directly upstream 
of the p42 translation initiation site (Kozak-WT). B. CEBPA/Clone-p30/F and 
CEBPA/Clone/R amplicons included only the p30 isoform CEBPA coding sequence and a 
Kozak consensus sequence was incorporated directly upstream of the p30 translation 
initiation site (Kozak-p30). C. CEBPA/Clone-UTR/F and CEBPA/Clone/R amplicons 
contained the entire CEBPA coding sequence and 165 base pairs (bp) of the 5′ untranslated 
region (WT or mutant) that included the endogenous Kozak consensus sequence.  
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(Figure 6.2 B). As above, the forward and reverse primer sequences included EcoRI and 
XhoI recognition sites and the forward primer contained a Kozak consensus sequence 
directly upstream of the translation initiation codon of the p30 isoform. This amplicon was 
termed Kozak-p30 (Figure 6.2 B). For reasons explained below (section 6.3), the Kozak-WT 
and Kozak-p30 C/EBPα constructs were only used as controls to produce protein for 
immunoblotting. 
 
Primers CEBPA/Clone-UTR/F and CEBPA/Clone/R were used to amplify a 1284 bp PCR 
product that contained the entire CEBPA coding sequence and 165 bp of the 5′ untranslated 
region (UTR) from gDNA that included the endogenous Kozak consensus sequence (Figure 
6.2 C).  These primer sequences included the restriction enzyme recognition sites as 
described above. These primers were used to produce PCR products for creating each of the 
CEBPA constructs given in Table 6.1 except for the two Kozak constructs, and a gDNA 
sample containing the desired CEBPA sequence (WT or mutant) was used as template 
(Table 6.2).  
 
The proof-reading enzyme Phusion Hot Start High-Fidelity DNA Polymerase was used for 
amplification with all three primer pairs to minimise the addition of incorrect nucleotides. 
The standard reaction mix was used (see section 2.1.2), except this was scaled up to 50µl 
and 5% DMSO was added. The annealing temperature was 62°C and the standard cycling 
conditions were used, except the extension time was increased from 42 seconds to 1 minute 
and the final extension step from 5 minutes to 10 minutes. The entire PCR product was 
electrophoresed in a 1% agarose gel along with a DNA ladder (Hyperladder I, Bioline, 
London, UK), and the correctly sized band was excised from the gel and purified using the 
QIAquick Gel Extraction kit (QIAGEN, Crawley, UK). 
 
6.2.3 Cloning of CEBPA amplicons into MSCV vectors 
 
Two different MSCV retroviral expression vectors, MSCV.I.GFP (6564 bp) and 
MSCV.I.eBFP2 (6541 bp), were used to create the CEBPA constructs. They were kindly 
provided by Dr. Martin Pule of the Department of Haematology, UCL Cancer Institute. Both 
plasmids contained an ampicillin resistance gene, an internal ribosome entry site (IRES) and 
a fluorescent marker gene, either green fluorescent protein (GFP) or enhanced blue 
fluorescent protein 2 (eBFP2), and the sequences were identical except for the GFP or 
eBFP2 sequence. The fluorescent marker genes were used to assess the efficiency of 
transfections. When two CEBPA constructs were co-transfected, each construct had a 
different marker gene and the different markers could be used to check that both CEBPA 
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constructs were in the same cells. All 16 CEBPA sequences were cloned into the 
MSCV.I.GFP vector, and the WT, N and C mutant controls were also cloned into the 
MSCV.I.eBFP2 vector. An overview of the cloning strategy is shown in Figure 6.3. 
 
The cloning site of the MSCV vectors contained an EcoRI and an XhoI restriction enzyme 
recognition sequence, which were also present at the 5′ and the 3′ end of the CEBPA 
amplicons (section 6.2.2), and digestion of vector and PCR products with both EcoRI and 
XhoI created complementary over-hanging ends enabling ligation of the insert into the vector 
in both the correct location and orientation (Figure 6.3). For digestion of either vector, 5µg 
of vector was incubated with 5µl of EcoRI, 5µl of XhoI and 10µl of EcoRI 10x reaction 
buffer (New England Biolabs Ltd., Hitchin, UK) in a total volume of 100µl at 37°C for 5 
hours. For digestion of the PCR amplicons, the digestion mix was identical except the entire 
purified product (section 6.2.2) was used rather than the vector. The entire digestion reaction 
for vectors and PCR amplicons was electrophoresed in a 1% agarose gel together with 
Hyperladder I and correctly sized bands were excised and purified using the QIAquick Gel 
Extraction kit.  
 
The DNA concentrations of the purified digested products and vectors were determined 
using a NanoDrop 1000 Spectrophotometer and the values used to calculate appropriate 
volumes of both vector and insert to use in the ligation reaction according to the formula: 
 
ng of insert =  length of insert, kilobase (kb) x ng of vector 
  length of vector, kb x insert:vector ratio 
 
The amount of vector used was always 1000ng and the insert:vector ratio 3:1. The ligation 
mix contained 3µl T4 DNA ligase (New England Biolabs UK Ltd.), 5µl T4 DNA ligase 
buffer, 1000ng of the digested vector, the calculated amount of digested insert and water to a 
total volume of 50µl, and this was incubated at 16°C for 15 minutes. The ligase reaction 
mix, 2µl, was then used to transform One Shot Max Efficiency DH5α-T1 E. coli (see section 
2.1.9).  
 
6.2.4 Analysis of bacterial clones 
 
For all constructs where sequencing was used to screen colonies (Table 6.1), between 2 and 
5 bacterial colonies per transformation were picked and individually seeded into 4ml of LB 
containing 100µg/ml carbenicillin and incubated with shaking at 37°C overnight.  
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Figure 6.3 Overview of CEBPA cloning. PCR amplicons of the CEBPA coding sequence 
were obtained from genomic DNA with primers that introduced an EcoRI restriction site at 
the 5′ end and an XhoI restriction site at the 3′ end of the PCR product to enable cloning into 
the MSCV vector. The insert and vector were digested with EcoRI and XhoI before ligation 
and transformation of E. coli.  
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Glycerol stocks of each clone were made and the plasmid DNA was extracted from the 
remaining culture using the QIAprep Spin Miniprep Kit (QIAGEN), as described in section 
2.1.10. The entire CEBPA insert was sequenced from primers that annealed in the vector, 
MSCV/F2 and MSCV/R2.  
 
For the remaining constructs, between 10 and 20 colonies per transformation were picked 
and individually seeded into 200µl of LB containing 100µg/ml carbenicillin in a well of a 
96-well plate and incubated overnight at 37°C (section 2.1.10). The region of the CEBPA 
sequence containing the location of the desired sequence alteration was then amplified using 
the bacterial culture as template with the primers given in Table 6.1 (see chapter 5 for PCR 
protocols). In four cases, fragment analysis with a fluorescently labelled primer was 
performed as described in chapter 5, with clones containing the required mutation selected 
by size. In six cases, PCR products were digested with a restriction enzyme that gave a 
different digestion pattern for WT and mutant clones, which could be detected by agarose 
gel electrophoresis. All restriction enzymes and digested fragment sizes for WT and mutants 
are given in Table 6.1. Two or three colonies per construct that were positive for the desired 
size change by fragment analysis or digestion pattern by restriction enzyme digestion were 
then selected for sequencing. The culture was used to inoculate 4ml of LB containing 
100µg/ml carbenicillin and incubated with shaking at 37°C overnight. Glycerol stocks of 
each clone were made and the plasmid DNA was extracted from the remaining culture using 
the QIAprep Spin Miniprep Kit (see section 2.1.10). The entire CEBPA insert was sequenced 
from primers MSCV/F2 and MSCV/R2. 
 
A single colony with the desired CEBPA sequence, either WT or mutant, was selected for 
each construct and the glycerol stock used to grow a 200ml culture from which the plasmid 
DNA was extracted using the HiSpeed Plasmid Midi Kit (QIAGEN), as described in section 
2.1.10. 
 
6.2.5 Co-transfection of 293T cells 
 
293T cells were transiently co-transfected with a mixture of plasmids using GeneJuice as a 
transfection reagent as described in section 2.2.4. Optimisation of the amounts of each 
construct per well in the transfection was performed and is described in section 6.3.1. 
Following optimisation, cells were co-transfected for dual-luciferase assays, immunoblotting 
and FACS analysis as detailed below. 
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For dual-luciferase assays, each well of a 24-well plate received 80ng pTK81-CSF3R-luc 
reporter construct, 1ng Renilla luciferase construct (Promega) and a total of 100ng of empty 
MSCV vector (V) or CEBPA construct, either a single construct or a 1:1 mixture of two 
constructs. For immunoblotting and FACS analysis, 293T cells were transfected in 6-well 
plates. The amount of DNA was increased to 320ng pTK81-CSF3R-luc, 4ng Renilla 
luciferase and 400ng of V or CEBPA construct per well, either a single construct or a 1:1 
mixture of two constructs. Cells were left for 24 hours at 37°C in a humidified atmosphere 
with 5% CO2, and the efficiency of the transfection checked by detection of GFP and/or 
eBFP2 expression with a fluorescence microscope before further analysis. 
 
6.2.6 Immunoblotting for C/EBPα protein 
 
Cell lysates from transfected and non-transfected 293T cells were prepared and between 
20µg and 30µg protein subjected to SDS-PAGE, as described in sections 2.3.4 to 2.3.6. The 
separated proteins were transferred to a nitrocellulose membrane that was then blocked 
(2.3.6 and 2.3.7). Two C/EBPα antibodies were used in this study, #2295 and #2843 (both 
rabbit anti-human from Cell Signaling Technologies). The epitope for #2295 is downstream 
of the p30 translation initiation site and therefore both p42 and p30 isoforms could be 
detected, while the epitope for #2843 is near the N-terminus and therefore detects p42, but 
not p30. C/EBPα antibody was incubated with the membrane over-night on a rocking 
platform at 4°C at a concentration of 1:1000 in 5% non-fat milk powder in TBST for #2295 
and in 5% BSA in PBS for #2843. Incubation with secondary antibody and detection were 
performed as described in section 2.3.7. If both C/EBPα antibodies were to be used, the 
membrane was stripped after detection of the first antibody and re-blocked before incubating 
with the second antibody. After detection of the primary antibody/antibodies, the membrane 
was re-blocked, without stripping, and incubated for 1-2 hours at room temperature with 
anti-tubulin antibody (mouse anti-human, Sigma-Aldrich Company Ltd.) as a loading 
control at a concentration of 1:5000 in 1% BSA in PBS. Incubation with the secondary 
antibody and detection were then performed as described in section 2.3.7. 
 
6.2.7 Flow cytometric analysis 
 
Growth medium was removed from cells in 6-well plates and the cells washed once in PBS, 
then incubated with 300µl trypsin-EDTA solution per well until they dissociated from the 
plate surface. The cell suspension was transferred to a FACS tube and centrifuged for 5 
minutes at 450g, the supernatant removed and the cells resuspended in 500µl PBS before 
analysis of GFP and BFP expression on a CyAn flow cytometer (Beckman Coulter). 
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6.2.8 Dual-luciferase reporter assays 
 
The Dual-Luciferase Reporter Assay System from Promega was used to measure the TA 
activity of C/EBPα variants (Figure 6.4). In this system, variation in transfection efficiency 
is controlled for by co-transfection of the C/EBPα and pTK81-CSF3R-luc constructs into 
293T cells together with a Renilla luciferase expression plasmid, supplied by Promega, as an 
internal control. The firefly luciferase reporter construct, pTK81-CSF3R-luc, contains four 
copies of the C/EBPα binding site from the CSF3R gene promoter upstream of a firefly 
luciferase gene, and transcription of the luciferase gene is caused by active C/EBPα (Pabst et 
al, 2001b). It was assumed that the Renilla luciferase expression was independent from the 
C/EBPα and firefly luciferase expression. The firefly and Renilla luciferases require 
different substrates (luciferin and coelenterazine, respectively) and this is exploited in the 
assay. 
 
As per the manufacturer’s instructions, co-transfected 293T cells were lysed in the supplied 
passive lysis buffer and the firefly luciferase reaction initiated by addition of the lysate to 
LARII, which contains luciferin (Figure 6.4). The luminescence generated, reflecting the TA 
activity of the C/EBPα, was measured using a TD-20/20 luminometer (Turner Designs) that 
was programmed for a 2 second pre-read delay followed by a 10 second measurement 
period. Addition of Stop & Glo Reagent simultaneously quenched the firefly luciferase 
reaction and initiated the Renilla luciferase reaction by supplying coelenterazine. The 
luminescence caused by the Renilla luciferase reaction was then measured and reflected the 
transfection efficiency of that sample. The mean luminescence over the measurement period 
was calculated for both the firefly (L) and the Renilla (R) luciferase for each sample. Results 
were normalised for transfection efficiency using the Renilla activity by calculating L/R for 
each sample. Unless indicated otherwise, within each experiment three separate wells were 
transfected per condition and the average L/R of the three measurements calculated before 
normalising all results in the same assay to the WT control, which was set at 100%, so that 
all results were expressed as a percentage of WT C/EBPα activity. Each condition was 
repeated in three or more separate experiments and the mean plotted with standard error of 
the mean as error bars. A t-test with two-tails was used to compare results and P-values < 
.05 were considered significant. 
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Figure 6.4 Overview of the dual-luciferase reporter assay. C/EBPα constructs with 
fluorescent marker genes (green fluorescent protein, GFP, or enhanced blue fluorescent 
protein 2, eBFP2) were co-transfected into 293T cells with the firefly luciferase reporter 
construct (pTK81-CSF3R-luc) and a Renilla luciferase construct as an internal control for 
the transfection. Using the Dual-Luciferase Reporter Assay System (Promega), firefly 
luciferase and Renilla luciferase activity were sequentially measured in cell lysates. 
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6.3 Results 
 
Three control CEBPA constructs, WT, an N-terminal mutant (Q83fs, N) and a C-terminal 
mutant (K313dup, C), were made by cloning PCR products of the entire CEBPA coding 
sequence and 165 bp of the 5′ UTR from a gDNA sample containing the desired CEBPA 
sequence into both MSCV.I.GFP and MSCV.I.eBPF2 (Figure 6.2 C). The conditions for the 
dual-luciferase assay were optimised using these control constructs. Two other control 
constructs, Kozak-WT and Kozak-p30, were made by cloning PCR products of the CEBPA 
coding sequence from known CEBPA-WT gDNA into MSCV.I.GFP, with Kozak-WT 
containing the entire p42 sequence and Kozak-p30 only the p30 isoform sequence. Both 
were amplified with a forward primer that contained a Kozak consensus sequence directly 
upstream of the translation initiation sites for the p42 and p30 isoforms, respectively (Figure 
6.2 A and B). The Kozak-WT construct was prepared first but it was found to be unsuitable 
for the luciferase-reporter assay as only the p42 isoform, not the p30, was expressed from 
this construct. Endogenous expression of the p30 isoform requires a conserved open reading 
frame (ORF) that initiates at “site D”, 25 bp upstream of the most commonly used p42 
isoform translation initiation site (Calkhoven et al, 2000). This short upstream ORF is in a 
different reading frame from the CEBPA coding sequence and terminates only five codons 
after initiation. With, presumably, insufficient space for re-initiation at the p42 ATG, this is 
predicted to lead to translation re-initiation by the ribosome further downstream at the p30 
isoform translation initiation site, with mutation of site D associated with a loss of p30 
isoform expression (Calkhoven et al, 2000). The Kozak-WT and Kozak-p30 constructs 
were, therefore, only used as controls to produce protein for immunoblotting. 
 
6.3.1 Optimising assay conditions 
 
Optimisation was performed to determine the amount of each construct that should be used 
in the co-transfection of 293T cells for the dual-luciferase assays. For the Renilla luciferase 
expression construct, transfection of 293T cells with 1ng per well of a 24-well plate resulted 
in strong luminescence from the Renilla luciferase reaction (R). For instance, the mean R 
across 24 transfected wells in one experiment was 1803 relative light units (range 1325 to 
2701). Therefore, this amount was used in all experiments.  
 
In order to investigate the impact of the amount of C/EBPα expression construct on the 
transfection efficiency, cells were transfected with 100ng, 200ng or 460ng of construct per 
well of a 24-well plate for each WT, N or C control MSCV.I.GFP construct. The proportion 
of cells expressing the fluorescent marker gene after 24 hours was determined by flow 
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cytometry (Figure 6.5). The average transfection efficiency overall was 58% (range 47% to 
74%), and there were no striking differences according to either the amount of construct per 
well or which construct was used.  
 
To examine the impact of the amount of CEBPA construct in the dual-luciferase assay, 50ng, 
100ng or 200ng of MSCV.I.GFP vector alone and each MSCV.I.GFP WT, N or C construct 
was co-transfected with 1ng of the Renilla luciferase expression construct and 80ng of the 
luciferase reporter construct, pTK81-CSF3R-luc. This amount of pTK81-CSF3R-luc was 
selected as it had been used in a previous report (Pabst et al, 2009). The firefly luciferase 
activity (L) and R were measured by dual-luciferase assay after 24 hours and the results 
normalised for variation in transfection efficiency by calculating L/R. The mean and 
standard error of the mean (SEM) of three separate transfections is shown in Figure 6.6 A. 
The background luminescence from the cells with the vector alone was very low (mean L/R 
0.006, range 0.004 to 0.007). Increasing the amount of construct per well from 50ng to 
200ng caused a slight increase in L/R but the differences were not significant for a specific 
construct (Figure 6.6 A). As expected, the WT construct strongly activated transcription, 
with an average 44-fold increase in L/R over the vector alone, and there were significant 
differences in the TA activity of the different C/EBPα control constructs, which will be 
discussed in section 6.3.2.3. 
 
The impact of different amounts of pTK81-CSF3R-luc on the dual-luciferase assay was also 
tested. 293T cells were transfected with 50ng, 80ng, 100ng or 150ng of the luciferase 
reporter construct and 50ng or 100ng of the V alone, WT, N or C MSCV.I.GFP C/EBPα 
expression construct together with 1ng of the Renilla luciferase expression construct per 
well, and TA activity measured after 24 hours (Figure 6.6 B). The experiment was only 
performed once. As before, the background L/R for the MSCV.I.GFP transfected cells was 
very low for all conditions (average 0.012, range 0.006 to 0.023). Overall, increasing the 
amount of pTK81-CSF3R-luc was associated with an increase in the L/R, regardless of the 
C/EBPα construct in the co-transfection, with the exception of a slight reduction in L/R from 
50ng to 80ng of the luciferase reporter construct. However, the amount of pTK81-CSF3R-
luc did not impact on the relative TA activity pattern of the different C/EBPα expression 
constructs within the same set of conditions, with the highest L/R values for the WT 
construct conditions and a reduction in L/R for the N and C mutant constructs (Figure 6.6 
B).
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Figure 6.5 Impact of CEBPA construct quantity on transfection efficiency. Representative FACS plots of 293T cells 24 hours after transfection with 
varying amounts (100ng, 200ng or 460ng) of WT, an N-terminal mutant (N) or a C-terminal mutant (C) C/EBPα MSCV.I.GFP construct per well of a 24-well 
plate. The percentage indicates the proportion of GFP positive cells. 
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Figure 6.6 Optimisation of transient transfections for dual-luciferase assays. Results of 
dual-luciferase assays (Promega) performed on 293T cells 24 hours after co-transfection 
with 1ng of the Renilla luciferase expression construct and varying amounts of the 
MSCV.I.GFP CEBPA construct and the luciferase reporter construct (pTK81-CSF3R-luc). 
Firefly luminescence (L) was normalised for variation in transfection efficiency by 
calculating L/ Renilla luciferase luminescence (R). A. Cells co-transfected with 80ng of 
pTK81-CSF3R-luc and 50ng, 100ng or 200ng of the MSCV.I.GFP vector alone (V) or a 
CEBPA construct (WT, N or C) per well. The mean and SEM of three separate experiments 
is shown. B. Cells co-transfected with 50ng, 80ng, 100ng or 150ng of pTK81-CSF3R-luc, 
and either 50ng or 100ng of a CEBPA construct or V alone per well. The results of a single 
experiment are shown.   
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For all subsequent dual-luciferase assays cells were therefore co-transfected with 100ng of 
the C/EBPα expression construct, 80ng of pTK81-CSF3R-luc and 1ng of the Renilla 
luciferase construct per well of a 24-well plate 
 
6.3.2 Transactivation activity of control CEBPA constructs 
 
Using the co-transfection conditions determined above, C/EBPα protein expression, marker 
gene expression and the TA activity of the control constructs (WT, N and C) in both 
MSCV.I.GFP and MSCV.I.eBFP2 were investigated. 
 
6.3.2.1 C/EBPα expression in cells transfected with single constructs 
 
To confirm that the control CEBPA constructs expressed C/EBPα protein, each control 
construct (WT, N and C in both MSCV.I.GFP and MSCV.I.eBFP2) was individually 
transfected into 293T cells and C/EBPα protein expression determined by Western blotting 
of lysates prepared 24 hours after transfection using an antibody that detects both the p42 
and p30 isoforms (Figure 6.7). The Kozak-WT construct lacked the upstream ORF and 293T 
cells transfected with this construct expressed the p42 protein, but not the p30 isoform 
(Figure 6.7, lane 2). The Kozak-p30 construct contained only the p30 isoform sequence and 
Western blotting detected the p30 isoform, but not the p42 isoform (Figure 6.7, lane 3). The 
WT, N and C constructs all contained 165 bp of the 5′ UTR, including the endogenous 
Kozak consensus sequence and the short upstream ORF. Accordingly, both the p42 and p30 
isoforms were expressed from the WT and C constructs (Figure 6.7, lanes 4, 5, 8 and 9). 
Only the p30 isoform was detected in cells transfected with the N-terminal frame-shift 
mutant construct (Figure 6.7, lanes 6 and 7). As determined visually, there were no striking 
differences in C/EBPα expression between the MSCV.I.GFP and MSCV.I.eBFP2 constructs 
containing the same CEBPA sequence (Figure 6.7). 
 
6.3.2.2 Marker gene and C/EBPα expression in cells co-transfected with two constructs 
 
For co-transfection of two constructs, the marker gene was different for each construct. The 
control C/EBPα expression constructs were co-transfected in a 1:1 mix to a total of 100ng of 
DNA per well of a 24-well plate, in order to create a mix equivalent to the two CEBPA 
alleles in patients.  
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Figure 6.7 C/EBPα protein expression from CEBPA control constructs. Western blots of 
293T cell lysates made 24 hours after transfection with control C/EBPα expression 
constructs (WT, N or C) with one of two fluorescent marker genes, GFP or eBFP2. All 
control constructs were individually transfected into cells. The Kozak-WT and Kozak-p30 
constructs were used to produce p42 and p30 protein, respectively, as controls. The epitope 
for the anti-C/EBPα antibody #2295 is downstream of the p30 translation initiation site and 
it therefore detects both the p30 and the p42 isoforms. 
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Figure 6.8 Marker gene expression in co-transfections of vector alone or CEBPA 
constructs. Representative FACS plots of 293T cells (A) untransfected or 24 hours post-
transfection with a 1:1 mix of MSCV.I.GFP and MSCV.I.eBFP2, either (B) vector alone or 
(C) CEBPA WT constructs. 
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The relative transfection efficiency of constructs with the different marker genes was tested 
by transfecting cells with either the MSCV.I.GFP and MSCV.I.GFP vectors alone (V), or 
the equivalent WT constructs. The transfection efficiency was assessed after 24 hours by 
flow cytometric analysis. Each condition was tested in four separate wells across two 
different transfections. Overall, the average proportion of cells expressing one or both of the 
fluorescent marker genes was 32% (range 22% to 39%). An example is shown in Figure 6.8. 
Using gates from the untransfected cells (Figure 6.8 A), 36% and 34% of cells expressed 
GFP and/or eBFP2 for the V alone and the WT constructs, respectively (R4 and R5, Figure 
6.8 B and C). Of these positive cells, approximately two thirds were both GFP and eBFP2 
positive. It was consistently observed that the remaining transfected cells expressed GFP, 
but not eBFP2. The reasons for this were not clear.  
 
To test the impact of the marker gene on C/EBPα protein expression in these co-
transfections, mix and match co-transfections of MSCV.I.GFP and MSCV.I.eBFP2 
constructs were performed with all six control constructs, WT, N and C with both GFP and 
eBFP2 marker genes in all possible combinations. The C/EBPα protein expression resulting 
from these was examined by Western blotting of lysates prepared after 24 hours (Figure 6.9). 
Both the p30 and the p42 isoforms were detected for all control C/EBPα construct 
combinations except the N-terminal mutant construct only condition, consistent with the loss 
of the p42 isoform expected for this mutant. For a particular construct combination no 
striking differences in protein expression were observed with respect to which marker gene 
was associated with which C/EBPα construct (Figure 6.9). 
 
6.3.2.3 Transactivation activity of co-transfected control constructs 
 
Dual-luciferase assays were performed on cells co-transfected with all the possible 
combinations of two control C/EBPα expression constructs (Table 6.3). The L/R was 
normalised to the WT activity within each assay, which was set at 100% so that TA activity 
was expressed as a percentage of the WT activity. Each condition was tested in between four 
and 11 separate experiments, and the means and SEMs are given in Table 6.4. The 
background TA activity of the V alone was very low at only 3% ± 0.4% (mean ± SEM) of 
the WT construct (Figure 6.10). 
 
The impact of the marker gene, GFP or eBFP2, on construct activity was explored for the 
three CEBPA construct combinations: the N mutant plus WT constructs, the C mutant plus 
WT constructs and the N plus C mutant constructs. Each combination was tested with both 
possible marker gene-C/EBPα configurations, i.e. GFP-N with eBFP2-WT and eBFP2-N  
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Figure 6.9 C/EBPα protein expression from co-transfected CEBPA control constructs 
Western blots of 293T cell lysates made 24 hours after co-transfection with a 1:1 mix of 
MSCV.I.GFP and MSCV.I.eBFP2 constructs either vector alone (V) or containing control 
CEBPA sequences: WT, N-terminal mutant (N) or a C-terminal mutant (C). 
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Figure 6.10 Transactivation activity of C/EBPα control constructs. 
Transactivation activity was determined in 293T cells co-transfected with a 1:1 mix of 
vector alone (V) or C/EBPα control constructs (WT, N or C), one an MSCV.I.GFP construct 
and the other an MSCV.I.eBFP2 construct, by dual-luciferase assay (Promega). The mean 
and standard error of the mean of between 4 and 11 experiments is shown. 
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Table 6.3 Combinations of CEBPA constructs tested in dual-luciferase assays 
 
Construct 2 None 
WT 
(eBFP2) 
N 
(eBFP2) 
C 
(eBFP2) 
Q209fs 
(GFP) 
      
Construct 1 (GFP)      
      
Control constructs      
WT      
N      
C      
6bp polymorphism
1
      
K304_Q305insL
2
      
      
Test mutations in 
CEBPA-doubles 
     
Q209fs      
A238fs      
K313fs      
A295P      
K276R
3
      
      
Test mutations in 
CEBPA-singles 
     
P187_P189del      
H193_P196del      
P183Q      
P233R      
G242S      
 
1
6bp polymorphism is the H195_P196dup polymorphism. 
2
Classical C-terminal mutation in 
the DBD rather than the LZD. 
3
Mutation in a CEBPA-single (patient 86) and CEBPA-double 
case (patient 71). The fluorescent marker gene in the MSCV CEBPA construct, either green 
fluorescent protein (GFP) or enhanced blue fluorescent protein (eBFP2) is indicated in each 
case. Abbreviations: WT, wild-type; N, Q83fs; C, K313dup. 
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with GFP-WT. Importantly, no significant differences were observed in the C/EBPα TA 
activity between the same CEBPA construct combinations with the alternate marker gene 
configuration (Table 6.4, Figure 6.10). For N+WT and WT+N the difference was only 4%, 
with a TA activity of 61% ± 2% (mean ± SEM) and 65% ± 3% of the WT C/EBPα TA 
activity, where the marker genes were GFP+eBFP2 respectively (P = .3). Similarly, for 
C+WT and WT+C a difference of 4% was also observed (103% ± 6% and 99% ± 5%, 
respectively) and for N+C and C+WT there was a difference of only 1% between the two 
marker gene configurations (15% ± 1% and 14% ± 1%). With an average difference of 3%, 
there was, therefore, no evidence that the choice of marker gene had an impact on the 
assessment of C/EBPα TA activity in the assay. Therefore, additional controls and test 
mutant constructs were all made with only the MSCV.I.GFP vector. 
 
Whilst the WT construct strongly increased the firefly luminescence, either mutant construct 
alone, equivalent to a homozygous mutation, had significantly reduced TA activity of 12% ± 
0.4% of the WT activity for the N mutant and 27% ± 7% for the C mutant construct (P < 
.0001 and P = .002, respectively; Figure 6.10). As given above, the combination of the N 
and C mutant constructs, equivalent to the most common situation observed in CEBPA-
double patients, also had significantly reduced TA activity of 15% ± 1% and 14% ± 1% of 
the WT activity for the different marker gene combinations (P < .0001 and P = .002, 
respectively; Figure 6.10). These results are consistent with loss-of-function mutations 
leading to almost complete loss of WT TA activity. 
 
To create a situation equivalent to a heterozygous mutation in a CEBPA-single case, the N 
and C mutant constructs were also each mixed 1:1 with the WT construct. In this context, the 
TA activity of the N-terminal mutant was 61% ± 2% and 65% ± 3% of the WT activity, 
depending on the marker gene combination (P = .0004 and P = .001, respectively; Figure 
6.10 and Table 6.4). However, this activity was still significantly higher than the N construct 
alone (P < .0001), with no evidence for dominant-negative activity over WT protein (Figure 
6.10). By contrast, the TA activity of the C mutant construct mixed with the WT construct 
was not different from the WT construct alone, with 103% ± 6% and 99% ± 5% of the WT 
activity, depending on the marker gene combination (P = .6 and P = .9, respectively; Figure 
6.10 and Table 6.4). 
 
The results from the control constructs indicated that the dual-luciferase assay was 
appropriate for assessing C/EBPα TA activity. The control construct combinations 
equivalent to a homozygous N-terminal mutation and to biallelic classical N- and C-terminal 
mutations had the lowest TA activity compared to WT C/EBPα, with each quantified as   
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Table 6.4 Transactivation activity of CEBPA control constructs 
 
CEBPA 
construct 1  
(GFP) 
CEBPA 
construct 2 
(eBFP2) 
Mean %  
of WT  
activity 
SEM,  
% 
P 
vs. WT 
P 
vs. WT+N 
P 
vs. WT+C 
Control constructs:    
WT WT 100 0 N.A.   
N N 12 0.4 <0.0001*   
C C 27 7 0.002*   
N WT 61 2 0.0004*   
WT N 65 3 0.001*   
C WT 103 6 0.6   
WT C 99 5 0.9   
N C 15 1 <0.0001*  <0.0001* 
C N 14 1 <0.0001* <0.0001*  
Additional controls:    
6 bp  
polymorphism 
None 91 11 0.5   
WT 87 4 0.1   
N 56 4 0.007* 0.1  
C 89 8 0.3  0.3 
K304_Q305insL 
None 36 7 0.01*   
WT 100 6 0.99   
N 14 2 0.0006* <0.0001*  
 
*P-value significant (< 0.05). Abbreviations: N.A., not applicable; WT, wild-type; SEM, 
standard error of the mean; N, Q83fs; C, K313dup. 
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between 12% and 15% of the WT activity (Figure 6.10). The combination equivalent to a 
homozygous C-terminal mutation also strongly reduced the TA activity by nearly three 
quarters compared to the WT activity, although not to the same extent as the N alone or N+C 
combinations. By contrast, the combinations equivalent to CEBPA alleles in CEBPA-single 
patients did not cause such striking reductions in TA activity. The C-terminal mutant did not 
impact on the C/EBPα TA activity when mixed 1:1 with WT construct and, whilst a 
significant reduction in activity was observed for the N-terminal mutant construct co-
transfected with WT as compared to WT activity, this was not to the same extent as the N 
mutant construct alone (Figure 6.10). 
 
6.3.3 Additional control constructs 
 
Two additional control CEBPA constructs were investigated in this study. The first was the 
known 6 bp polymorphism (H195_P196dup). 293T cells transfected with this construct 
expressed both the p30 and p42 isoform proteins by immunoblotting (Figure 6.11, last lane). 
The polymorphism was tested in dual-luciferase assays on its own, as well as in combination 
with the WT, N and C constructs, because as a polymorphism it could occur in all of these 
allelic contexts. No significant difference in TA activity was observed between the 
polymorphism alone (91% ± 11% of the WT activity [mean ± SEM of three experiments], P 
= .5) nor the combination with either the WT (87% ± 5%, P = .1) or C (89% ± 8%, P = .3) 
constructs when compared with the WT control (Table 6.4 and Figure 6.12). Whilst the 
polymorphism mixed with the N construct had significantly reduced TA activity versus the 
WT control, this could simply be attributed to the N-terminal mutation, with no significant 
difference between the polymorphism+N and the WT+N construct combinations (56% ± 4% 
and 65% ± 3%, respectively, P = .1; Table 6.4). These results indicate that the 6 bp 
duplication polymorphism does not have a significant impact on C/EBPα TA activity. 
 
The second additional control construct was a C-terminal in-frame insertion that affected the 
DBD, rather than the LZD (K304_Q305insL; Table 6.1). Both the p30 and the p42 isoforms 
were expressed from this construct by Western blotting (Figure 6.11). As with the LZD C-
terminal control mutation (C), the DBD mutation K304_Q305insL was tested alone and 
mixed with the WT or N construct (Table 6.3). The K304_Q305insL mutant C/EBPα had a 
very similar impact on TA activity to the C mutant construct, with 36% ± 7% of the WT 
activity in the homozygous state (P = .01 versus WT activity) and 14% ± 2% in combination 
with the N construct (P = .0006) (Table 6.4 and Figure 6.12). No impact on TA activity was 
observed when the K304_Q305insL construct was mixed with the WT construct (100% ± 
6.4% of the WT activity, P = .99; Figure 6.12). Given the similarity in TA activity in the   
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Figure 6.11 C/EBPα protein expression from test CEBPA constructs. 
Western blots of lysates made from 293T cells either untransfected or 24 hours post-
transfection with MSCV.I.GFP vector alone (V) or MSCV.I.GFP CEBPA constructs. Last 
lane 6 bp poly is the H195_P196dup polymorphism. 
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Figure 6.12 Transactivation activity of additional control C/EBPα expression 
constructs. Dual-luciferase assay results from 293T cells 24 hours after co-transfection with 
a 1:1 mix of MSCV.I.GFP and MSCV.I.eBFP2 either vector alone (V) or constructs 
containing control and additional control CEBPA sequences. The mean and standard error of 
the mean from 3 experiments is shown. Abbreviations: WT, wild-type CEBPA; N, Q83fs; C, 
K313dup.  
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different construct combinations between the K304_Q305insL mutant in the DBD and the 
K313dup (C) mutant in the LZD, only the LZD mutant (C) was used for the investigation of 
the atypical mutations. 
 
6.3.4 Atypical mutations from CEBPA-double cases 
 
In the cohort of patients presented in chapter 3, there were 14 mutations identified in 
CEBPA-double cases that were neither heterozygous out-of-frame insertions/deletions in the 
N-terminus nor in-frame insertions/deletions in the C-terminus. Nine of these atypical 
mutations occurred in patients who also had a classical N- or C-terminal mutation, three 
were homozygous mutations in the DBD or LZD, and the remaining two mutations were 
identified in the same patient. As described in section 6.2.1, five mutations were selected for 
functional analysis to investigate whether CEBPA-double patients with such atypical 
mutations had similar C/EBPα TA activity to those with two classical mutations. The 
selected mutations and the patients they were identified in are given in Table 6.1 and Table 
6.2. Four of these mutations were an out-of-frame deletion in the middle of the gene 
(Q209fs), an out-of-frame insertion in the middle (A238fs), an out-of-frame insertion in the 
LZD (K313fs) and a missense mutation in the DBD (A295P). Each of them occurred in just 
one CEBPA-double case in the cohort studied and were combined with an out-of-frame 
insertion/deletion in the N-terminus (Table 6.3). The final mutation, K276R, was located just 
5′ of the DBD and was identified in both a CEBPA-single case, and a CEBPA-double case 
together with an out-of-frame deletion in the middle of the gene.  
 
Strong p42 and p30 C/EBPα isoform protein expression was seen from both the K276R and 
A295P constructs (Figure 6.11). For the Q209fs, A238fs and K313fs constructs, probing 
with the #2843 C/EBPα antibody that has an epitope within the N-terminus upstream of the 
p30 translation initiation site, proteins of a slightly smaller size than the p42 control band 
were identified, but no signal was detected when probing with the #2295 C/EBPα antibody 
that has an unknown epitope but detects both the p30 and p42 isoforms (Figure 6.11). These 
results are consistent with frame-shift/truncating mutations if the antibody epitope is after 
amino acid K313. In silico, all three constructs were predicted to produce a peptide of 
approximately 33kDa, in line with the immunoblotting results. 
  
In order to test the TA activity of these atypical mutations in a context equivalent to that 
found in the patients, the Q209fs, A238fs and K313fs constructs were all tested in 
combination with the N construct, and the K276R construct was mixed with both the WT 
construct, as in patient 86, and with the Q209fs to substitute for L178fs, as in patient 71 
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(Table 6.1, Table 6.2). Four of these construct combinations (Q209fs, A238fs, K313fs and 
A295P with the N construct), had very low TA activity of 9% ± 1%, 10% ± 1%, 12% ± 1% 
and 15% ± 3% of the WT C/EBPα activity, respectively (mean ± SEM of three experiments; 
Figure 6.13). These TA activities were highly significantly reduced versus both the WT 
activity (P ≤ .002 for all) and versus the 65% ± 3% observed for the WT+N construct 
combination (P ≤ .0001 for all; Table 6.5). These results indicated that they were behaving 
as classical pathogenic mutations in this assay. By contrast, the combination of K276R+WT 
constructs increased C/EBPα TA activity to 129% ± 14% and of the K276R+Q209fs 
constructs to 155% ± 25% of the WT construct activity (Figure 6.13). These were not 
significantly different from the WT activity (P = .2 for each), and indicated that K276R 
mutant C/EBPα can still dimerise, bind to DNA and activate transcription as least as well as 
WT C/EBPα. These results have implications for the classification of patient 71 as a 
CEBPA-double case. 
 
6.3.5 Atypical mutations from CEBPA-single cases 
 
Of the 48 CEBPA-single patients in the present cohort, 28 (58%) had non-classical 
mutations. Of these, five were selected for functional analysis in order to further explore the 
functional impact of a range of CEBPA sequence alterations (Table 6.1). The mutations 
selected were two in-frame deletions in TAD2 (P187_P189del and H193_P196del) and three 
missense mutations, one in TAD2 (P183Q) and two between TAD2 and the DBD (P233R 
and G242S). The P187_P189del mutation was identified in two patients and H193_P196del 
in a single case (Table 6.2). These were of interest because the common in-frame 
H195_P196dup polymorphism is in the same region, demonstrating that amino acid changes 
in that location do not necessarily affect protein function. P183Q and P233R were each 
detected in a single case, while G242S was identified in two CEBPA-single patients, and 
these missense mutations all occurred outside of the C-terminal DBD and LZD (Table 6.2). 
 
Western blotting showed that both the p30 and p42 isoforms were expressed from all of the 
constructs, although G242S was expressed less strongly than the other mutant constructs 
(Figure 6.11). To explore the functional impact of these mutations in a range of allelic 
contexts, each was tested by co-transfection with either the WT, N or C control constructs 
(Table 6.3). The results of these assays are shown in Figure 6.14 and Table 6.5. Of the five 
mutations, three appeared to have no significant impact on C/EBPα TA function when 
combined with the WT or the C control constructs: H193_P189del, P183Q and G242S. For 
each of these constructs in combination with the WT construct the TA activity was 104% ± 
8% (P = .7 vs. WT construct alone), 98% ± 11% (P = .9) and 99% ± 5% (P = .9) of the WT   
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Figure 6.13 Transactivation activity of test mutants from CEBPA-double patients 
Dual-luciferase assay results from 293T cells 24 hours post-transfection with a 1:1 mix of 
vector alone (V) or CEBPA constructs. The mean and standard error of the mean from 3 
experiments is shown. Abbreviations: WT, wild-type CEBPA; N, Q83fs; C, K313dup. 
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Figure 6.14 Transactivation activity of test mutants from CEBPA-single patients. 
Dual-luciferase assay results from 293T cells 24 hours post-transfection with either a 1:1 
mix of vector alone (V) or CEBPA constructs. The mean and standard error of the mean of 3 
experiments is shown. Abbreviations: WT, wild-type CEBPA; N, Q83fs; C, K313dup. 
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Table 6.5 Transactivation activity of CEBPA constructs with atypical mutations 
 
CEBPA 
construct 1  
(GFP) 
CEBPA 
construct 2 
(eBFP2) 
Mean %  
of WT 
activity 
SEM, 
% 
P 
vs. WT 
P 
vs. WT+N 
P 
vs. WT+C 
Atypical mutations in CEBPA-doubles:    
Q209fs N 9 1 0.0002* <0.0001*  
A238fs N 10 1 0.0001* <0.0001*  
K313fs N 12 1 <0.0001* <0.0001*  
A295P N 15 3 0.002* 0.0001*  
K276R 
WT 129 14 0.2   
Q209fs (GFP) 155 25 0.2   
Atypical mutations in CEBPA-singles:    
P187_P189del 
WT 93 5 0.3   
N 52 3 0.004* 0.03*  
C 85 4 0.07  0.09 
H193_P196del 
WT 104 8 0.7   
N 68 4 0.02* 0.6  
C 109 11 0.5  0.4 
P183Q 
WT 98 11 0.9   
N 59 6 0.02* 0.4  
C 95 9 0.6  0.7 
P233R 
WT 85 3 0.03*   
N 51 4 0.007* 0.04*  
C 78 7 0.08  0.04* 
G242S 
WT 99 5 0.9   
N 63 4 0.01* 0.6  
C 95 9 0.6  0.6 
 
*P-value significant (< 0.05). Abbreviations: WT, wild-type; SEM, standard error of the 
mean; N, Q83fs; C, K313dup. 
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C/EBPα activity, and in combination with the C construct the TA activity was 109% ± 11% 
(P = .5 vs. WT construct alone), 95% ± 9% (P = .6) and 95% ± 9% (P = .6), for 
H193_P189del, P183Q and G242S, respectively. Although a significant reduction in TA 
activity was seen for each of these mutants co-transfected with the N construct as compared 
with WT (68% ± 4% [P = .02], 59% ± 5% [P = .02] and 63% ± 3% [P = .01], respectively), 
this is attributable to the N mutant construct, as these differences were lost in comparison to 
the WT+N construct combination (P = .6 for all).  
 
There was some evidence that the remaining atypical mutants, P187_P189del and P233R, 
caused a slight reduction in C/EBPα TA activity. The TA activity of the P233R missense 
mutant combined with the WT construct was 85% ± 3% of the WT C/EBPα activity (P = .03 
vs. WT alone), 51% ± 4% in combination with the N construct (P = .04 vs. WT+N) and 78% 
± 7% in combination with the C construct (P = .04 vs. WT+C). The P187_P189del did not 
significantly impact on TA activity in combination with the WT construct, with 93% ± 5% 
of the WT C/EBPα activity (P = .3 vs. WT alone), but did cause a significant reduction in 
TA activity when co-transfected with the N construct with 52% ± 3% activity (P = .03 vs. 
WT+N) and a trend to reduced activity in combination with the C construct (85% ± 5%, P = 
.09 vs. WT+C). However, the TA activity of the P233R and P187_P189del mutants when 
combined with an N or C control mutant was much closer to the activity of the control 
mutant mixed with WT than the control mutants either alone or in combination with each 
other, and therefore these mutations did not appear to impact on TA activity as strongly as 
the control mutants and could be the result of technical variation. 
 
The data on the impact of all the CEBPA variants investigated in this study on C/EBPα TA 
activity is summarised in Table 6.6. The reduction in TA activity for a particular 
combination versus the WT construct in that context was calculated and the condition 
assigned to one of four groups: no difference, a reduction of less than 20% that was 
nonetheless still significant, a significant reduction of between 20% and 40%, or greater than 
40% of the WT activity. 
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Table 6.6 Summary of the impact of CEBPA sequence alterations on C/EBPα 
transactivation activity 
 
 CEBPA status modelled 
CEBPA 
construct 
CEBPA-single 
+WT 
CEBPA-double 
+N 
CEBPA-double 
 +C 
Impact versus: WT alone WT + N WT + C 
    
Controls:    
N ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ 
C ↔ ↓ ↓ ↓ ↓ ↓ ↓ 
6 bp polymorphism ↔ ↔ ↔ 
K304_Q305insL ↔ ↓ ↓ ↓  
   
Atypical mutations: CEBPA-doubles   
Q209fs  ↓ ↓ ↓  
A238fs  ↓ ↓ ↓  
K313fs  ↓ ↓ ↓  
A295P  ↓ ↓ ↓  
K276R ↔ ↔  
   
Atypical mutations: CEBPA-singles   
P187_P189del ↔ ↓ ↓ 
H193_P196del ↔ ↔ ↔ 
P183Q ↔ ↔ ↔ 
P233R ↓ ↓ ↓ ↓ 
G242S ↔ ↔ ↔ 
 
Abbreviations: WT, wild-type; N, Q83fs; C, K313dup. 
Arrows indicates the impact on C/EBPα activity in the luciferase reporter assay of the test 
vs. a WT construct in that particular context, as indicated. No significant impact is indicated 
by “↔” and significantly reduced activity by “↓”, with the number of arrows demonstrating 
the strength of this reduction (↓, < 20%; ↓ ↓, 20% - 40%; ↓ ↓ ↓, > 40%). P-values < .05 were 
considered significant. 
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6.4 Discussion 
 
The impact of classical N- and C-terminal CEBPA mutations on C/EBPα protein function 
has been explored in both in vitro and in vivo models. By contrast, the consequence of non-
classical mutations is less well understood. Non-classical sequence alterations constituted 
over one quarter of the mutations detected in the patient cohort described in chapter 4, and 
therefore the impact of selected nucleotide changes on C/EBPα TA activity was explored 
using a luciferase reporter assay.  
 
The entire CEBPA coding sequence and 165 bp of the endogenous 5′ UTR was amplified 
from gDNA samples containing WT, a classical N-terminal mutation (Q83fs) or a classical 
C-terminal mutation (K313dup) and these amplicons were cloned into both MSCV.I.GFP 
and MSCV.I.eBFP2. These control constructs were used to optimise a luciferase reporter 
assay to assess the ability of C/EBPα variants to activate transcription of a luciferase gene 
from a target sequence (Figure 6.1). A luciferase reporter assay was selected for this study as 
this has been used successfully for this purpose in a number of previous reports (Pabst et al, 
2001b;Gombart et al, 2002;Cleaves et al, 2004;Pabst et al, 2009;Kato et al, 2011). 
 
The results of luciferase reporter assays need to be normalised across different samples for 
the variation in transfection efficiency. A Renilla expression construct was selected as an 
internal control for this purpose as both the firefly and Renilla luciferase activities could be 
measured simply in a single assay using the Dual-Luciferase Reporter Assay System 
(Promega) (Figure 6.4). There was also a requirement for the equal transfection of cells with 
two C/EBPα expression constructs, equivalent to the two different CEBPA alleles present in 
patients. To facilitate the evaluation of this, 293T cells were transfected with equal amounts 
of CEBPA constructs containing different fluorescent marker genes, either GFP or eBFP2. 
Transfected cells could be analysed by fluorescent microscopy or flow cytometry to 
determine the presence of both constructs in the same cells by detection of both green and 
blue fluorescence. An alternative strategy for ensuring 1:1 expression of two C/EBPα 
constructs could have been generation of a bicistronic expression vector encoding a 2A 
peptide sequence between two different CEBPA gene sequences, which would undergo 
cleavage to produce equal expression. However, having separate constructs allowed several 
different combinations of vectors to be tested without the requirement for further cloning. 
 
Optimisation of transfections for the dual-luciferase assay was performed using the three 
C/EBPα control constructs (WT, N and C) transfected individually. Varying the amount of 
CEBPA construct in the transfection between 100ng and 460ng per well of a 24-well plate 
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did not have a striking impact on transfection efficiency, as determined by flow cytometric 
analysis for fluorescent marker gene expression (Figure 6.5). In dual-luciferase assays, 
increasing the amount of C/EBPα expression construct from 50ng to 200ng did cause a 
slight, but not significant, increase in the firefly luciferase activity normalised for the 
transfection efficiency (L/R) for each control (P = .16; Figure 6.6 A). Increasing the amount 
of the luciferase reporter construct also increased the L/R for a given C/EBPα expression 
construct, although this experiment was only performed once (Figure 6.6 B). The conditions 
selected for the transfections were: 1ng of the Renilla expression construct, 80ng of the 
luciferase reporter construct and a total of 100ng of the CEBPA construct(s) per well of a 24-
well plate. Using these conditions, C/EBPα protein was strongly expressed in cells 24 hours 
after transfection and, whilst the WT and the C constructs produced both the p42 and the p30 
isoforms, as expected only the p30 isoform could be detected in cells transfected with the N 
construct (Figure 6.7). In dual-luciferase assays, the background L/R of the vector alone was 
very low, whilst the WT MSCV.I.GFP caused a 41-fold increase in L/R over the vector 
alone, by contrast the N and C mutant constructs caused 4-fold and 9-fold increases, 
respectively (Figure 6.6 A). This reduction in TA activity for the control mutant constructs 
was in line with the expected results for loss-of-function mutations. 
  
The selected transfection conditions were explored further in co-transfection experiments of 
equal amounts of MSCV.I.GFP and MSCV.I.eBFP2 control C/EBPα constructs to check for 
equal expression of the two constructs. By FACS analysis, an average of 32% of cells (range 
22% to 39%) were GFP and/or eBFP2 positive 24 hours after transfection (Figure 6.8). 
Whilst approximately two thirds of the positive cells were both GFP and eBFP2 positive, the 
remaining transfected cells expressed GFP, but not eBFP2. The reasons for this were 
unknown, but there was no apparent effect on C/EBPα protein expression with no striking 
differences observed by Western blotting between cells transfected with the same 
combination of control C/EBPα constructs in the two possible marker gene configurations 
(Figure 6.9). Importantly, the marker gene did not impact on the results obtained in 
luciferase reporter assays (Figure 6.10). It was, therefore, assumed that marker gene 
selection did not affect the assay results. 
 
In these co-transfection experiments, when the results were normalised to the WT C/EBPα 
activity, the N-terminal mutant alone, the C-terminal mutant alone or both together had 
strongly reduced TA activity compared to the WT activity (Table 6.4, Figure 6.10). These 
data are in line with several reports that classical N-terminal or C-terminal mutations cause 
substantial loss of TA activity either alone (Pabst et al, 2001b;Gombart et al, 2002;Kato et 
al, 2011), or in combination with each other (Pabst et al, 2009). These combinations were 
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equivalent to a homozygous N-terminal mutant, a homozygous C-terminal mutant, and 
biallelic N- and C-terminal mutations, respectively, and the TA activity was consistent with 
a substantial loss of normal WT function. Of the 59 CEBPA-double cases identified in 
chapter 3, the majority (83%) had both a classical N- and C-terminal mutation, only three 
(5%) had a homozygous C-terminal mutation and none had a homozygous N-terminal 
mutation. Across nine published cohorts studying a total of 2641 patients, only one (0.04%) 
patient with a homozygous N-terminal mutation has been reported (Pabst et al, 
2001b;Snaddon et al, 2003;Frohling et al, 2004;Bienz et al, 2005;Marcucci et al, 
2008;Wouters et al, 2009;Pabst et al, 2009;Renneville et al, 2009a;Dufour et al, 2010). 
Therefore, whilst similar TA activities were observed for the N alone, C alone and N plus C 
constructs, the classical N- plus classical C-terminal mutation is much more likely to be 
selected for during leukaemogenesis in patients, suggestive of roles for the different C/EBPα 
mutants beyond their impact on TA activity. 
 
When the C-terminal mutant was mixed equally with WT, equivalent to a heterozygous C-
terminal mutation in a CEBPA-single patient, there was no difference in activity as 
compared with the WT control alone (Figure 6.10). Similar results were obtained from a 
second classical C-terminal mutant, K304_Q305insL, located in the DBD rather than the 
LZD (Figure 6.12). This is in line with two other studies that also observed no reduction in 
TA activity for classical C-terminal mutants in combination with WT C/EBPα (Gombart et 
al, 2002;Kato et al, 2011), although a reduction in TA activity to 36% of the WT activity 
was reported in one study (Pabst et al, 2001b). By contrast, the N-terminal mutant mixed 
equally with WT, equivalent to a CEBPA-single case with an N-terminal mutation, reduced 
TA activity to approximately two thirds of the WT activity (Figure 6.10). This is equivalent 
to other studies in which TA activity has been reported for an N-terminal mutant, or the p30 
isoform, in combination with WT (Pabst et al, 2001b;Gombart et al, 2002;Cleaves et al, 
2004;Pabst et al, 2009;Kato et al, 2011). The magnitude of reduction in the present study 
was similar to that in one of these reports, although actual values were not available 
(Gombart et al, 2002). However, others have reported larger reductions to 16% of the WT 
activity in one study (Pabst et al, 2001b) and 18% in another (Pabst et al, 2009), and it has 
been suggested that the p30 isoform has a dominant-negative effect over the p42 isoform 
(Pabst et al, 2001b;Cleaves et al, 2004). However, there was no evidence for this effect in 
the present study. Comparisons between different studies can be problematic due to the use 
of different cell lines, expression vectors and ratios of WT to N-terminal mutant or p30 
isoform constructs. This is particularly the case when the aim of the reported study was very 
different to that of the present work. For instance, for the purpose of exploring the 
relationship between the WT and the p30 isoform, the WT:p30 construct ratio was titrated 
192 
 
from 1:3 to 1:7 in one study (Cleaves et al, 2004) and 1:2 to 1:6 in another (Gombart et al, 
2002), both observing a decrease in TA activity with increasing p30 construct. Overall, in 
the present studies, the TA activities of the control C/EBPα expression construct 
combinations were broadly in line with those reported in the literature, with the greatest loss 
of activity seen in combinations equivalent to homozygous or biallelic CEBPA mutations. 
These results indicated that the assay developed for these studies was appropriate for 
determining the impact of atypical CEBPA mutations on TA activity. 
 
Five of the 14 non-classical mutations identified in the 59 CEBPA-double patients were 
selected for analysis, including two frame-shift/truncating mutations in the middle of the 
gene (Q209fs and A238fs) and one in the LZD (K313fs), all predicted to truncate both the 
p30 and the p42 isoforms, and two missense mutations, one just upstream of and one within 
the DBD (K276R and A295P, respectively; Table 6.1). Five representative atypical 
mutations were selected from the 28 CEBPA-single cases with non-classical alterations. 
These included two in-frame deletions (P187_P189del and H193_P196del) and three 
missense mutations in the middle of the gene (P183Q, P233R and G242S; Table 6.1). 
Mutations from CEBPA-double cases were all tested in combination with a CEBPA 
construct equivalent to the second mutation present in the patient they were identified in, 
whilst those from CEBPA-single cases were tested in combination with the WT, N and C 
constructs (Table 6.1 and Table 6.2). 
 
All three frame-shift/truncating mutations (Q209fs, A238fs and K313fs) expressed a 
truncated C/EBPα peptide of a size consistent with that predicted in silico (Figure 6.11), 
showing that, in vitro, these mutations caused loss of both the normal p42 and the p30 
isoforms. In combination with the N construct they all resulted in levels of TA activity 
similar to that of the classical N+C construct combination (Figure 6.13). These observations 
are not unexpected, given that each lacks either the entire DBD/LZD (Q209fs and A238fs) 
or a substantial portion of the LZD (K313dup). A similar mutation, R165fs, was investigated 
in one other report, where a strong increase in TA activity was observed (Pabst et al, 2001b). 
This result is unexpected and no explanation was given. 
 
The two in-frame deletions (P187_P189del and H193_P196del) affected similar residues to 
the 6 bp duplication polymorphism (H195_P196dup), which did not appear to have a 
detrimental effect on activity (Figure 6.12). In line with this, H193_P196del had no impact 
on activity in this assay (Figure 6.14). P187_P189del did cause a slight, but significant, 
reduction in combination with either an N- or C-terminal mutation (Table 6.5), but the 
activity was much closer to that of the N or C construct in combination with the WT than the 
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activity of the N+C construct combination (Table 6.4). These data suggest that in-frame size 
changes in this region of CEBPA do not impact on TA activity. 
 
In total, five missense mutations were tested, four located in the middle of the gene (K276R, 
P183Q, P233R and G242S) and one located in the C-terminal DBD (A295P).Using 
PolyPhen-2 prediction software (http://genetics.bwh.harvard.edu/pph2/), three were assessed 
as probably damaging (A295P, K276R and P233R), P183Q as possibly damaging and 
G242S as benign. In line with the prediction, the G242S mutation did not have any impact 
on TA activity in combination with any of the three control constructs (Figure 6.14 and 
Table 6.5). This was not unexpected given that this residue is not located in either the DBD 
or LZD. The A295P mutation, detected in a CEBPA-double case, was only tested in 
combination with the N mutant construct, which resulted in TA activity equivalent to that of 
the N+C combination, compatible with a prediction of probably damaging to C/EBPα 
(Figure 6.13). This missense mutation changes a residue in the DBD functional domain of 
C/EBPα and it is, therefore, not surprising that a loss of TA activity was observed. Although 
there was some evidence that the P233R mutation, assessed as probably damaging, slightly 
reduced TA activity when in combination with the control constructs (Figure 6.14 and Table 
6.5), the TA activity of the P233R+N or P233R+C construct combinations remained 
significantly higher than that of the classical N+C combination (P = .01 and P = .01, 
respectively). These observations are not unexpected given that the amino acid substitution 
is located in a region between known functional domains, TAD2 and the DBD. Despite the 
predictions of probably and possibly damaging, K276R and P183Q did not negatively affect 
TA activity when combined with the control constructs (Table 6.5). The P183Q substitution 
is located in TAD2, the same domain as the 6 bp duplication polymorphism, rather than the 
DBD/LZD and it is not unexpected that no impact on TA activity was observed. The K276R 
mutation is located only two residues upstream of the DBD, according to one definition of 
this region (Figure 3.1). However, there was no evidence that K276R mutant C/EBPα had 
impaired TA activity as compared to the WT construct, in line with its location outside of 
the DBD. 
 
The evidence presented above indicates that in-frame insertions/deletions or missense 
mutations in the middle region of CEBPA do not prevent C/EBPα binding to a target DNA 
sequence as a dimer and activating transcription. These types of atypical mutations were 
detected in nine cases (0.6%) in the cohort described in chapter 3 and they could either have 
no functional consequence or they could affect functions of C/EBPα that were not assayed 
here, and so be selected for during leukaemogenesis. For instance, the middle portion of 
CEBPA contains a region that mediates the interaction between C/EBPα and the cyclin-
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dependent kinases cdk2 and cdk4, which are important for cell cycle progression (Wang et 
al, 2001). In addition, another region in TAD2 is required for C/EBPα to interact with the 
SWI/SNF chromatin remodelling complex, an interaction which was required for C/EBPα to 
suppress cell proliferation (Muller et al, 2004). In theory, mutations in these regions could 
disrupt these interactions and lead to an increase in cell proliferative capacity and further 
experiments are required to determine if this is the case. 
 
In conclusion, whilst there have been several in vitro and in vivo studies of the impact of 
classical N- and C-terminal CEBPA mutations on C/EBPα function, similar data for non-
classical mutations is very limited. Therefore, the impact of ten atypical mutations on TA 
activity was investigated in this chapter. In general, it was found that mutations affecting the 
DBD or LZD caused loss of TA function equivalent to the classical mutations, whether by 
an amino acid substitution or by truncation of the C-terminus. By contrast, mutations 
affecting the middle of the gene, between the translation initiation site for the p30 isoform 
and the DBD, did not strongly impact on TA activity. Remission samples were not available 
for the majority of CEBPA-mutant cases in this study, but may be helpful in order to 
determine whether sequence changes are germline or acquired only in the leukaemic cells. 
However, as pathological germline CEBPA mutations have been reported in cases of familial 
AML (Smith et al, 2004;Pabst et al, 2008;Renneville et al, 2009b), a decision would still 
need to be made regarding whether a particular sequence change was pathogenic. 
Constitutional CEBPA mutations in pedigrees with AML have all been classical N-terminal 
alterations. A small number of cases without a family history of myeloid malignancies have 
been reported as having germline mutations located outside of the N-terminus, including 
three missense mutations in the C-terminus (Taskesen et al, 2011). One of these cases was 
CEBPA-single and two were CEBPA-double, with an additional classical N-terminal 
mutation in one and a classical C-terminal mutation in the other. Moreover, the two CEBPA-
double cases clustered with other CEBPA-double cases by GEP (Taskesen et al, 2011). 
Reports of this kind underline the importance of further functional study of non-classical 
mutations. 
 
This data has implications for the classification of several patients included as CEBPA-
mutant in this study. For instance, if K276R is a non-pathogenic passenger alteration, then 
patient 71 may more appropriately be classified as CEBPA-single, rather than CEBPA-
double, and patient 86 as CEBPA-WT (Table 6.2). It should be noted that outcome analyses 
were performed excluding patients with missense mutations and in-frame size changes in the 
middle of the gene, and the favourable prognosis of CEBPA-double patients was maintained 
(Figure 4.2 D and Appendix Table 2).  
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CHAPTER 7: CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
The clinical outcome of younger adult patients with AML is highly heterogeneous and there 
are a number of clinical and molecular features that can be utilised to define groups of 
patients with distinct prognoses (chapter 1).  These prognostic factors are useful for 
developing risk-adapted treatment strategies for personalised therapy, where the most 
intensive and/or experimental therapies can be targeted at patients with high-risk, rather than 
those with low-risk, features. This is particularly pertinent for the debate regarding which 
patients should receive an allo-SCT, for instance there is evidence that the benefit of this 
treatment outweighs the risk of TRM in patients with adverse-risk, but not favourable-risk, 
cytogenetics (Cornelissen et al, 2007). However, there is also heterogeneity within 
established risk-groups and questions remain regarding a number of the currently identified 
molecular markers, particularly concerning the interaction between different markers, and 
greater understanding is required. Knowledge of these markers can also be important for 
understanding the underlying biology of the leukaemia and thereby aid in the development 
of novel treatment strategies, for instance as with FLT3 inhibitors in patients with activating 
FLT3 mutations.  
 
This thesis presents an investigation of CEBPA mutations, which are known to be a 
prognostic factor in AML. The incidence of mutations was determined in a large cohort of 
young adult patients treated in the UK MRC AML 10 and AML 12 trials (chapter 3), and the 
biological characteristics and clinical outcome of the CEBPA-mutated patients were 
explored in chapter 4, along with factors which modify this impact. The mutations identified 
in patient samples were then further investigated with regard to their mutant level and allelic 
distribution (chapter 5), and the impact of non-classical mutations on C/EBPα function in a 
luciferase reporter assay (chapter 6). 
 
A method was developed to detect CEBPA mutations across the whole coding sequence 
using dHPLC analysis of three overlapping PCR products. This technique was shown to be 
effective at detecting both point mutations and size changes in all three fragments, and both 
heterozygous and homozygous mutations were identified in a large cohort of 1427 patients, 
and at a comparable frequency to other studies (chapter 3). Overall, 107 (7%) patients were 
classified as CEBPA-mutant, including 48 cases with one heterozygous mutation, CEBPA-
single, and 59 with two heterozygous or one homozygous mutation, CEBPA-double. The 
types and locations of mutations differed between CEBPA-single and CEBPA-double 
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patients. Mutations in CEBPA-single cases were distributed across the entire gene, whilst 
those in CEBPA-double cases clustered quite tightly in the N- and C-terminal hotspots, with 
most cases having one of each of these types (Figure 3.7 and Table 3.3). 
 
There were a number of characteristics in common between CEBPA-single and CEBPA-
double cases as compared with the CEBPA-WT group, such as an association with FAB 
types M1 or M2 and with intermediate-risk cytogenetics, in particular a normal karyotype 
(Table 4.3). However, there were several striking differences including younger age and a 
lack of NPM1 and FLT3/ITD mutations in CEBPA-double cases, but not CEBPA-single 
patients. Importantly, there were significant differences in clinical outcome at 8 years when 
patients were stratified by CEBPA status. The presence of CEBPA-double mutations was an 
independent favourable factor for OS, RFS and relapse in multivariate analysis (Table 4.5), 
while the outcome of CEBPA-single cases was similar to that of CEBPA-WT patients (Table 
4.4). At the time this work was completed, only three other reports, all in smaller cohorts, 
had analysed patients by CEBPA-WT, CEBPA-single and CEBPA-double status, with two 
groups reporting that the benefit for CEBPA mutations was restricted to CEBPA-double 
cases (Wouters et al, 2009;Pabst et al, 2009), and one finding little difference in outcome 
between CEBPA-single and CEBPA-double cases (Table 4.2) (Renneville et al, 2009a). 
However, the data from the present study together with three subsequent reports on different 
patient groups (Hou et al, 2009;Dufour et al, 2010;Taskesen et al, 2011) all confirm a 
favourable prognosis in CEBPA-double, but not CEBPA-single, patients, compared with 
those lacking CEBPA mutations.  
 
A further important consideration was the potential interaction between CEBPA mutations 
and other known characteristics. Whilst the favourable outcome of CEBPA-double patients 
could be observed in both intermediate-risk AK and NK patients, it was lost in the presence 
of a FLT3/ITD (Figure 4.4 A and B). In the whole cohort just seven (0.5%) patients were 
both CEBPA-double and FLT3/ITD-positive, however these had a very poor outcome with 
only one case alive 3 years after trial entry. The strong negative impact of a FLT3/ITD 
observed in these CEBPA-double cases is in line with recent data from mouse models where 
a FLT3/ITD has been co-expressed with mutant CEBPA. Reckzeh et al (2012) generated a 
knock-in model where biallelic CEBPA mutations (p30 isoform and K313dup) and a 
FLT3/ITD were co-expressed from their endogenous promoters and found that the presence 
of a FLT3/ITD shortened the latency of mutant CEBPA-driven leukaemogenesis, with 
median survival reduced from 33.8 to 22.5 weeks. In addition, Kato et al (2011) transduced 
murine BM mononuclear cells with retroviruses to co-express a C-terminal C/EBPα mutant 
together with a FLT3/ITD and transplanted them into syngeneic mice. The recipient mice 
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developed leukaemia in a much shorter period of time than mice transplanted with cells 
expressing the mutant C/EBPα alone (2 to 3 weeks vs. 4 to 12 months).  
 
The potential interactions between single CEBPA mutations and other characteristics were 
also investigated in the studies presented here, and there was no evidence that the presence 
of a CEBPA-single mutation further improved the favourable outcome of an NPM1 mutation 
(Figure 4.4 C). Taken together, these data suggest screening for CEBPA mutations at disease 
presentation should only be performed in patients with intermediate-risk karyotypes without 
a FLT3/ITD or NPM1 mutation, which would have limited CEBPA mutation analysis to only 
a third of patients in the current cohort. There are an ever-increasing number of recurrently 
mutated genes identified in AML and identifying which markers should be screened in the 
molecular work-up of new AML patients will be increasingly challenging. Therefore, studies 
of this kind are important to aid in rationalisation of which markers should be analysed at 
diagnosis. 
 
The mutant level of 101 mutations from 75 patients was quantified by fragment analysis of 
fluorescently labelled PCR products (chapter 5). The level of the majority of mutations was 
consistent with the level expected for a heterozygous mutation present in nearly all cells, 
suggesting that the CEBPA mutation was acquired early in leukaemogenesis in these 
patients. A low CEBPA mutant level (< 25%) was observed for only five mutations from 
five different patients, and in one of these patients an NPM1 mutant level of 49% had been 
identified, indicating that acquisition of a CEBPA mutation is not always an early event. In 
CEBPA-double cases, paired mutant levels were highly correlated in the 26 patients where 
both mutant levels were available, and cloning of CEBPA alleles in 13 patients confirmed 
the presence of biallelic mutations. Taken together, these data indicated that in all 
probability the different mutations were on different alleles in the same cells in CEBPA-
double cases. 
 
The majority of mutations identified in the current cohort were classical N-terminal (out-of-
frame insertions/deletions or nonsense mutations in the N-terminus) or classical C-terminal 
(in-frame insertions/deletions in the DBD or LZD), and there have been several 
comprehensive studies investigating the in vitro and in vivo consequences of these types of 
mutations. However, non-classical mutations accounted for over a quarter of the non-
synonymous sequence alterations identified, and the impact of non-classical mutations on 
protein function remains unclear. Understanding whether particular sequence alterations are 
pathogenic changes or non-functional bystanders is important if CEBPA status is to be used 
to aid clinical decisions. Therefore a luciferase reporter assay was developed to test the 
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transactivation activity of selected non-classical mutations, where two CEBPA constructs 
were co-transfected into 293T cells with the reporter construct (chapter 6). Three control 
C/EBPα expression constructs were used to test the assay: WT, a classical N-terminal 
mutation (Q83fs, N) and a classical C-terminal mutation (K313dup, C).Whilst the WT 
construct alone strongly activated transcription of the reporter luciferase construct, control 
mutant construct combinations equivalent to biallelic or homozygous CEBPA mutations in 
CEBPA-double patients (N alone, C alone or both together) all had a transactivation activity 
less than one third that of the WT activity. In co-transfections with an equal amount of the 
WT construct, equivalent to a heterozygous mutation in a CEBPA-single case, the N 
construct had approximately two thirds of the WT activity, however the C construct 
combination did not impact on transactivation activity in this assay. Five atypical mutations 
identified in CEBPA-double cases and five from CEBPA-single patients were selected for 
analysis. Four mutations from CEBPA-double cases in combination with the N construct had 
transactivation activities equivalent to the N+C control construct combination. These 
included two frame-shift/truncating insertions/deletions in the middle of the gene and one in 
the LZD, and a missense mutation in the DBD. By contrast, three missense mutations (two 
from CEBPA-single cases and one detected in both a CEBPA-single and CEBPA-double 
case) and an in-frame deletion (from a CEBPA-single case), all in the middle of the gene, 
had no impact on transactivation activity in this assay. There was some evidence that the 
remaining two atypical mutations, an in-frame deletion and a missense mutation in the 
middle of the gene (both from CEBPA-single cases), had a slight negative impact on 
C/EBPα transactivation activity, but not to the same extent as the control mutants. These 
data, whilst preliminary, highlight the challenges present in predicting the functional 
consequences of sequence alterations. 
 
 
7.1 Future directions 
 
If CEBPA mutant status is to be included in the molecular investigation of newly diagnosed 
AML patients, particularly of intermediate-risk karyotype patients without a FLT3/ITD or 
NPM1 mutation, a robust method of mutation detection is required. There are a number of 
different techniques that have been used to identify CEBPA mutations, including Sanger 
sequencing and fragment analysis for size changes (chapter 3). However, there are caveats to 
these techniques. For instance, fragment analysis does not detect mutations that do not alter 
amplicon length, which accounted for 14% of the mutations in this study. Sanger sequencing 
is relatively labour intensive and can lack sensitivity for low level mutations. In addition, the 
high GC content of the CEBPA coding sequence (75%) makes optimisation of PCR and 
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sequencing protocols challenging. For the large retrospective cohort studied here, dHPLC 
analysis was an effective method for identifying CEBPA mutations. However, it should be 
noted that the WAVE platform is not widely available, can be technically demanding, and 
the sensitivity of detection depends on the particular sequence involved. Next generation 
sequencing techniques are being explored for targeted mutation analysis, particularly in 
multiplexed assays of a number of genes. As with conventional PCR amplification followed 
by Sanger sequencing, the high GC content of CEBPA can make amplification steps 
challenging, reducing the number of reads obtained. For instance, in a study of whole 
genome amplification by multiple displacement amplification, the median GC content of 
regions where amplification failed was 60% (Hou et al, 2012), whilst the CEBPA coding 
sequence has a GC content of 75%. More specifically, 454 deep sequencing of CEBPA in 
patient samples has been explored in one study (Grossmann et al, 2011). Using a standard 
protocol, amplification failed for two of four overlapping fragments across the entire CEBPA 
coding sequence of two test samples, although these difficulties could be overcome after 
optimisation of the amplification protocols (Grossmann et al, 2011). This highlights the 
difficulties of developing novel assays for the detection of CEBPA mutations. However, 
streamlining the molecular work-up of samples in the future is desirable, and the inclusion of 
CEBPA in targeted multiplexed NGS-based assays is important due to the impact of 
mutations on patient prognosis. 
 
The data presented in this thesis, together with observations from several other studies 
(Wouters et al, 2009;Pabst et al, 2009;Hou et al, 2009;Dufour et al, 2010;Taskesen et al, 
2011), has indicated a favourable prognosis for CEBPA-double patients. In the present 
cohort the outcome of CEBPA-double cases with a FLT3/ITD was very poor (chapter 4), 
however this is based on a small number of patients and requires further confirmation. It has 
not yet been explored in other cohorts. This is likely due to the low co-incidence of these 
two types of mutations, such that in smaller cohorts either no cases (Hou et al, 2009) or a 
single case (Dufour et al, 2010) were identified within this subgroup, and confirmation of 
this issue may require a meta-analysis. Given that CEBPA-double cases with a FLT3/ITD are 
infrequent, constituting only 0.5% of the present cohort and 0.6% of a large cohort of 1182 
NK patients (Taskesen et al, 2011), it could be argued that understanding the impact of 
FLT3/ITDs in this subgroup is relatively unimportant. However, if FLT3/ITDs are associated 
with a poor outcome regardless of CEBPA status, there is a rationale for limiting screening 
for CEBPA mutations at patient presentation to those lacking a FLT3/ITD. 
 
For the identification of patients who would not benefit from an allo-SCT, a working 
threshold of 35% relapse rate at 4 years has been suggested, below which the transplant 
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related mortality outweighs any benefit due to a reduced tendency to relapse (Cornelissen et 
al, 2007). In the 52 CEBPA-double patients lacking a FLT3/ITD and identified as having a 
relatively favourable prognosis, the relapse rate was approximately 39% at 4 years, similar 
to the working cut-off of 35%. Across the patients stratified as CEBPA-WT, -single and –
double, there were no differences in treatment allocation, nor did censoring patients at 
transplant affect the positive impact of CEBPA-double status on clinical outcome (chapter 
4). However, further investigation is clearly required to determine the role of CEBPA status 
in determining therapy with regard to whether an alloSCT is beneficial in CEBPA-double 
cases without a FLT3/ITD in first remission, or should perhaps be delayed to second 
remission. In addition, the impact of age within this context is of interest given that the 
intensive conditioning given before transplantation is better tolerated in patients less than 40 
years of age, and the benefit of CEBPA-double status in this study was predominantly 
observed in this age group. These types of studies remain challenging due to the relatively 
small numbers of patients in the CEBPA-double and FLT3/ITD-negative subgroup (52 of 
1427, 4%), indeed even a large study of 509 patients with an NK lacked sufficient CEBPA-
mutant cases to investigate the impact of related-donor transplantation in first remission 
(Schlenk et al, 2008), and a meta-analysis may be required. 
 
Alternative ways in which CEBPA mutations may aid clinical decisions have been explored, 
including as a marker for MRD detection. However, whilst RQ-PCR assays have been 
developed for the sensitive detection of particular CEBPA mutations (Smith et al, 2006), the 
individual nature of the mutations so far identified means that it would be challenging to 
develop a specific assay for MRD analysis of every CEBPA-mutant patient. 
 
The reduction of C/EBPα activity has been reported to occur by a variety of mechanisms 
(Koschmieder et al, 2009), including suppression of C/EBPα translation by the CBFB-
MYH11 fusion in AML with inv(16) (Helbling et al, 2005), reduction of activity as a 
consequence of phosphorylation by FLT3/ITD (Radomska et al, 2006), and the silencing of 
CEBPA transcription by the RUNX1-RUNX1T1 in t(8;21) AML (Pabst et al, 2001a) or by 
promoter hypermethylation (Chim et al, 2002;Wouters et al, 2007a). Whilst CEBPA 
promoter hypermethylation is not common (Chim et al, 2002), a subset of patients with 
silenced CEBPA, associated with proximal promoter hypermethylation, activating NOTCH1 
mutations and a mixed myeloid/lymphoid phenotype were identified by GEP (Wouters et al, 
2007a). In view of this, it would be interesting to explore whether silencing of the normal 
allele occurs in some patients with a single heterozygous CEBPA mutation, thereby creating 
a de facto CEBPA-double mutant. 
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Evidence from mouse models and from study of familial AML suggests that mutation of 
CEBPA is a founding event in some leukaemias, however there can be a long latency before 
the on-set of disease. In 16 cases with germline N-terminal mutations, the median age at 
AML presentation was 25.5 years, range 4 to 46 years (Smith et al, 2004;Sellick et al, 
2005;Nanri et al, 2006;Pabst et al, 2008;Renneville et al, 2009b;Taskesen et al, 2011). The 
acquisition of further genetic “hits” is likely required for the leukaemic phenotype, although 
the number of these driver mutations may be small, for instance recent whole genome 
sequencing of 12 NK AMLs with FAB-type M1 found approximately three mutations per 
genome with translational consequences that were expressed in the patient and recurrent in 
other AML samples (Welch et al, 2012). The evidence presented in chapter 4 demonstrates 
that other characteristics may impact on outcome in CEBPA-double patients, such as 
FLT3/ITD, and whilst CEBPA-double status is associated with a relatively favourable 
outcome it is clear that there are a significant number of patients within this group that have 
a poor clinical prognosis, for instance, 10% did not achieve a CR and 46% were not alive 8 
years after trial entry. Therefore, exploration of what the cooperating events are is important. 
Clarification of the role of more recently identified gene mutations in CEBPA-mutant AML 
is required, for instance DNMT3A mutations are both frequently identified in AML and 
associated with poor patient outcome (Table 1.4). Subsequent to the work presented in this 
thesis, the DNMT3A mutant status has been determined in 916 patients with intermediate-
risk cytogenetics from AML 10 and AML 12, including the 856 cases in the cohort 
presented in chapter 4.  DNMT3A mutations were less common in patients with CEBPA 
mutations, with 5 of 52 (10%) CEBPA-double, 5 of 34 (15%) CEBPA-single and 231 of 934 
(25%) CEBPA-WT cases also positive for a DNMT3A mutation, although there were no 
significant differences in pair-wise comparisons (CEBPA-WT vs. CEBPA-single, P = .5; 
CEBPA-WT vs. CEBPA-double, P = .07; CEBPA-single vs. CEBPA-double, P = .5, 
Pearson’s Chi-square), and the impact of DNMT3A mutations on patient outcome in this 
context has not yet been investigated (personal communication from Professor Rosemary 
Gale). 
 
A recent study investigated novel markers in CEBPA-double/NK AML by exome 
sequencing of five cases and identified a strong association between biallelic CEBPA 
mutations and mutations in GATA2, a transcription factor important for megakaryocytic 
differentiation and the proliferation and maintenance of haemopoietic stem/progenitor cells 
(Greif et al, 2012). Mutations affecting the first zinc finger domain of GATA2 were detected 
in 13 (39%) of 33 CEBPA-double cases, but not in 38 CEBPA-single or 89 CEBPA-WT 
patients. A subsequent report identified GATA2 mutations in 18 (18%) of 98 CEBPA-double, 
but not in 22 CEBPA-single, cases (Fasan et al, 2012). In the context of CEBPA-double 
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mutated AML, no significant difference was found in clinical outcome between GATA2-
mutant and GATA2-WT patients by Greif et al, whilst Fasan et al found a trend to improved 
OS for GATA2-mutant cases, but saw no significant difference for event-free survival. In 
light of this, 98 of the 107 CEBPA-mutant patients identified in chapter 3 were screened for 
GATA2 mutations, including 55 CEBPA-double and 43 CEBPA-single cases. GATA2 
mutations were detected in 15 of 55 (27%) CEBPA-double and in 7 of 43 (16%) CEBPA-
single cases, this difference not being significant (P = .2), and the GATA2 mutations were 
mutually exclusive with FLT3/ITDs. Overall, there was no evidence that a GATA2 mutation 
significantly affected the clinical outcome of either CEBPA-single or CEBPA-double cases, 
with the latter retaining an improved prognosis over the former. However, with small 
numbers in subgroups for this and other reported cohorts, a meta-analysis of the available 
data is desirable. In addition, there are several avenues of investigation regarding the 
functional implications of the association between CEBPA and GATA2 mutations, such as 
the interaction between the two proteins, with GATA2 variously reported as a negative 
(Tong et al, 2005) and positive (Greif et al, 2012) regulator of C/EBPα activity on the basis 
of in vitro assays. 
 
As described above, exome sequencing of five CEBPA-double cases with an NK enabled the 
discovery of the association between CEBPA and GATA2 mutations, and a similar approach 
could be taken to determine other cooperating events, particularly those predicting CEBPA-
double cases with a poor prognosis. One approach would be to obtain exome sequencing on 
a small cohort of CEBPA-double cases with poor response to therapy or early relapse and 
compare this to a group with long-term disease-free survival. 
 
The functional consequence of missense mutations and in-frame insertions/deletions in the 
middle of the CEBPA gene is still unclear. Whilst they did not appear to impair the TA 
activity of C/EBPα, it is possible that they may prevent the interaction of C/EBPα with other 
molecules, such as cdk2, cdk4 and the SWI/SNF complex, or impact on other unknown 
functions. Further in vitro and in vivo experiments are required to determine whether these 
types of atypical mutations are indeed functional mutations or non-pathogenic bystander 
mutations. Initially, mutants could be exogenously expressed in cell lines and their impact 
on cell cycle, proliferative capacity and ability to differentiate analysed. In addition, knock-
in mouse models of these mutants would be useful to further explore the implications of 
these mutations. 
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7.2 Conclusions 
 
This thesis describes an investigation of CEBPA mutations in AML, clarifying their impact 
on patient prognosis and the factors that modify this effect. Novel findings were also made 
with regard to CEBPA mutant level in patient samples and the impact of non-classical 
mutations on protein function. This data has made a significant contribution to the current 
understanding of both the clinical and biological role of CEBPA mutations in AML, as well 
as provided further avenues for exploration. 
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Appendix Table 1 Primer sequences 
 
Primer name Primer sequence (5’ to 3’) Location in gene1 
CEBPA/1F
2
 TCGCCATGCCGGGAGAACTCTAAC -30 to -7 
CEBPA/1R TAGCCGGCGGCCGCGCAGCCGTAG 390 to 413 
CEBPA/1R3 AGCTGCTTGGCTTCATCCTCCT 497 to 518 
CEBPA/2F GCCCCGGCGGCGCCGTCATGC 341 to 361 
CEBPA/2F2 GCTGGTGATCAAGCAGGAGC 471 to 490 
CEBPA/2R CCGCCACTCGCGCGGAGGTCG 783 to 803 
CEBPA/3F GGCAGCGCGCTCAAGGGGCTG 748 to 768 
CEBPA/3R
2
 CACGGCTCGGGCAAGCCTCGAGAT *71 to *94 
CEBPA/C693G/R(MM) CGGGGTGCGGGCTGGGCACCGG 691 to 712 
CEBPA/G964T/R(MM) CTGTTCCACCCGCTTGCGCAGGCGGTAA 963 to 990 
CEBPA/G157A/R(MM) ATGGACGTCTCGTGCTCGCAGATGCCGCTC 156 to 185 
CEBPA/Clone/F
3,4
 TGTTCCCTACCGGAATTCGGATCCGCCACCATGGAGTCGGCCGACTTCTACG 1 to 22 
CEBPA/Clone-p30/F
3
 TGTTCCCTACCGGAATTCGGATCCGCCACCATGCCCGGGGGAGCGCACGGGC 358 to 379 
CEBPA/Clone-UTR/F
3
 TGTTCCCTACCGGAATTCGGATCCACGCGGCCTGCCGGGTATAAAAGCT -165 to -141 
CEBPA/Clone/R
3,4
 AAGGCCTTCGACCTCGAGTCACGCGCAGTTGCCCATGGCC 1056 to 1077 
MSCV/F2 CTTGAACCTCCTCGTTCGAC NA 
MSCV/R2 CACACCGGCCTTATTCCAAGCG NA 
 
 
1
Nucleotides in CEBPA covered by primer sequence. Numbered with 1 as A of ATG for p42 isoform, 5′ of ATG are -1, -2 etc. and 3′ of stop codon are *1, *2 
etc. 
2
Primers as per PP1F and PP2R from Pabst et al (2001b).
 3Primers were designed so that the 3′ end was complementary to CEBPA, in bold, and the 5′ end 
incorporated a restriction enzyme recognition site, either EcoRI (green) or XhoI (purple), and a Kozak consensus sequence (red), if required. 
4
Primers were 
designed by Dr. Martin Pule of the Department of Haematology, UCL Cancer Institute. 
For mismatch (MM) primers altered nucleotide is underlined. F and R indicate forward and reverse primers, respectively. NA indicates not applicable. 
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Appendix Table 2 CEBPA sequence alterations detected 
 
Patient No. DNA change 1 
Predicted AA 
change 1 
DNA change 2 
Predicted AA 
change 2 
CEBPA-single, 
-double or SNP 
1 52dupC H18fs 925_927del E309del double 
2 63_64delinsA S21fs 918_935del N307_Q312del double 
3 68_78del P23fs   single 
4a 68delC P23fs 68dupC H24fs single 
5 68_78del P23fs 912_913insTTG K304_Q305insL double 
6 68dupC H24fs   single 
7 68dupC H24fs 625delC Q209fs double 
8 68dupC H24fs 912_913insTTG K304_Q305insL double 
9 68dupC H24fs 912_920dup K304_R306dup double 
10# 67_68dup H24fs 925_926insTCG V308dup double 
11 68dupC H24fs 934_935insTTC Q311_Q312insL double 
12 86_94delinsT A29fs 943_945dup L315dup double 
13 98_116del F33fs 977_978ins66nt K326delins23aa double 
14 103delC R35fs 925_927dup E309dup double 
15 107_113del G36fs 543C>A Y181X double 
16 105_120del G36fs 890_934dup R297_Q311dup double 
17 107delG G36fs 910_936dup K304_Q312dup double 
18 107_113del G36fs 920_921insACAGCGCAA R306_N307insKQR double 
19# 106_113del G36fs 925delinsAAAACGC E309delinsKTQ double 
20 111_124del G38fs 929_934del T310_Q312delinsK double 
21 113delG G38fs 938_939insTA K313fs double 
22 117delC A40fs 925_951dup E309_L317dup double 
23 126_132del P43fs   single 
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Appendix Table 2 Continued 
 
Patient No. DNA change 1 
Predicted AA 
change 1 
DNA change 2 
Predicted AA 
change 2 
CEBPA-single, 
-double or SNP 
24# 126_132del P43fs 934_936dup Q312dup double 
25 129dupC A44fs 883G>C A295P double 
26 135dupA P46fs   single 
27 146delC P49fs 911_946dup Q305_E316dup double 
28 148_167del E50fs 905_943dup V314_L315ins13aa double 
29 158_161del G53fs 937_939dup K313dup double 
30 155dupT G54fs 499dupG E167fs double 
31 158_159insTCCGCCAC G54fs 911_916dup Q305_R306insQQ double 
32 166dupT C56fs 903_917dup K302_R306dup double 
33 175G>T E59X   single 
34# 178dupA T60fs   single 
35 179_180dup S61fs   single 
36 183_184insGCACGTC I62fs 925_926insCAC E309delinsAQ double 
37 184_186delinsG I62fs 986_987ins105nt E329_Q330ins35aa double 
38 196dupG A66fs   single 
39 191_194dup A66fs 949_950insGTC E316_L317insR double 
40 198_201dup I68fs   single 
41 198_201dup I68fs 890G>C R297P double 
42 201_202del I68fs 919_920insGGCGCA R306_N307insRR double 
43 201dupC I68fs 937_939dup K313dup double 
44 230_233del F77fs 917_934del R306_Q311del double 
45 233delT L78fs 896_973dup R300_L324dupinsR double 
46 230_231dup L78fs 922_981dup V308_R327dup double 
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Appendix Table 2 Continued 
 
Patient No. DNA change 1 
Predicted AA 
change 1 
DNA change 2 
Predicted AA 
change 2 
CEBPA-single, 
-double or SNP 
47 230_231dup L78fs 927_986dup E309_V328dup double 
48 232delC L78fs 937_939dup K313dup double 
49 245_246insGTGTT F82fs 909_923dup K304_V308dup double 
50 247delC Q83fs   single 
51 247delC Q83fs 898_936dup R300_Q312dup double 
52# 247delC Q83fs 937_939dup K313dup double 
53 248dupA H84fs 904_912dup K302_K304dup double 
54# 271dupG A91fs 956_957insACT S319delinsRL double 
55 278dupC A94fs   single 
56 280_283dup V95fs 707_708insT A238Rfs double 
57b 282delC V95fs 
922G>T 
934_936dup 
V308L 
Q312dup 
double 
58 291_292insCC T98fs 928_930dup T310dup double 
59 296_302del G99fs 912_913insTTG K304_Q305insL double 
60 296_299dup G101fs 934_936dup Q312dup double 
61 315delC F106fs 903_926dup D301_V308dup double 
62 317_318dup D107fs 897_956dup S299_T318dup double 
63 318dupT D107X 901_903del D301del double 
64# 326_327insTA G110fs 934_936dup Q312dup double 
65 339_342del G114fs 934_936dup Q312dup double 
66c 343C>A P115T 363_364ins19nt G122fs single 
67 368delG G123fs   single 
68 496G>T E166X   single 
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Appendix Table 2 Continued 
 
Patient No. DNA change 1 
Predicted AA 
change 1 
DNA change 2 
Predicted AA 
change 2 
CEBPA-single, 
-double or SNP 
69 500_501dup D168fs   single 
70 500_501dup D168fs   single 
71† 533_548del L178fs 827A>G K276R double 
72 539delC P180fs   single 
73† 548C>A P183Q   single 
74† 558_566del P187_P189del   single 
75† 558_566del P187_P189del   single 
76† 578_589del H193_P196del   single 
77 644_665dup G223fs   single 
78 683delC P228fs   single 
79† 698C>G P233R   single 
80† 724G>A G242S   single 
81† 724G>A G242S   single 
82 745_748dup G250fs   single 
83 756_778del L253fs   single 
84 797_798insAG S266fs   single 
85 822delC K275fs   single 
86† 827A>G K276R   single 
87 854A>C Y285S   single 
88 825_873dup N292fs   single 
89 887T>A V296E   single 
90 899G>C R300P   single 
91† 899_901delinsAAA[HOM] R300_D301delinsQN   double 
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Appendix Table 2 Continued 
 
Patient No. DNA change 1 
Predicted AA 
change 1 
DNA change 2 
Predicted AA 
change 2 
CEBPA-single, 
-double or SNP 
92 899_901delinsAGT R300_D301delinsQY   single 
93 902_946dup D301_L315dup   single 
94† 917_943dup R306_V314dup 962A>G N321S double 
95# 914_917dup N307fs   single 
96 937_939dup K313dup   single 
97 937_939dup K313dup   single 
98 937_939dup K313dup   single 
99† 937_939dup K313dup 1035_1045dup S349fs double 
100 966_968del R323del   single 
101†# 941T>G [HOM] V314G   double 
102† 962A>G [HOM] N321S   double 
103 992T>A L331Q   single 
104 1021A>G I341V   single 
105 1027delC R343fs   single 
106 1066_1071del N356_C357del   single 
107 1066_1071del N356_C357del   single 
108 24G>A E8E   SNP 
109 111G>C A37A   SNP 
110 612G>C P204P   SNP 
111 612G>C P204P   SNP 
112 888G>A V296V   SNP 
113 *5C>T    SNP 
114 *18C>T    SNP 
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Appendix Table 2 Continued 
 
Patient No. DNA change 1 
Predicted AA 
change 1 
DNA change 2 
Predicted AA 
change 2 
CEBPA-single, 
-double or SNP 
115 *18C>T    SNP 
116 *18C>T    SNP 
117 *37G>A    SNP 
118 *44A>T    SNP 
119 *69G>A    SNP 
 
 
Nucleotides numbered from the major translational start codon at nucleotide position 1. All mutations were heterozygous unless specifically stated otherwise. Abbreviations: 
AA, amino acid; HOM, homozygous mutations; ins, insertion; del, deletion; dup, duplication; nt, nucleotide; SNP, single nucleotide polymorphism. †Cases excluded from 
analysis of classical N- and/or C-terminal mutations. 
a 
Mutations on different alleles, however WT sequence still visible at about 50% level so patient scored as single. 
b
 Case 
has two C-terminal mutations, not known if on the same allele. 
c
 Both mutations on the same allele so case scored as single. The 19 bp insertion occurs after second start site 
so no functional p30 translated from mutated allele. 
# 
Mutations not present in samples taken during complete remission. 
 
